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Fetal exposure to excess glucocorticoids has been proposed as a key determinant 
of pregnancy outcome, as well as a predictor of long term health of the offspring 
through a phenomenon known as ‘developmental programming’. Obesity and 
‘stress’ during pregnancy are two potential sources of altered fetal exposure to 
glucocorticoids. One in five pregnant women is obese at antenatal booking, and 
maternal obesity increases risk of offspring complications including higher birth 
weight, potentially leading to long-term programming effects on the offspring. 
Likewise, maternal anxiety during pregnancy has been identified as a 
programming factor, increasing the risk of psychopathology in the offspring. 
This thesis tests the hypothesis that in humans this association is mediated by 
altered action of glucocorticoids, by examining circulating levels of maternal 
glucocorticoids during pregnancy and through measurement of key genes in the 
placenta regulating fetal glucocorticoid exposure.  
 
Serum cortisol levels were measured at 16, 28 and 36 weeks gestation in n=173 
class III obese (BMI 44.0±4.5kg/m2) and n=107 lean (BMI 22.8±1.6kg/m2) 
pregnant women. Serial corticosteroid binding globulin (CBG) concentrations 
were measured in a subset (n=39 lean, 26 obese) and free cortisol levels 
calculated using Coolen’s equation. CRH concentrations were measured at the 
same time points in obese (n=20) and lean (n=22) pregnant women Salivary 
cortisol was measured in samples collected at bed-time, waking and 30 minutes 
after waking.  mRNA levels of candidate genes regulating glucocorticoids and 
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fetal/placental growth including 11-beta hydroxysteroid dehydrogenase type 2 
(11βHSD2), which inactivates cortisol, insulin-like growth factor 2 (IGF2) and 
glucocorticoid receptor (GR) were measured in first trimester (n=32), second 
trimester (n=15) and term (n=60) placental samples. DNA methylation of key 
regions controlling the expression of the IGF2, GR and 11βHSD2 genes was 
measured by pyrosequencing in first trimester and term samples. 
 
Levels of mRNAs encoding 11βHSD1, 11βHSD2, GR and MR were measured in 
term placentas collected from women from Helsinki, Finland in whom anxiety 
during pregnancy had been prospectively assessed using validated 
questionnaires. Term placental samples from a subset of the obese and lean 
women who had also completed stress questionnaires during pregnancy were 
used to examine replication of findings.  
 
Cortisol levels rose similarly during pregnancy in obese and lean but were 
significantly lower throughout pregnancy in obese women (p<0.05). The diurnal 
rhythm of cortisol was maintained. CBG levels also increased, though this 
change was lower in obese (1.21-fold (±0.9) vs 1.56-fold (±0.07), p<0.01). In 
obese women, lower calculated free cortisol at 16 weeks gestation was 
associated with higher birth weight after adjustment for other factors (r=-0.46, 
p<0.05).  
 
Placental mRNA encoding 11βHSD2 increased in association with increasing 
obesity in early pregnancy (r=0.44, p<0.01) and was highest in term placenta in 
obese women with macrosomic (>4000g) offspring (p<0.05). Placental transcript 
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abundance of GR also increased in association with increasing obesity in early 
pregnancy (r=0.38, p<0.05), but was lowest in term placenta from obese with 
macrosomic offspring (p<0.05). IGF2 mRNA abundance was lower in the 
placentas of obese women with macrosomic offspring at term compared to both 
lean women and obese women with normal weight offspring (p<0.01). 
Methylation results are reported. 
Placental mRNA levels encoding 11βHSD1 (which converts inactive cortisone 
to active cortisol) at term was found to positively associate with maternal 
anxiety measured in the first trimester of pregnancy in a group of pregnant 
Finnish women (β=0.3, p<0.05). Findings were similar in the replication sample 
in lean women only (β=4.6, p<0.05). 
 
Lower circulating and bioavailable cortisol levels in early pregnancy, together 
with a greater placental ‘barrier’ to maternal glucocorticoids represent key 
mechanisms contributing to higher birth weight in offspring of obese women. 
Regeneration of active glucocorticoids in placenta and increasing placental 
sensitivity to glucocorticoids increases fetal glucocorticoid exposure and offers 
insight into the biological mechanisms underlying adverse offspring effects of 
maternal prenatal anxiety.  
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Chapter 1:  
Introduction 
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1.1 Fetal Programming 
Fetal programming is the phenomenon by which in utero events can influence 
fetal development and therefore later offspring health. It has been proposed that 
the developing fetus responds to in utero cues that indicate the conditions of the 
external environment (Wells 2007). The fetus responds to conditions 
experienced in utero, such as limited nutrient supply, by making permanent 
changes in physiology, metabolism and structure, and these changes are thought 
to affect the long term health of the offspring (Barker 1998). The physiological, 
cellular and molecular mechanisms by which these programming effects occur 
have yet to be clearly elucidated, although a number of systems have been 
identified as possible candidates. 
For many years, the orthodoxy regarding lifestyle diseases such as metabolic 
syndrome and coronary heart disease has been that such illnesses result from a 
combination of unhealthy lifestyle and genetics. In the UK however, rates of 
heart disease following the Second World War were found to follow a 
paradoxical geographical profile: rates were lowest in the most prosperous areas 
and amongst the highest income groups, a group traditionally thought to be at 
higher risk (Gardner et al. 1969). A study by David Barker, involving over a 
million deaths from coronary heart disease, found that differences in rates of 
death from coronary heart disease in different parts of England and Wales 
paralleled past differences in neonatal mortality rates, providing the first 
suggestion that coronary heart disease may be linked to early life experiences 
(Barker and Osmond 1986; Barker 2007). Rates of neonatal death, which in the 
early 20th Century was a phenomenon most commonly associated with low birth 
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weight, were found to be particularly associated with later risk of coronary heart 
disease (Barker 2007). The association between infant mortality and later heart 
disease was not unique to England and Wales: in Norway, a positive association 
was found between county heart disease mortality rates in people aged between 
40 and 69 years and the county infant mortality rates in the early years of the 
same cohorts (Forsdahl 1977); in the USA, a similar association was observed 
between rates of infant mortality from diarrhoea in the 1917-1921 cohort and 
later heart disease rates in middle age (Buck and Simpson 1982). In a study of 
26,000 employees of the US-based Bell System of telecommunication 
companies, rates of coronary heart disease were found to be higher amongst 
workers from so-called ‘blue collar’ families when compared to those whose 
parents were viewed as ‘white collar’ workers, again suggesting a link between 
early life conditions and illness in later life (Hinkle 1973).  A similar study in the 
UK, the highly influential Whitehall study, found that rates of death were higher 
in London civil servants of lower social class and physical stature, again 
suggesting that those with a worse environment early in life were at highest risk 
of poor health later in life (Rose and Marmot 1981; Marmot et al. 1984). 
The unexpected relationship between geography of birth and later disease risk 
led to the fetal origins of health and disease, or ‘Barker’, hypothesis: that 
inappropriate fetal nutrition in utero leads to permanent and life-long changes in 
physiology, anatomy and metabolism and thus leads to an increased risk of 
coronary heart disease and metabolic disorders such as diabetes later in life 
(Hales and Barker 1992; Barker 1995; Barker 1998). Low birth weight, often 
used as a marker of poor intra-uterine conditions, has been associated with 
increased incidence of a number of diseases of later life, including 
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cardiometabolic disorders and mental health disorders (Barker et al. 1993a; 
Barker 1995; Fall et al. 1995; Moore et al. 1996; Forsen et al. 1997; Rich-
Edwards et al. 1997; Thompson et al. 2001; Räikkönen K and et al. 2008). This 
phenomenon has been observed in both the developed and developing worlds, 
particularly where low birth weight offspring of nutritionally-restricted mothers 
in poor or rural areas are met with urban diets of relative energy excess in 
adolescence and adulthood (Prentice et al. 2005; Prentice 2009). 
This phenomenon of in utero conditions influencing later disease risk has come 
to be termed ‘fetal programming’, and is a consequence of developmental 
plasticity (Barker et al. 1993b; Seckl 1998; Barker 2007). During critical periods 
of development, the fetus is sensitive and plastic to substances and conditions in 
the in utero environment. Following these periods, plasticity is reduced, and a 
fixed functional capacity is established (Bateson et al. 2004). A number of 
factors, including maternal malnutrition, obesity and stress have been associated 
with alterations in fetal growth and development during these windows of 
developmental sensitivity (Seckl 2001; Jones 2005; Cottrell and Seckl 2009; 
Jones et al. 2009b).  Fetal programming has been linked to an increased risk of a 
number of diseases of adulthood, including cardiovascular disease, metabolic 
syndrome, type 2 diabetes, cancers and obesity; taken together, these diseases 
represent a large proportion of mortality in the developed world, as well as a 
high burden on the resources of healthcare systems. 
A number of authors have suggested that fetal programming may be due in part 
to adaptive responses made by the fetus in response to the in utero environment 
(Bateson et al. 2004; Gluckman and Hanson 2004b). When confronted with a 
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nutritionally poor environment, the mother may signal to the fetus, causing its 
development to be modified in such a way as to prepare it for survival in a harsh 
postnatal environment (a ‘predictive adaptive response’); her baby may thus be 
born with certain physical characteristics (e.g. modified metabolism, a small 
body) which will help it survive in an environment where food is scarce 
(Bateson et al. 2004; Gluckman and Hanson 2004a). This response has been 
dubbed the ‘thrifty phenotype’, and may rely upon epigenetic changes (Hales 
and Barker 1992; Weaver et al. 2004). However, it is likely that many 
programming effects are non-adaptive, and are rather due to toxins or other 
insults either disrupting fetal development or forcing the fetus to adapt in such a 
way as to secure its immediate survival, with potential long term tradeoffs 
(Bateson et al. 2004; Gluckman et al. 2005). Such early-life metabolic 
adaptations to a difficult environment, whether predictive adaptations or not, 
may result in deleterious health consequences later in life, particularly if there is 
a mismatch between expected and actual environmental conditions.  
 
1.1.1 Programming and Glucocorticoids 
Glucocorticoids have come under particularly close scrutiny as possible 
candidates for mediating programming effects for a number of reasons. 
Exposure to excess glucocorticoids has been shown to reduce birth weight in 
both animal models and humans, particularly if exposure occurs during the later 
stages of pregnancy (Reinisch et al. 1978; Nyirenda et al. 1998; French et al. 
1999; Bloom et al. 2001). Birth weight itself is a potent predictor of future 
offspring health, with low birth weight associated with the later development of 
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a number of common cardiovascular and metabolic diseases (Barker et al. 
1993a; Barker et al. 1993b; Curhan et al. 1996; Forsen et al. 1997; Rich-
Edwards et al. 1997). Glucocorticoid production and tissue sensitivity are altered 
in pregnancy, with dramatic rises in the production of both the glucocorticoid 
cortisol and the regulatory hormone corticotrophin-releasing hormone (CRH) 
observed during human pregnancy (Okamoto et al. 1989; Lindsay and Nieman 
2005). Glucocorticoids also appear an attractive target when considering the 
potential programming effects of diet and stress: glucocorticoids are important 
regulators of metabolism; glucocorticoid production and clearance is altered in 
obesity; and glucocorticoids form a major component of the stress response 
(Jung 1984; Dallman et al. 1993; Pasquali et al. 1993; Torres and Nowson 
2007). 
  




Human pregnancy involves a number of modifications to the maternal 
physiology, including hormonal and immunological changes, in order to 
adequately support the mother and developing fetus. Disturbances to this 
process, for example through poor nutrition, exposure to toxins, or disruption in 
hormonal or immune function, can have major consequences on birth outcome. 
A key component of pregnancy is the placenta, which forms the main interface 
between the mother and her developing offspring. The placenta is a unique and 
transient organ responsible for the exchange of nutrients between mother and 
fetus, as well as diverse endocrine and metabolic functions, all of which play key 
roles in pregnancy.  
 
1.3 The Hypothalamic-Pituitary-Adrenal Axis 
1.3.1 Overview 
A number of important bodily processes, including digestion, immunity, energy 
storage and the stress response are influenced by the action of glucocorticoids. 
Glucocorticoid production is regulated by the hypothalamic-pituitary-adrenal 
(HPA) axis, a complex set of feedback interactions between the hypothalamus 
(specifically the paraventricular nucleus), the anterior pituitary and the cortex of 
the adrenal glands. These interactions are mediated by the action of a small 
group of hormones: corticotropin releasing hormone (CRH), arginine 
vasopresssin (AVP), adrenocorticotropic hormone (ACTH) and cortisol (see 
Figure 1-1). Cortisol production is regulated by CRH, AVP and ACTH produced 
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in the hypothalamus and pituitary, and is self-inhibitory through a negative 
feedback loop. During episodes of acute stress, CRH production by the 
hypothalamus is greatly increased while AVP is only moderately increased, 
resulting in an increase in ACTH and cortisol production. Chronic stress 
however elicits a greater increase in AVP secretion while CRH production is 
paradoxically lowered. 
CRH and AVP are released from the hypothalamus and transported to the 
anterior pituitary, where they act to stimulate secretion of stored ACTH. ACTH 
is transported in the blood to the adrenal cortex of the adrenal glands, where it 
stimulates synthesis of corticosteroids including cortisol. Importantly, cortisol 
negatively feeds back to inhibit production of both CRH and ACTH in the 
hypothalamus and pituitary gland respectively. In healthy individuals a 
distinctive diurnal rhythm of cortisol production can be observed: levels 
generally rise rapidly shortly after wakening, reaching a peak within 30 minutes, 
before gradually falling throughout the rest of the day. Levels of cortisol rise 
once again in the late afternoon, before falling in the late evening to a trough 
during the middle of the night. 
 
While the secretion of glucocorticoids is widely recognised as a classic 
endocrine response to stress, the physiological purpose of glucocorticoids in the 
stress response has been controversial (Sapolsky et al. 2000). The classical view, 
as espoused in the 1930s by the pioneering Hungarian endocrinologist Hans 
Seyle, is that glucocorticoids mediate the stress response either through actively 
stimulating the stress response, or through permissive effects (Sapolsky et al. 
2000). A subsequent revisionist interpretation suggested that glucocorticoids in 
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fact suppress the stress response, in effect protecting against the defence 
reactions activated during the stress response (Munck et al. 1984). This change 
in view was in part a consequence of the unexpected discovery in 1949 that 
glucocorticoids had anti-inflammatory effects (Hench et al. 1949). More 
recently, the permissive and suppressive effects of glucocorticoids have been 
suggested to be complementary, with the former priming and enhancing the 
stress response and the latter limiting its actions (Munck and Náray-Fejes-Tóth 
1992). 






Figure 1-1. The hypothalamic-pituitary-adrenal axis in humans.  
 
  





Glucocorticoids have multiple functions on a vast number of cell and tissue 
types. These include suppression of inflammation and immune reactions, 
inhibition of glucose uptake by peripheral tissues, stimulation of hepatic 
gluconeogenesis and effects on lipolysis (Munck et al. 1984; Djurhuus et al. 
2002). 
The primary glucocorticoid in humans is cortisol. Cortisol is synthesised from 
cholesterol in a process known as steroidogenesis. Synthesis occurs within the 
zona fasciculata of the adrenal cortex. The synthesis of cortisol is stimulated by 
ACTH through regulation of a number of key factors involved in 
steroidogenesis: ACTH increases the uptake of cholesterol by the adrenals 
through an upregulation of LDL receptors, stimulates the conversion of 
cholesterol to pregnenolone by upregulation of the side chain cleavage enzyme 
cytochrome P450SCC encoded by the CYP11A1 gene (Hu et al. 2001), and 
hydroxylates pregnenolone to produce 17-OH-pregnenolone, a precursor to 11-
deoxycortisol. 
Most organs and physiological systems in the body are sensitive to 
glucocorticoids, with glucocorticoids having major effects on cardiovascular 
tone, fluid volume, immunity and inflammation, metabolism, neural function 
and reproduction (Sapolsky et al. 2000). Glucocorticoids also exert powerful 
effects upon metabolism. In response to stress, blood glucose levels rise rapidly 
as a consequence of both mobilisation from existing stores and inhibition of 
storage as a consequence of insulin resistance (Black et al. 1982). These 
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responses are largely the result of the influence of catecholamines, glucagon and 
growth hormone (Sapolsky et al. 2000). Glucocorticoids act to increase the 
levels of circulating glucose via a number of mechanisms, including stimulation 
of appetite (Santana et al. 1995), as well as to mobilise lipids through lipolysis in 
fat cells (Xu et al. 2009). Interestingly, appetite stimulation by glucocorticoids 
occurs at basal rather than stress levels (Dallman et al. 1993). At stress levels, 
glucocorticoids suppress appetite; this occurs by stimulating a burst of insulin 
secretion, which essentially negates the appetite-stimulating effects of 
glucocorticoids (Dallman et al. 1993; Sapolsky et al. 2000). Cortisol also 
increases the sensitivity of tissues to catecholamines, suggesting an integrative 
effect on the stress response; cortisol has been shown to regulate the sensitivity 
of vascular tissue to catecholamines, for example (Ullian, 1999; Magiakou et al., 
2006). 
 
1.3.3 Intracellular Action of Glucocorticoids 
Glucocorticoids mainly act within the cell through the glucocorticoid receptor 
(GR) and the mineralocorticoid receptor (MR). The GR protein is encoded by 
the gene NR3C1 (Nuclear receptor subfamily 3, group C, member 1; GR), and is 
ubiquitously expressed (Yudt and Cidlowski 2002). The receptor can act as both 
a transcription factor and as a regulator of other transcription factors (Yudt and 
Cidlowski 2002). 
Unliganded GR proteins form large heterocomplexes in the cytoplasm with heat 
shock protein 90 (hsp90) and other heat shock proteins (Pratt and Toft 1997). On 
hormone binding, the hormone-receptor complex is transformed, leading to an 
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activated hormone-receptor complex monomer that becomes 
hyperphosphorylated and binds to structures in the nucleus (Ortí et al. 1993). 
The activated hormone-receptor complex then binds to target genes via short 
palindromic nucleotide sequences in the target promoter region known as 
glucocorticoid response elements (GREs) in the case of transactivation, or 
negative GREs, disrupting the binding of positively acting factors at adjacent 
sites in the process, in the case of transrepression (Lucas and Granner 1992; 
Sapolsky et al. 2000). GR may also affect transcription through binding or 
‘tethering’ to other transcription factors, rather than directly to DNA, a process 
that generally interferes with transcription (Sapolsky et al. 2000). For example, 
glucocorticoid suppression of the reproductive hormone GnRH is thought to 
occur via GR tethering to Oct-1, which binds directly to the GNRH gene 
(Chandran et al. 1999). Activated GR complexes are also thought to interact 
directly with general transcription factors that comprise the RNA polymerase II 
transcription complex. 
GR is highly expressed in the placenta, and is thought to play an important role 
in the placental development and function (Jones et al. 1989a; Ringler et al. 
1989; Hahn et al. 1999; Chan 2003; Lee et al. 2005). However, information 
concerning the possible gene targets of GR in the placenta is limited. 
Peroxisome proliferator-activated receptor gamma (PPARγ), a gene important 
for placental growth and function, appears to be regulated by GR (García-Bueno 
et al. 2008; Giaginis et al. 2008). PPARγ mRNA and protein levels in abdominal 
subcutaneous adipose tissue are also reduced in obese pregnancy complicated by 
gestational diabetes (Catalano et al. 2002). 





Corticosteroid-binding globulin (CBG, also known as transcortin) is thought to 
be a major modulator of cortisol availability in humans. This 50-60kDa 
glycoprotein binds to cortisol and transports it in the plasma. CBG is primarily 
secreted from hepatocytes with a slight diurnal variation, fluctuating in 
opposition to the diurnal variation in plasma cortisol levels (Hsu and Kuhn 1988; 
Lewis et al. 2006). Although there is evidence for some secretion of CBG in the 
kidney and testis, this is thought to regulate local glucocorticoid availability in 
those tissues only (Henley and Lightman 2011). 
While CBG is generally defined as a serine proteinase inhibitor (or serpin), it 
does not act as a proteinase inhibitor, but rather as a substrate for specific 
proteinases such as neutrophil elastase (Hammond et al. 1990). Neutrophil 
elastase is found in high concentration at sites of inflammation, and through 
proteolytic cleavage causes the destruction of the steroid-binding site of CBG, 
thus releasing the steroid ligand (Hammond et al. 1990; Klieber et al. 2007; Lin 
et al. 2010). 
Only about 5% of secreted cortisol is unbound in the plasma and thus free to 
bind to GR and MR. The remaining 95% of secreted cortisol is bound to carrier 
proteins in plasma: between 80 and 90% is bound to CBG in the plasma, with a 
further 10 to 15% bound to albumin (Lewis et al. 2005). The ‘free hormone 
hypothesis’ proposes that steroid hormones bound to carrier proteins such as 
CBG can be considered biologically inactive (Mendel 1989). The bound 
substance provides a reservoir of inactive hormone that is used to finely regulate 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  
26 
the levels of free hormone available for diffusion into cells (Henley and 
Lightman 2011).  Following stress, CBG production can be downregulated in 
order to increase free cortisol levels (Neufeld et al. 1994; Fleshner et al. 1995; 
Spencer et al. 1996). 
However, there is also evidence to suggest that CBG may function as a cortisol 
transporter, and that it may release cortisol at clinically relevant temperatures, 
i.e. between 34 and 37°C, and that it may have an active role in the local 
delivery and signaling of glucocorticoids (Petersen et al. 2006; Cameron et al. 
2010). A number of Other roles have also been suggested for CBG, including 
regulation of intestinal sodium absorption, and direct effects in the brain (Henley 
and Lightman 2011). 
Circulating levels of CBG are sensitive to hormonal changes; concentrations are 
increased by estrogens and decreased by glucocorticoids (Henley and Lightman 
2011). CBG has also been shown to negatively correlate with insulin secretion 
(Crave et al. 1995; Fernandez-Real et al. 1999). 
 
1.3.3.2 Free cortisol versus total cortisol 
Traditionally, serum total cortisol has been used as a measure of HPA-axis 
activity (le Roux et al. 2003). This measurement does not, however, differentiate 
between unbound and bound levels of cortisol. Furthermore, variation in CBG 
concentration has been shown to significantly affect total serum cortisol levels 
(Dhillo et al. 2002). As approximately 80% of serum cortisol is bound to CBG, 
measurements of the unbound, or free, cortisol are thought to be a more useful 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  
27 
measure of available glucocorticoids (Arafah 2006). Free cortisol can be 
calculated from total cortisol and CBG measurements using the Coolen’s 
equation (Coolens et al. 1987). 
 
1.3.4 The HPA-Axis During Pregnancy 
Pregnancy has been described as ‘a state of mild but sustained hypercortisolism’, 
and human gestation has been shown to dramatically affect the HPA axis (see 
Figure 1-2)(McLean and Smith 1999). Maternal plasma concentrations of 
cortisol, CRH and ACTH all rise during pregnancy (Okamoto et al. 1989; 
Lindsay and Nieman 2005). The diurnal rhythm of ACTH and cortisol, as well 
as the cortisol response to stress, are maintained. Placental estrogen production 
stimulates the hepatic production of CBG, thus stimulating cortisol production 
and increasing levels of total and bound cortisol in the circulation (Lindsay and 
Nieman 2005). However, HPA axis reactivity decreases throughout pregnancy 
as measured by ACTH response to CRH, and stress response appears to be 
similarly diminished (Schulte et al. 1990; Lindsay and Nieman 2005).  
While the rise in total plasma cortisol may be partly explained by an estrogen-
related rise in CBG levels during pregnancy, free cortisol levels also increase 
(Scott et al. 1990). It is thought that increased placental CRH production is the 
primary factor in the increased HPA activity observed during pregnancy 
(McLean and Smith 1999). However, it is also important to note that the 
retention of the stress response and diurnal rhythm of cortisol production, even 
in the third trimester of pregnancy, suggests that the placenta does not entirely 
usurp the role of the hypothalamus in HPA axis function during pregnancy  




Figure 1-2. The HPA axis during human pregnancy. During pregnancy, the placenta 
influences maternal HPA-axis activity (ACTH, cortisol and CBG production) through the 
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(Magiakou et al. 1996). It is also thought that AVP (produced by the 
parvocellular neurons of the paraventricular nucleus), rather than CRH, becomes 
the main regulator of pituitary ACTH secretion; this is similar to HPA axis 
regulation in chronic stress (Chowdrey et al., 1995; Engelmann et al., 2004). 
 
1.3.4.1 CRH 
Corticotrophin releasing hormone (CRH) is a peptide hormone produced in the 
hypothalamus responsible for stimulation of ACTH production by the pituitary, 
which in turn stimulates glucocorticoid secretion from the adrenals (Vale et al. 
1981). The synthesis of CRH by the hypothalamus is regulated by negative 
feedback from cortisol, ACTH, as well as CRH itself. 
During pregnancy, CRH is found at high concentrations in the maternal plasma 
and increases exponentially throughout gestation, reaching a peak concentration 
at term of between 1 and 10 nmol/l (Campbell et al. 1987; Mastorakos and Ilias 
2003). This rapid rise in CRH levels is a result of production by the placenta, 
particularly the syncytiotrophoblast and intermediate trophoblast (Shibasaki et 
al. 1982; Riley et al. 1991). Unlike hypothalamic CRH, placental CRH 
production is stimulated by glucocorticoids; this stimulation is indicative of a 
positive feedback loop driving increasing production of CRH throughout 
pregnancy (Robinson et al. 1988; Jones et al. 1989b). CRH is an important 
regulator of implantation, and is thought to be involved in the production of 
estrogen by the fetal adrenal (Smith et al. 1998; Mastorakos and Ilias 2003). 
The effects of CRH during pregnancy are regulated by CRH binding protein 
(CRH-BP), which is produced by the placenta and may be involved in reducing 
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stress reactivity during pregnancy by preventing inappropriate stimulation of the 
HPA axis (Petraglia et al. 1993).  
 
1.3.4.1.1 CRH and timing of parturition 
It has been suggested that CRH plays a crucial role in the timing of parturition; 
CRH levels at 31 weeks have been shown to predict incidence of preterm birth, 
indicating a role for this hormone as a ‘placental clock’ (Sandman et al. 2006). 
The high levels of CRH in both the maternal and fetal compartments near term, 
coupled with the presence of CRH receptors in the myometrium, placenta and 
fetal membranes, as well as the fetal pituitary and adrenal cortex, further 
underline the importance of this hormone during pregnancy (Ackland et al. 
1986; Petraglia et al. 1990; Hillhouse et al. 1993; Smith et al. 1998). 
Furthermore, plasma levels of CRH-BP have been shown to fall in the third 
trimester of pregnancy, increasing the availability of free, unbound CRH (Linton 
et al. 1993). CRH is thought to stimulate cortisol production by the fetal adrenals 
(Lockwood et al. 1996; Sirianni et al. 2005). Cortisol, whether of maternal or 
fetal origin, may be the main driver of organ maturation, an important precursor 
to parturition (Challis et al. 2001). CRH is also thought to stimulate the release 
of prostaglandins from the amnion, chorion and decidua, aiding in cervical 
ripening, as well as regulating fetal estrogen production (Jones and Challis 1989; 
Smith et al. 1998). 
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1.3.5 The Placental Glucocorticoid Barrier: 11βHSD2 
During pregnancy, the placenta acts as a barrier to potentially harmful 
substances in the maternal circulation. Of particular importance is the role of the 
placenta as a barrier to maternal glucocorticoids. This barrier is largely 
dependent upon the enzyme 11-beta hydroxysteroid dehydrogenase type 2 
(11βHSD2). 
Postnatally, 11βHSD2 is expressed in mineralocorticoid-target tissues 
throughout the body, and allows for selective access of aldosterone to the 
mineralocorticoid receptor, MR, by conversion of active glucocorticoids (e.g. 
cortisol) to an inactive form (e.g. cortisone). This allows aldosterone, generally 
present in much lower concentrations than cortisol, to bind to the non-specific 
MR (Edwards et al. 1988; Funder et al. 1988).  
In the placenta, 11βHSD2 is thought to have an additional, crucial, function. 
Placental 11βHSD2 inactivates cortisol by converting it into cortisone, thereby 
protecting the fetus from the deleterious effects of excess exposure to maternal 
glucocorticoids as well as enabling an intricate regulation of glucocorticoid 
transit and subsequent fetal exposure (Brown et al. 1996; Wyrwoll et al. 2011). 
While 11βHSD2 expression in mice appears to be switched off in the mid-
gestation placenta (from E16.5), in humans 11βHSD2 expression increases 
approximately 50-fold throughout gestation (with the greatest increase during 
the third trimester), peaking at term, and expression is localised to the 
syncytiotrophoblast (Krozowski et al. 1995; Brown et al. 1996; McTernan et al. 
2001). The role of mid-term silencing of 11βHSD2 expression in the mouse 
placenta is unknown; while it has been suggested that 11βHSD2 protein may 
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persist until later in gestation, placental 11βHSD2 activity has been found to 
dramatically decrease by E17.5 in rodent placentas (Brown et al., 1996; Diaz et 
al., 1998). Intriguingly, placental silencing of 11βHSD2 in the rodent placenta is 
paralleled by a reduction in 11βHSD2 expression in the mid-gestation rodent 
brain; similarly, 11βHSD2 expression is silenced between gestational weeks 19 
and 26 in the developing human brain (Stewart et al., 1994; Brown et al., 1996). 
This suggests that elevated glucocorticoid exposure may be necessary for late-
gestational brain development in both rodents and humans; the different patterns 
of placental 11βHSD2 expression may reflect differences in the level of 
exposure necessary and the different developmental trajectories of rodents and 
humans. Low levels of expression and null mutations of 11βHSD2 have been 
associated with intra-uterine growth restriction (IUGR), underlining the 
importance of this enzyme for proper growth and development prenatally 
(Kitanaka et al. 1996; Dave-Sharma et al. 1998).  
In humans, the 11βHSD enzyme exists in two isoforms: 11βHSD1 and 
11βHSD2 (Seckl 1997). While 11βHSD2 converts cortisol to its inactive form, 
cortisone, the isoform 11βHSD1 is involved in the reduction of cortisone to the 
active hormone cortisol. 11βHSD1 thus acts to regenerate active glucocorticoids, 
and amplify their action. 11βHSD1 is expressed throughout the adult central 
nervous system, and plays a key role in HPA axis function; 11βHSD1 is also 
thought to be an important regulator of brain development, particularly during 
late gestation (Wyrwoll et al., 2011). 
Both 11βHSD1 and 11βHSD2 are expressed in the placenta (McMullen et al., 
2004). In rodents, 11βHSD1 is expressed in the placenta in the latter half of 
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pregnancy, and has been suggested to contribute to the late-gestation rise in 
glucocorticoids that ensure fetal maturation (Burton et al., 1996). Furthermore, 
both 11βHSD1 and 11βHSD2 have been found to co-localise with GR in the 
rodent placenta, suggesting that these enzymes may act as regulators of 
glucocorticoid activity in placental tissues (Waddell et al., 1998). It has been 
suggested that placental 11βHSD1 and 11βHSD2 may limit or enhance the 
bioactivity of maternal cortisol in different regions of the placenta; 11βHSD1 
and 11βHSD2 may interact physiologically in relation to substrate availability 
(Waddell et al., 1998). However, the different patterns of localization of the two 
enzymes appear to preclude direct interaction to finely regulate glucocorticoid 
activity within individual cells or tissues. 
Inside the cell, the 11β-HSD2 enzyme is localised to the endoplasmic reticulum 
with a cytosol-facing active site and co-factor binding domain (Odermatt et al. 
2006). 11βHSD2 binds to cortisol with approximately 100 times the affinity that 
11βHSD1 binds to cortisone; this finding implies that the glucocorticoid 
oxidising activity of 11βHSD2 may play a greater role in glucocorticoid 
regulation in tissues where the two enzymes are expressed (Wyrwoll et al. 
2011). However, 11βHSD1 and 11βHSD2 rarely co-localise to the same cells, 
complicating the interplay between the two isoforms (Waddell et al. 1998). 
However, the opposing effects of the two isoforms make them of great interest 
when considering the effects of glucocorticoids on a macroscopic level.  
Changes in the placental expression of 11βHSD2 and 11βHSD1 may lead to 
altered fetal development: levels of 11βHSD1 mRNA are increased in chorion of 
placentas from pregnancies complicated by IUGR, while 11βHSD2 activity and 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  
34 
gene expression is downregulated in the decidua of the same (Wachter et al. 
2009). Furthermore, 11βHSD2 is highly expressed in fetal tissues, including the 
brain until mid-term, as well as in a number of adult brain structures, potentially 
leading to developmental effects if expression is altered (Yu et al. 2002; 
Wyrwoll et al. 2011). 
 
1.4 Stress and Obesity as Programming Factors 
While maternal under-nutrition has been well documented as a potential 
programming factor, there is increasing evidence to link maternal obesity and 
nutrient intake during pregnancy, as well as maternal exposure to stressors, to 
increased risk of a number of programmed outcomes in the offspring, such as 
cardiovascular disease risk later in life. The focus of this thesis is on the effects 
of maternal obesity (i.e. over-nutrition) and psychological stress, conditions that 
are increasingly relevant in the context of modern lifestyles. 
Maternal stress is associated with an increased risk of offspring behavioural 
problems, attention deficit hyperactivity disorder (ADHD) and anxiety (Van den 
Bergh and Marcoen 2004; Gutteling et al. 2005; Rodriguez and Bohlin 2005b; 
Gutteling et al. 2006). Prenatal stress is also associated with altered HPA axis 
activity in the offspring (Gutteling et al. 2004; Gutteling et al. 2005; O'Connor et 
al. 2005; Yehuda et al. 2005; Brennan et al. 2008; Entringer et al. 2009; Grant et 
al. 2009). In humans, maternal experience of stressful events during the second 
trimester is associated with increased incidence of offspring schizophrenia in 
humans (Welberg et al. 2001; Koenig et al. 2002). Traumatic events have been 
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shown to alter HPA-axis response in adult humans, and schizophrenia in 
particular has been associated with reduced expression of glucocorticoid 
receptor in the brain as well as attenuated HPA-axis feedback regulation 
(Goldman et al. 1993; Goenjian et al. 1996; Koenig et al. 2002). Animal studies 
have suggested that prenatal maternal restraint enhances the HPA-axis 
responsiveness of the offspring in adulthood (Henry et al. 1994), and restraint 
during the final week of gestation in particular is associated with decreased 
hippocampal neurogenesis (Lemaire et al. 2000); intriguingly, maternal 
adrenalectomy has been shown to abolish the effects of maternal restraint, 
suggesting that maternal glucocorticoids are responsible for the increased risk of 
schizophrenia otherwise observed (Barbazanges et al. 1996). Furthermore, 
studies in rodents have established that overexposure to glucocorticoids 
prenatally is associated with altered adult behaviour and HPA-axis 
reprogramming (Welberg et al., 2001).  
Maternal obesity has also been implicated as a programming factor in a number 
of studies, and a number of prenatal mechanisms have been proposed to explain 
this finding (Figure 1-3) (Whitaker 2004; Catalano and Ehrenberg 2006; 
Catalano et al. 2009; Drake and Reynolds 2010; Reynolds et al. 2010; Harmon 
et al. 2011; Hochner et al. 2012). Fetuses of obese mothers have been shown to 
have increased body fat, increased risk of insulin resistance, and higher levels of 
the inflammatory factor IL-6; furthermore, fetal adiposity has been shown to 
correlate with insulin resistance in these individuals (Catalano et al., 2009). 
Another study has shown that 24 hour glucose area under the curve is higher in 
obese pregnant women compared with lean women in both early and late 
pregnancy; infants born to obese women were also found to have increased 
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adiposity (Harmon et al. 2011). Maternal obesity during early pregnancy is 
associated with a doubling in risk of obesity at 2 and 4 years of age (Whitaker 
2004). The Jerusalem Perinatal Family Follow-up Study found that higher 
maternal BMI before and during pregnancy is positively associated with 
offspring adiposity in young adulthood (Hochner et al. 2012). It has been 
suggested that these effects may simply be a result of the increased birthweight 
often seen among offspring of obese women, or environmental factors; however, 
studies such as the Jerusalem Perinatal Family Follow-up Study show strong 
associations even when controlling for these factors in the analysis, suggesting 
that the effect is independent of birthweight (Hochner et al. 2012). The 
mechanisms by which these programming effects occur remain unclear, 
although a number of processes have been proposed, including direct effects of 
nutrient availability and altered placental structure and function (Jones 2005; 
Mcmillen and Robinson 2005; Fowden et al. 2006b; Fowden et al. 2009). 
Whether changes in fetal glucocorticoid exposure are important in obese 
pregnancy has not been explored. 
 
1.5 Obesity 
Obesity has been classically defined as a state of excess energy or fat storage 
(Haslam and James 2005; Peeke and Chrousos 1995). In humans, obesity is 
associated with increased morbidity and mortality due to an increased risk of 
diabetes, cardiovascular disease and cancer (Haslam and James ; James et al. 
2004).  
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Obesity has an increasing prevalence throughout the world, and represents an 
increasing burden on healthcare (Alberti and Zimmet 1998; Heslehurst et al. 
2008). WHO estimates suggest that in 2008 more than 1.4 billion adults aged 20 
and over were overweight, with 200 million men and 300 million women classed 
as obese; furthermore, 40 million children under the age of five were estimated 
to be overweight in 2010 (WHO 2013). In the UK, rates of obesity rose from 
7.6% to 15.6% over the period between 1989 and 2007, and obesity has major 
effects on healthcare services and resources (Heslehurst et al. 2007a; Heslehurst 
et al. 2007b; Heslehurst et al. 2010). 
The effects of obesity are dependent in part on the distribution of fat in the body. 
Central or abdominal obesity, for instance, is strongly associated with 
cardiovascular disease, as well as other metabolic and vascular conditions 
(Yusuf et al. 2004). Importantly, abdominal obesity and waist circumference are 
also strongly associated with dysregulation of insulin homeostasis increased 
incidence of metabolic syndrome via increased levels of the hormone resistin 
(Pouliot et al. 1992; Despres 2001). Other fat depots, such as subcutaneous fat, 
are not associated with increased risk of heart disease, cancer, or other 
pathologies, and has in fact been suggested to be potentially protective (Porter et 
al. 2009).  
 




Figure 1-3. Selected factors hypothesised to influence the long-term risk of offspring obesity, 
including maternal influences, in utero mechanisms, and postnatal effects.  Figure adapted from 
O’Reilly and Reynolds, 2013. 
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Body mass index, or BMI, is often used as a simple index of weight-for-height and is 
defined as a person’s weight in kilograms divided by the square of their height in 
metres (kg/m2). This index is commonly used to define overweight (a BMI greater 
than or equal to 25 kg/m2) and obesity (a BMI greater than or equal to 30 kg/m2) 
(Alberti and Zimmet 1998).  
 
1.6 Obesity during Pregnancy 
Just as obesity rates have risen amongst the general population, the rates of obesity 
among pregnant women have also increased over the last few decades (Heslehurst et 
al. 2007a; Heslehurst et al. 2007b; Heslehurst et al. 2010). Obesity has effects upon 
female reproductive health, including increased risk of polycystic ovarian syndrome 
and infertility (Heslehurst et al. 2008). During pregnancy, there is an increased risk 
of obese mothers developing gestational diabetes, hypertension and pre-eclampsia 
(Sibai et al. 1995a; Sibai et al. 1995b; Solomon et al. 1997; Sebire et al. 2001). The 
incidence of late fetal loss and stillbirth is also increased (Lashen et al. 2004). 
Obesity has also been suggested as a risk factor for a number of structural birth 
defects, including spina bifida, heart defects and hypospadias (Waller et al. 2007). 
Interestingly, increasing severity of obesity has been shown to inversely correlate 
with gestational weight gain during pregnancy (Bodnar et al. 2010). In previous 
studies, low gestational weight gain has been associated with preterm birth and low 
birth weight, although low gestational weight gain may be beneficial in obese 
women (Hickey et al. 1990; Siega-Riz et al. 1996; Nohr et al. 2008), while high 
gestational weight gain is associated with macrosomia and an increased offspring 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  
40 
BMI throughout life (Hedderson et al. 2006; Oken et al. 2008; Schack-Nielsen et al. 
2010; Hinkle et al. 2012). It is therefore important to account for the influence of 
gestational weight gain when investigating the effects of maternal obesity on 
pregnancy outcome and long-term offspring health effects. 
 
1.7 Obesity and the HPA Axis 
The link between stress, the HPA axis and obesity has been examined in a number of 
human and animal studies. Glucocorticoids are an important regulator of metabolic 
processes such as lipogenesis and gluconeogenesis (Dallman et al. 1993). Stress has 
been demonstrated to alter food consumption; human studies have reported both 
increases and decreases in eating in response to stress (Michaud et al. 1990; Stone 
and Brownell 1994; Oliver and Wardle 1999). Stress has also been associated with 
higher fat diet and less frequent exercise in humans, and there are suggestions that 
there may a gender-dependent relationship with women more likely to engage in 
stress-related eating (Laitinen et al. 2002; Ng and Jeffery 2003). While acute stress is 
thought to lead to a decrease in food intake through a catecholamine-mediated 
inhibition of appetite and digestion, chronic stress may in fact lead to an increase in 
food intake and weight gain through the actions of the HPA axis, and glucocorticoids 
in particular (Santana et al. 1995; Torres and Nowson 2007). Elevation of cortisol in 
chronic stress may thus stimulate appetite, and potentially lead to obesity (see figure 
1-4). Increased secretion of glucocorticoids, as seen in Cushing’s syndrome, is 
associated with obesity (Peeke and Chrousos 1995). Cortisol may also increase the 
accumulation of abdominal fat depots (Strack et al 1995; Dallman et al. 2003). 
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Defects or changes in the activity of the HPA axis would thus be expected to alter 
energy metabolism, potentially increasing the risk of obesity (Jessop et al. 2001). 
Obesity is associated with alterations in some HPA axis parameters, but not others 
(Pasquali et al. 1993). Plasma cortisol concentrations, including the circadian rhythm 
of plasma cortisol, have been shown to be normal in obese individuals, although 
some data suggests that plasma cortisol levels may be lower in uncomplicated 
obesity (Glass et al. 1981; Jung 1984; Praveen et al. 2011). However, cortisol 
production and metabolism are thought to increase in obesity (Dunkelman et al. 
1964; Jung 1984; Pasquali et al. 1993). This suggests that while HPA axis activity is 
increased in obesity, metabolic clearance of cortisol acts to maintain glucocorticoids 
at a normal physiological level. Interestingly, HPA axis hyperactivity is thought to 
be most pronounced in obese women with abdominal fat distribution (Pasquali et al. 
1993; Jessop et al. 2001).  
 
  





Figure 1-4. Differential effects of acute and chronic stressors on digestion and appetite. 
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1.7.1 Maternal Obesity and Programming 
The increasing prevalence of maternal obesity has prompted research into its 
potential long-term health consequences on the offspring. A number of studies have 
linked maternal obesity during pregnancy with an increased risk of childhood and 
adulthood obesity and metabolic disorders among offspring (Catalano and Ehrenberg 
2006; Catalano et al. 2009; Drake and Reynolds 2010). Maternal obesity has been 
associated with increased birth weight and fat mass as well as increased adiposity in 
childhood and adulthood (Parsons et al. 2001; Sebire et al. 2001; Whitaker 2004; 
Sewell et al. 2006; Reynolds et al. 2010; Harmon et al. 2011; Gaudet et al. 2012; 
Hochner et al. 2012). The increased birth weight that occurs in the children of obese 
women has itself been linked to an increased risk of obesity later in life, with 
macrosomia and maternal gestational weight gain being strong predictors of high 
BMI at 1 year of age, itself a predictor of weight status aged 5 to 8 years (Lindberg 
et al. 2012). While diabetes is common among obese women, the effects of maternal 
obesity on offspring weight status are thought to be independent of maternal 
diabetes, with increased adiposity also seen in the offspring of non-diabetic obese 
women (Sewell et al. 2006). 
Maternal obesity has also been linked to insulin resistance in offspring. Offspring of 
obese mothers are more insulin resistant at delivery, and more likely to exhibit 
neonatal hyperinsulinaemia (Catalano et al. 2009; Group 2010). Offspring of 
overweight or obese women are also more likely to develop insulin resistance by age 
11, as well as in their early 20s (Boney et al. 2005; Mingrone et al. 2008). A study 
conducted in Finland also suggested that higher maternal BMI during pregnancy also 
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contributes to an increased risk of death from coronary heart disease in the offspring 
(Forsen et al. 1997). 
 
1.7.2 Programming versus Postnatal Obesogenic Lifestyle 
In human studies of the programming effects of obesity, it has proven difficult to 
separate the pre- and post-natal influences on later offspring health beyond including 
lifestyle factors such as behaviour, level of sedentary activity and diet as 
confounding factors in statistical analyses. Indeed, as lifestyle factors such as diet 
and exercise habits do tend to cluster within families, the separation of prenatal 
programming effects from postnatal influences becomes an important consideration 
(Rogers 2003; Reilly et al. 2005; Branum et al. 2011). A number of investigators 
have attempted to separate pre- and post-natal influences through sibling/sibling 
studies and adoption studies, with conflicting findings (Branum et al. 2011; Lawlor 
et al. 2011). Sibling and twin studies allow the genetic contribution to traits such as 
obesity to be measured. Such studies allow for comparisons of individuals with 
similar familial environments and similar (or in the case of monozygotic twins, 
identical) genotypes. Classical twin studies compare monozygotic and dizogtic twins 
to determine the genetic contribution to traits of interest. If a specific trait is found to 
be more similar between monozygotic twins than in dizygotic twins (or non-twin 
siblings), it can be implied that the trait has a genetic basis. In the case of obesity, 
genetic factors have been suggested to explain between 20% and 90% of variance in 
offspring BMI, suggesting an important role for environmental factors in at least 
some instances (Maes et al. 1997). Studies involving twins report a genetic influence 
on obesity of between 50% and 90%, with the heritability of obesity increasing with 
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age from childhood to adolescence; genetic factors also appear to have a greater 
influence on levels of trunk fat compared with limb fat (Brook et al. 1975; Maes et 
al. 1997). In adults, however, hereditability of obesity appears to decrease with age, 
and is generally higher for males versus females (Korkeila et al. 1995; Maes et al. 
1997). Adoption studies have shown that obesity among adopted adult offspring 
correlates less strongly with adoptive parents than with the biological parents (Price 
et al. 1987). However, twin studies have been criticized on the grounds that they 
may not be generalizable to the larger population, that there are often difficulties in 
determining whether twins are monozygotic or dizygotic, and that the assumption 
that environmental factors are identical for twins (Maes et al. 1997). 
A particularly interesting approach to the problem of separating prenatal and 
postnatal influences on offspring obesity can be seen in a study by Barisione et al, in 
which women who underwent biliopancreatic diversion as a weight loss measure 
between pregnancies were observed (Barisione et al. 2011). Offspring born before 
the surgery were found to have significantly higher body weights by age 12 and in 
early adulthood compared to offspring born after the surgery, suggesting that 
maternal obesity may indeed have influences on offspring weight status which are 
independent of genetics, postnatal lifestyle and environmental factors.  
 
1.7.3 Stress and the HPA Axis 
Stress may be loosely defined as a state in which the internal homeostasis of an 
organism is disrupted by external factors (Peeke and Chrousos 1995). In the 1930s, 
Seyle proposed that the stress response was intended to accommodate such brief 
challenges to the body’s homeostasis, with the ultimate result being a return to 
normal homeostatic equilibrium. The HPA axis forms a major component of the 
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stress response, along with the sympathetic nervous system, which is mediated 
largely through the action of the catecholamines: epinephrine and norepinephrine 
(Chrousos and Gold 1992; Peeke and Chrousos 1995). 
Seyle also highlighted the potential for prolonged or chronic stress to lead to the 
manifestion of pathological disease states, which he termed ‘diseases of adaptation’ 
(Peeke and Chrousos 1995). Subsequently, a number of chronic conditions, 
including depression, anorexia nervosa, alcoholism, and seasonal affective disorder 
have been linked to disruption of normal HPA axis activity (Gold et al. 1986; Gold 
et al. 1988; Joseph-Vanderpool et al. 1991; Wand and Dobs 1991) 
 
1.7.4 Acute and Chronic Stress 
The HPA axis is involved in the response to both acute and chronic stress. In 
response to acute stress, catecholamines are rapidly secreted from the sympathetic 
nervous system. This is followed shortly by secretion of CRH by the hypothalamus, 
in turn leading to ACTH and cortisol production by the pituitary and adrenal glands 
(Lightman and Young 1988). Decreased hypothalamic release of GnRH and 
gonadotrophins is also observed, as are increased pituitary secretion of prolactin and 
GH and pancreatic secretion of glucagon. These changes allow for the diversion of 
energy resources to the musculature, increased cardiovascular tone, inhibition of 
energy storage, stimulation of immune function, inhibition of reproductive 
physiology, decreased appetite and feeding behaviour and increased cerebral glucose 
utilisation. These effects are characteristic of a ‘fight or flight’ response, whereby the 
physiology of the organism is shifted into a state where energy supply to the 
musculature is maximised for escape or combat, and cognition is enhanced, at the 
expense of digestion, reproduction and other processes. 
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In cases of chronic stress however, the response of the HPA axis is different. While 
levels of the ACTH-precursor pro-opiomelanocortin (POMC) are chronically raised 
in the anterior pituitary, mRNA levels of CRH in the paraventricular nucleus and 
levels of CRH in the blood are lower (Harbuz et al. 1992). This decline is paralleled 
by a rise in AVP mRNA levels and portal blood concentrations of AVP, indicating 
that the activation of the HPA axis in chronic stress is regulated predominantly by 
AVP rather than CRH (Chowdrey et al. 1995).  
 
1.7.5 Maternal Stress and Programming 
While glucocorticoids are of clear physiological importance during pregnancy, there 
are data to suggest that excess exposure to glucocorticoids is associated with reduced 
birth weight and adverse programmed health effects in the offspring, particularly if 
the exposure is in late pregnancy (Reinisch et al. 1978; French et al. 1999; Bloom et 
al. 2001). Animal studies have demonstrated a link between prenatal exposure to 
excess glucocorticoids late in gestation and altered adult behaviour, particularly 
coping and learning behaviours in aversive situations; treatment of pregnant rats with 
dexamethasone leads to reduced birth weight, permanent adult hypertension as well 
as hyperglycemia and hyperinsulinemia (Benediktsson et al. 1993; Nyirenda et al. 
1998; Nyirenda et al. 2001; Sugden et al. 2001; Welberg et al. 2001; Seckl 2004).  
There is evidence that stress and anxiety may also reduce birth weights and affect 
emotional behaviour (Khashan et al. 2008b). Offspring of women who report high 
levels of stress during pregnancy may have behavioural problems as toddlers, as well 
as impaired attention at 6 years of age (Gutteling et al. 2005; Gutteling et al. 2006). 
ADHD and increased anxiety are associated with prenatal maternal stress (Van den 
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Bergh and Marcoen 2004) (Rodriguez and Bohlin 2005b). MRI studies have also 
demonstrated that high anxiety during mid-gestation is associated with decreased 
grey matter density between 6 and 9 years of age, particularly in the prefrontal 
cortex, an area involved in cognition and regulation of the stress response (Diorio et 
al. 1993; Buss et al. 2010). Taken together, these studies suggest that prenatal stress 
can affect brain development and behaviour in the later life of the offspring. The 
importance of the timing of exposure also suggests that maternal stress may affect 
fetal development during critical windows of sensitivity: maternal stress during the 
first trimester, but not later in pregnancy, is associated with an increased risk of 
schizophrenia for example (Khashan et al. 2008a); in contrast, the risk of autism is 
elevated with exposure to maternal stress in mid to late gestation (Kinney et al. 
2008). 
Prenatal stress has also been associated with modifications to HPA axis function in 
the offspring. However, the results of studies have proven variable, possibly 
reflecting to the nature of the stressor. A study by Entringer et al found that severe 
prenatal life events were associated with lower cortisol but higher ACTH response to 
the Trier Social Stress Test, while a study by Yehuda et al found that cortisol levels 
were lower in infants born to mothers who suffered PTSD after exposure to the 
events of 9/11 (Yehuda et al. 2005; Entringer et al. 2009). Other studies however 
have suggested that prenatal stress and depressed mood may be associated with 
raised cortisol levels and increased reactivity in offspring (Gutteling et al. 2004; 
Gutteling et al. 2005; O'Connor et al. 2005; Brennan et al. 2008; Grant et al. 2009). 
Different forms of anxiety or stress may involve different psychological processes, 
possibly explaining the varied responses to prenatal mood (Glover et al. 2010). 
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A number of studies have attempted to address whether maternal stress associates 
with altered maternal glucocorticoid levels. Evans et al. reported elevated cortisol in 
pregnant women with co-morbid anxiety or depression, but not in women with 
anxiety or depression alone (Evans et al. 2008). Other studies have demonstrated 
only modest associations between maternal cortisol and stress and state anxiety 
(Diego et al. 2006; Sarkar et al. 2006). Mothers exposed to traumatic life events or 
high anxiety may display alterations to their circadian production of cortisol 
however, with one study suggesting that evening cortisol levels may rise in response 
to such conditions, and a second suggesting that trait anxiety is associated with a 
flattened afternoon decline in cortisol (Obel et al. 2005; Kivlighan et al. 2008). 
 HPA axis reactivity appears to be diminished during pregnancy: women 
administered CRH tests during late pregnancy were found to lack an ACTH or CRH 
response, and pregnant women exposed to simple physical stressors in late 
pregnancy were also found to lack a cortisol response (Schulte et al. 1990; 
Kammerer et al. 2002). This may help explain the low correlation between maternal 
stress and circulating glucocorticoids seen in other studies. As maternal cortisol 
production increases near term, under the influence of placental CRH, the maternal 
adrenal cortex may have limited capacity to respond to stress. Nevertheless, even in 
studies where the association between maternal anxiety and child outcome is weak, 
maternal cortisol levels have been found to predict infant outcomes, suggesting that 
the mother’s HPA axis may be able to influence fetal development (Gutteling et al. 
2006).   
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1.8 Programming and the Placenta 
The placenta is likely to be an important site of mediation for programming effects. 
This organ develops early in pregnancy, and plays crucial roles in regulating proper 
fetal development, endocrine function, metabolism, nutrient exchange and also 
works as a barrier and filter against a number of potential toxins in the maternal 
bloodstream. Placental function is an important factor in fetal growth and 
development. The balance between placental and fetal growth, and any 
developmental compromises of each relative to one another, is also likely to be an 
important component of programming effects. 
 
1.8.1 Placental Structure and Development 
The placenta essentially comprises an inner network of vasculature surrounded by an 
outer epithelium, or trophoblast (Cross 2000). The trophoblast layer is highly 
differentiated, with numerous cell subtypes that have specialized endocrine, 
immunological and transport functions. Among these subtypes are cells that fuse into 
a syncytium termed the syncytiotrophoblast. In order to maximize the surface area 
over which nutrient exchange can take place, the conceptus must initiate intimate 
contact with the maternal bloodstream through extensive invasion of the lining of 
uterus. This involves a number of complex processes occurring throughout much of 
pregnancy. 
The first stage of placental development involves decidualisation of the uterus, a 
process involving the conversion of uterine stromal cells to large, secretory decidual 
cells, as well as the recruitment of macrophages and lymphocytes (Malassine et al. 
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2003). In humans, rapid trophoblast proliferation takes place shortly after blastocyst 
adhesion (Malassine et al. 2003). The trophoblast cell lineage first appears at the 
blastocyst stage, just prior to implantation, as a simple epithelium termed the 
trophectoderm. Differentiation at this stage is determined in two ways: location and 
gene expression. Only cells in the outer layer of the blastocyst will form the 
trophoblast lineage, while cells on the interior differentiate into the inner cell mass. 
Furthermore, trophoblast lineage cells discontinue expression of the transcription 
factor OCT4 at the time of differentiation, while ICM cells continue to express it 
(Cross 2000). By day 21 of human pregnancy, the definitive structure of the placenta 
is apparent as the chorionic villus becomes established; and the trophoblast further 
differentiates into villous and extravillous trophoblast (Malassine et al. 2003). 
The villous phenotype involves the cytotrophoblastic cells of the floating villi 
remaining attached to the basement membrane to form an epithelial cell monolayer 
(Malassine et al. 2003). It is these cells that will, through proliferation and fusion, 
form the syncytiotrophoblast, a multinucleated cell layer that covers the entire 
surface of the villus. While the primary function of the syncytiotrophoblast is 
absorption and exchange, it also has important hormonal functions. 
The extravillous trophoblast is formed as cytotrophoblasts of the anchoring villi in 
contact with the uterine wall begin to proliferate, detaching from the basement 
membrane and forming columns of cells that invade the uterine wall. Invasion takes 
place through two routes: the first involves invasion via the uterine stroma as 
trophoblastic cells migrate towards the decidual arterial wall, while the second 
involves infiltration of the lumens and walls of the spiral arteries by extravillous 
trophoblastic cells, leading to complete remodeling of the spiral artery wall and the 
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destruction of the muscle layer and replacement of the endothelial layer with 
trophoblastic cells (Pijnenborg et al. 1981; Kaufmann et al. 2003). In order to protect 
the developing fetus from excess oxygen early in gestation, endovascular 
trophoblasts form intra-arterial plugs, which prevent maternal blood from entering 
the intervillous space until the 12th week of gestation. Defects in arterial remodelling 
are thought to be involved in the development of pre-eclampsia. 
The placenta is a glucocorticoid responsive organ: glucocorticoids are key regulators 
of the production of a number of substances in the placenta, including human 
chorionic gonadotrophin (hCG), CRH as well as glucose transporters (Jones et al. 
1989a; Ringler et al. 1989; Hahn et al. 1999; Lee et al. 2005). Glucocorticoids are 
also crucial for the expression of extracellular matrix proteins by placental 
fibroblasts, and are thus important for placental growth and integrity (Lee et al. 
2004). 
 
1.8.2 Placental function 
The primary function of the placenta is nutrient exchange, and the major determinant 
of intrauterine growth is placental nutrient supply (Fowden et al. 2006a). Placental 
weight, used as a surrogate measure of the surface area of the maternal-fetal 
interface, has been found to correlate with fetal weight in a number of species 
(Fowden et al. 2009). The nutrient transfer capacity of the placenta is dependent 
upon a number of factors, including size, morphology, transporter abundance and 
blood supply (Fowden et al. 2006a; Fowden et al. 2006b; Fowden et al. 2009). If 
any of these factors are altered, intrauterine growth may be affected (Fowden et al. 
2006a; Jones et al. 2007). Expression of a number of key placental nutrient 
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transporters, including System A Amino Acid Transporters 1 and 2 (SNAT1 and 
SNAT2), are upregulated in the placentas of rats fed high fat diets; furthermore, 
expression of these nutrient transporters is increased in human placental trophoblast 
cells when exposed to inflammatory cytokines such as IL-6 and TNF-α, suggesting 
that inflammation may increase placental transport (Jones et al. 2009a; Jones et al. 
2009b). Cortisol has also been shown to stimulate SNAT2 expression in human 
placental cells, suggesting that alterations in maternal HPA activity may influence 
nutrient availability to the offspring (Jones et al. 2006). 
The placenta also has important endocrine functions, many of which influence fetal 
growth and pregnancy outcome (Fowden et al. 2009). In humans, the placenta 
produces the steroid hormones estrogen and progesterone, as well as CRH and hCG 
(Shibasaki et al. 1982; Pepe and Albrecht 1995 ). 
 
1.8.3 The Programming Effects of Placental 11βHSD2 
A number of studies have highlighted the potential role that 11βHSD2 may play in 
mediating programming effects. Downregulation of placental 11βHSD2 may lead to 
an increased fetal exposure to maternal cortisol, with potential effects on 
development. Pharmacological blockage of 11βHSD2 by carbenoxolone during 
pregnancy has been associated with an increase in amygdalar glucocorticoid receptor 
mRNA expression and increased basal corticosterone in mice (Welberg et al. 2000). 
Genetic knockout of the gene encoding the enzyme in pregnant mice resulted in 
increased anxiety in the adult offspring, although corticosterone levels did not differ 
from controls (Holmes et al. 2006). 
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In humans, reduction in placental 11βHSD2 has been found in a number of 
complications of pregnancy, including pre-eclampsia, preterm birth and IUGR 
(McCalla et al. 1998; Murphy et al. 2002b; Kajantie et al. 2006; Dy et al. 2008). 
Birth weight and placental size have been shown to correlate with reduced placental 
11βHSD2 (Stewart et al. 1995; Murphy et al. 2002a). Congenital 11βHSD2 
deficiency has also been associated with low birth weight and increased risk of 
hypertension (Edwards et al. 1993; Kotelevtsev et al. 1999).  
Maternal prenatal stress has been shown to affect placental 11βHSD2 activity and 
mRNA transcript levels. Pregnant rats exposed to stressors near the end of pregnancy 
have been found to have reduced levels of placental 11βHSD2 mRNA and activity; 
offspring were smaller and had smaller adrenals (Mairesse et al. 2007). Chronic 
stress may have particular effects: while acute stress in rats has been associated with 
increased 11βHSD2 activity, chronic stress did not alter 11βHSD2 activity (Welberg 
et al. 2005). Crucially, rats previously exposed to chronic stress did not show 
increased placental 11βHSD2 activity in response to an acute stressor, suggesting 
that chronic stress may prevent the potentially protective upregulation in 11βHSD2 
(Welberg et al. 2005). In humans, maternal stress may increase the permeability, or 
‘leakiness’, of the 11βHSD2 barrier as indicated by a strong positive correlation 
between maternal and fetal amniotic cortisol concentrations in women with high 
anxiety (Glover et al. 2009). A stress-induced downregulation of 11βHSD2 may 
allow more cortisol to cross the placenta into the fetal compartment, resulting in 
decreased fetal ACTH, impaired fetal adrenal growth and lower birth weight and 
immaturity. 
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Maternal diet may also affect the activity of placental 11βHSD2. Reducing protein 
intake by 50% in pregnant rats has been shown to reduce activity of 11βHSD2 by 
33%, along with reduced birth weight and increased blood pressure at 7 weeks in the 
offspring (Langley-Evans et al. 1996a; Langley-Evans et al. 1996b). Similar effects 
have been observed in sheep (Lesage et al. 2001a; Whorwood et al. 2001). The 
effects on blood pressure were reversed when maternal glucocorticoid production 
was blocked with metyrapone (Langley-Evans 1997). These findings suggest that 
maternal diet may influence fetal growth and development via alterations to 
placental 11βHSD2 and the fetal HPA axis, potentially leading to programming 
effects.  
A recent study by Cottrell et al found that pregnant mice fed a low protein diet 
through pregnancy showed elevated fetal glucocorticoids and reduced placental 
growth in mid-gestation, with reduced fetal growth near term; taken together, these 
results suggest that maternal diet can impact fetal glucocorticoid exposure and HPA 
axis function (Cottrell et al. 2012). However, the study also found that despite a fall 
in 11βHSD2 activity near term, activity was higher earlier in gestation, suggesting 
that the observed increase in fetal glucocorticoids may be independent of changes in 
placental 11βHSD2 (Cottrell et al. 2012). The study also raises the possibility that 
the fetal HPA axis takes the primary role in regulating fetal exposure to 
glucocorticoids and maturation and growth rates in situations of limited nutritional 
availability. 
In light of the lack of evidence for a correlation between maternal stress and 
increased cortisol levels during pregnancy, an alternative mechanism has been 
proposed which will still result in fetal glucocorticoid overexposure: maternal stress 
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has been shown to downregulate expression of the placental glucocorticoid barrier 
enzyme 11βHSD2, leading to increased fetal exposure to maternal glucocorticoids 
independent of alterations in maternal HPA axis activation (O'Donnell et al. 2012).  
 
1.9 Epigenetics 
The term ‘epigenetics’ was coined in 1942 by Conrad Waddington to describe how 
genotype regulates development, with the epigenetic ‘landscape’ determining the 
eventual fate of genetically homogenous cells through differentiation (Holliday 
2006). However, the term is now more commonly used to describe changes in gene 
function without alterations to the DNA sequence (Jaenisch and Bird 2003). A 
number of epigenetic marks are thought to mediate this effect, including DNA 
methylation, histone modifications and non-coding RNAs (Reik and Walter 2001; 
Jaenisch and Bird 2003; Holliday 2006; Bird 2007). 
DNA methylation, an important regulator of gene transcription, involves the addition 
of a methyl group to a cytosine, and most commonly occurs at cytosines in cytosine-
guanine (CpG) dinucleotides (Jaenisch and Bird 2003). In humans, 60 to 90% of all 
CpGs are methylated, depending on cell type (Ehrlich et al. 1982). DNA methylation 
generally inhibits the expression of genes in two ways: by physically blocking the 
binding of transcription factors and/or through the binding of methyl-CpG-binding 
domain proteins (MBDs) (Wade 2001; Jaenisch and Bird 2003; Fatemi and Wade 
2006; Choy et al. 2010). MBDs recruit histone deacetylases and other proteins 
involved in chromatin remodelling, leading to the formation of inactive 
heterochromatin (Wade 2001; Jaenisch and Bird 2003).  
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Environmental cues may influence DNA methylation, particularly during critical 
periods of development (Jaenisch and Bird 2003). In a recent study of the Dutch 
Hunger Winter, a severe wartime famine in the Netherlands at the end of the Second 
World War, adulthood DNA methylation of the gene IGF2 was found to be lower 
among individuals who were prenatally exposed to the famine compared to their 
unexposed siblings (Heijmans et al. 2008). Exposure to the famine was also 
associated with increased risk of impaired glucose tolerance, obesity, coronary heart 
disease and hypertension (Kyle and Pichard 2006). Alteration to DNA methylation at 
birth has also been suggested to predict later health: increased methylation of GR in 
neonatal cord blood has been associated with increased stress responsiveness at three 
months (measured using salivary cortisol obtained before and after a non-noxious 
stressor) itself a marker of later life disease (Oberlander et al. 2008). 
 
DNA methylation is especially important in the regulation of transcription of 
imprinted genes. These are genes that are expressed monoallelically in a parent-of-
origin specific manner. A number of disorders of human pre- and postnatal growth 
are associated with aberrant imprinting, including Beckwith-Wiedemann syndrome 
(which is associated with prenatal overgrowth) and Silver-Russell syndrome 
(associated with IUGR). IGF2 is an imprinted gene of crucial importance in 
mediating normal prenatal growth, and is expressed solely from the paternally 
inherited allele (Constancia et al. 2002) (Giannoukakis et al. 1993). Other key 
imprinted genes include the maternally-expressed gene PHLDA2, increased placental 
expression of which has been associated with low birth weight and IUGR, and 
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maternally-expressed CDKN1C, also associated with IUGR (McMinn et al. 2006; 
Apostolidou et al. 2007). 
 
1.9.1 IGF2 
IGF2 is a paternally expressed gene in both the fetus and all zygote-derived cell 
types in the placenta, and acts as a growth factor during development (Reik et al. 
2003). In the placenta, IGF2 is a major regulator of placental growth, acting as a 
potent growth factor; knockout of IGF2 in murine placentas leads to reduced growth 
of the placenta as well as fetal growth restriction (DeChiara et al. 1990; Constancia 
et al. 2002; Reik et al. 2003). In small for gestational age children, placental 
expression of IGF2 is lower compared to controls at term (Guo et al. 2008).  
The epigenetic control of IGF2 expression is unusual, as silencing of IGF2 is not a 
direct result of methylation of the maternal allele. In humans, imprinting of IGF2 is 
controlled by CG-rich differentially methylated regions (DMRs), including the IGF2 
DMR0 located between exons 2 and 3, IGF2 DMR2, located between exons 8 and 9, 
and the H19 DMR, located 4kb upstream of the non-protein coding gene H19 
(Dejeux et al. 2009). Methylation of IGF2 in placental samples, particularly at DMR 
0 and DMR 2, correlates with neonatal birth weight in humans (St-Pierre et al. 
2012). Studies involving the children of the Dutch Hunger Winter found that 
prenatal exposure to famine conditions was associated with lower DNA methylation 
of IGF2, suggesting that methylation of the IGF2 DMRs may modulate birth weight 
in a diet-dependent manner (Heijmans et al. 2008). 
The H19 DMR is responsible for establishing the imprinting of both the paternally-
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expressed IGF2 as well as that of the maternally-expressed H19 (Leighton et al. 
1995; Ripoche et al. 1997; Thorvaldsen et al. 1998; Szabo et al. 2004). The activity 
of this DMR is dependent upon its methylation status (see Figure 1-5). The DMR is 
hypomethylated on the maternal chromosome, and is able to bind the protein CTCF 
(Bell and Felsenfeld 2000). This binding blocks the interaction of the IGF2 promoter 
with downstream enchancers, leading to silencing of IGF2 (Schoenherr et al. 2003; 
Szabo et al. 2004). Hypomethylation of the DMR, and CTCF binding, is necessary 
for the initiation of maternal H19 expression (Thorvaldsen et al. 2006). On the 
paternal allele, the DMR is hypermethylated, a condition that is maintained 
throughout development (Tremblay et al. 1997). This not only silences H19 
expression, but also prevents CTCF binding, in turn allowing the paternal IGF2 to 
access downstream enhancers and be expressed (Bell and Felsenfeld 2000; Engel et 
al. 2006). 
IGF2 is further regulated by a gene expressed from the maternal allele, the insulin-
like growth factor 2 receptor (IGF2R). IGF2R targets IGF2 proteins for degradation, 
thereby attenuating the signalling effects of IGF2 (Wang et al. 1994; Coan et al. 
2005). This interaction is characteristic of the ‘conflict theory’, whereby the paternal 
genome drives feto-placental growth (to ensure healthy offspring) while the maternal 
genome constrains it (thus protecting the health of the mother). 
 
 





Figure 1-5. Imprinting regulation of H19 and IGF2 on paternal and maternal chromosomes by 
the H19 DMR. Filled lollipops indicate CpG methylation, black arrows indicate interaction 
between enhancers and genes. IGF2 DMR0, located upstream of IGF2, is not shown. Adapted 
from Engel, Thorvaldsen and Bartolomei, 2006. 
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1.9.2 Methylation and the regulation of glucocorticoid 
exposure: GR and 11βHSD2 
A number of studies have attempted to address the possible role of methylation of 
GR and 11βHSD2 in pregnancy outcome.  
Transcription of the gene encoding GR is regulated in part by a complex 5’ structure, 
made up of a number of alternative untranslated first exons that are spliced onto a 
common acceptor site in exon 2 (McCormick et al. 2000; Presul et al. 2007; Turner 
et al. 2010). These alternative first exons are located in two promoter regions: a 
proximal promoter region approximately 5kb upstream of the translation start site, 
and a distal promoter region more than 30kb further upstream (Presul et al. 2007). 
These alternative first exons are thought to regulate GR expression in a tissue-
specific manner, with the majority of placental GR derived from the GR 1C 
promoter (Johnson et al. 2008a). 
Studies have suggested that methylation of the GR promoter is affected by maternal 
stress in the early-life environment, potentially leading to programming effects 
(Mueller and Bale 2008; Oberlander et al. 2008; Turner et al. 2008; Turner et al. 
2010; Cao-Lei et al. 2011; Hompes et al. 2013). There is also evidence to suggest a 
role for GR methylation in predicting birth weight: increased methylation of the GR 
promoter in the placenta, predicted to result in lower expression of GR and thus 
reduced glucocorticoid signalling, has been linked to higher birth weight (Filiberto et 
al. 2011). Furthermore, a small study demonstrated a link between maternal 
depression/anxiety and increased methylation of the GR promoter in neonate cord 
blood, itself associated with increased stress response 3 months postnatally, a marker 
of later life disease (Oberlander et al. 2008). 
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The regulation of 11βHSD2 transcriptional activity may be an important determinant 
in pregnancy outcomes, including birth weight. Increased methylation of the 
11βHSD2 promoter is associated with lower transcription, and increased methylation 
of this gene in the placenta has also been shown to associate with lower birth weight 
(Alikhani-Koopaei et al. 2004; Marsit et al. 2012). Increased placental 11βHSD2 
methylation was associated with altered newborn behaviour with reduced quality of 
movement scores (Marsit et al. 2012).  
Few studies have examined the effects of maternal obesity on methylation of either 
GR or 11βHSD2 during pregnancy. However, a study by Drake et al found that both 
11βHSD2 and GR methylation positively associated with increased adiposity and 
blood pressure in buffy coat samples taken from adults whose mothers had 
consumed unbalanced diets during pregnancy; importantly, methylation of GR was 
increased in the offspring whose mothers had the most unbalanced diets, suggesting 
that nutrient intake may affect glucococorticoid exposure and sensitivity via 
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Aims and Hypothesis 
This thesis aims to test the hypothesis that in humans the programming effects of 
maternal obesity and maternal stress are mediated by altered action of 
glucocorticoids on the developing fetus. 
 
In chapter 3, the effects of maternal obesity on the maternal HPA axis are explored 
through the measurement of circulating cortisol, CBG and CRH throughout 
pregnancy in a cohort of very severely obese and lean women. The relationships 
between maternal HPA axis activity, maternal weight gain and birth outcomes are 
investigated. 
In chapter 4, whether maternal obesity is associated with altered placental expression 
of genes regulating fetal glucocorticoid exposure and fetal/placental development in 
each trimester of pregnancy is explored. 
In chapter 5, pyrosequencing is used to test whether differences in gene mRNA 
levels associated with maternal obesity in the placenta are explained by differences 
in DNA methylation. 
Finally, in chapter 6, the effects of maternal stress and anxiety on placental 
expression of genes regulating glucocorticoid exposure are explored in two 
prospective cohorts of women who completed stress and anxiety questionnaires 
during pregnancy. 




Chapter 2:  
Materials and Methods 
 
!
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2.1 Clinical Methods 
2.1.1 Longitudinal study of very severely obese pregnancy   
2.1.1.1 Subject Recruitment 
The University of Edinburgh and NHS Lothian Hospitals Trust established an 
Antenatal Metabolic Clinic (AMC) in Edinburgh, with support from Tommy’s the 
Baby Charity (www.tommys.org), to care for pregnant women who are very severely 
obese at antenatal booking (i.e. with a BMI >40kg/m2). The main research focus of 
the clinic is to understand problems that arise during pregnancy due to maternal 
obesity. Women attending this clinic receive normal antenatal care and are also seen 
by a specialist dietician who provides them with personalised advice about healthy 
eating during pregnancy. A lean group (with a BMI between 20 and 25kg/m2) was 
recruited in parallel. These women received their antenatal care in the community 
but attended the research clinic for research visits. Exclusion criteria included pre-
existing type 1 or type 2 diabetes mellitus and non-singleton pregnancy. All women 
participating in the research study are characterised in terms of BMI, stress and 
anxiety levels and blood pressure throughout pregnancy. The ethical approval for 
this study was obtained from the NHS Lothian Research Committee (REC reference 
number 08/S1101/39). Written informed consent was obtained from all participants. 
 
 
2.1.1.2 Assessing Maternal Mood and Anxiety 
Participants were asked to complete validated questionnaires to assess mood 
(including stress at home, work, stress over money, stress over life events, 
satisfaction with life and anxiety) as well as the Spielberger State and Trait Anxiety 
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Inventory. !Maternal anxiety was measured using the Spielberger State and Trait 
Anxiety Inventory (STAI), commonly used to measure acute situational anxiety 
(‘state’ anxiety) as well as anxiety as a general, long term personality trait (‘trait’ 
anxiety). The test consisted of 25 items including both positive (e.g. ‘I feel calm’) 
and negative (e.g. ‘I feel exhausted’) emotions, each scored using a four-point scale 
ranging from ‘Never’ (score 1) to ‘Always’ (score 4). Questionnaires were 
completed at Visit 1 (~16 weeks gestation) and at Visit 2 (~28 weeks gestation). 
2.1.1.3 Sample Collection 
Fasting morning blood samples were taken; height and weight were measured by 
nurses at three time points during pregnancy: 16 weeks gestation (‘visit 1’), 28 
weeks gestation (‘visit 2’), and 36 weeks gestation (‘visit 3’). Participants were also 
invited to attend a follow-up visit at 3 months postnatal. Samples were immediately 
centrifuged and serum and plasma stored at -80C for subsequent analysis. Three 
saliva samples were taken at visit 1, one at bedtime, a second at waking, and a third 
30 minutes after waking. Samples were centrifuged and stored at -20C for 
subsequent analysis. 
 
2.1.2 First Trimester Placenta Study 
Pregnant women with a healthy singleton pregnancy who underwent surgical 
termination of pregnancy during the first trimester were eligible for the study.  
The ethical approval for first trimester tissue study was obtained from the NHS 
Lothian Research Committee (LREC/04/S1103/20 (F)). Written informed consent 
was obtained from all participants. Patients with diabetes mellitus, patients receiving 
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corticosteroid-based medications, and patients who smoked were excluded from this 
study. 
2.1.2.1 Tissue Collection 
First trimester placental samples were collected from surgical terminations of 
pregnancy conducted between weeks 8 and 12 of gestation (mean gestation: 10 
weeks). Trophoblast tissue was separated from decidua and fetal tissues immediately 
following termination, and placed into RNAlater solution at 4˚C for 24 hours before 
freezing at -80˚C. Tissues for immunohistochemistry were collected and stored in 
4% neutral buffered formalin solution for 24 hours before transfer to ethanol. 
 
 
2.1.3 Second Trimester Placental and Liver Study 
Pregnant women with a healthy singleton pregnancy who underwent termination of 
pregnancy during the second trimester were eligible for the study. Written informed 
consent was obtained from all participants prior to tissue collection. 
 
2.1.3.1 Tissue Collection 
Second trimester placental and liver samples were collected from terminations of 
pregnancy conducted between weeks 12 and 16 of gestation. 
Approximately 30mg of tissue from the fetal side of the placenta was collected and 
stored in RNAlater solution at 4˚C for 24 hours before freezing at -80˚C. Tissues to 
be used for immunohistochemistry were collected and stored in 4% neutral buffered 
formalin solution for 24 hours before transfer to ethanol. 
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2.1.4 Term placental samples 
Term placenta samples (n = 60) were collected from healthy singleton term 
pregnancies after elective caesarean delivery as part of the Edinburgh Reproductive 
Tissue BioBank (http://www.crh.ed.ac.uk/biobank/). A single large biopsy was 
obtained from each placenta, equidistant between the edge of the placenta and the 
umbilical cord, avoiding areas of obvious infarction or damage. Biopsies were used 
for both gene expression and histology specimens. Placenta samples were stored in 
RNAlater solution for 24 hours prior to freezing at -80°C. Tissues for 
immunohistochemistry were collected in 4% neutral buffered formalin solution 
within 2 hours of birth, and stored for 24 hours before transfer to ethanol. 
 
2.1.5 PREDO Stress In Pregnancy Study 
2.1.5.1 Subject Recruitment 
The placental samples for this work were collected by our collaborator Professor 
Katri Raikonnen of the University of Helsinki, Finland. Participants in this study 
were recruited as part of the multidisciplinary PREDO-Project (‘Prediction and 
Prevention of Pre-eclampsia’). The PREDO study is composed of two arms, both of 
which provided placental samples for the gene expression study. The first arm 
comprised 947 pregnant women at high risk for pre-eclampsia and 117 pregnant 
control women without known pre-eclampsia risk factors. The recruitment of these 
women took place between September 2005 and December 2009, when the women 
attended their first ultrasound screening (between 12 and 14 weeks of gestation) in 
one of the ten hospital maternity clinics participating in the PREDO Project (the 
Women’s Hospital, Kätilöopisto Maternity Hospital and Jorvi Hospital at Helsinki 
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University Central Hospital, Kanta-Häme Central Hospital, Päijät-Häme Central 
Hospital, Tampere University Hospital, Kuopio University Hospital, Northern 
Karelia Central Hospital and Iisalmi Hospital). The inclusion and exclusion criteria, 
and the aspirin trial embedded in the study design of the first study arm, are 
described in Villa et al 2013. A further 4171 mothers were recruited for the 
epidemiological arm of the PREDO project between April 2007 and February 2010 
while attending their first ultrasound screening (between 12 and 14 weeks of 
gestation) in one of the five hospital maternity clinics participating in the PREDO 
Project (Women’s Hospital, Kätilöopisto Maternity Hospital and Jorvi Hospital at 
Helsinki University Central Hospital, Kanta-Häme Central Hospital, or Päijät-Häme 
Central Hospital). Written informed consent was obtained from all participants in 
both study arms. 
Maternal age, smoking status, parity, occupation, pre-pregnancy body mass index 
(BMI), and medical/obstetric history were derived from hospital birth records and 
the Finnish national birth register. Education and alcohol consumption during 
pregnancy were self-reported. 
2.1.5.2 Assessing Maternal Mood and Anxiety 
All participants of the PREDO study were invited to complete a set of standardized 
and validated questionnaires, aimed at measuring stress, depression, anxiety and 
anger throughout pregnancy at two-week intervals beginning between 12 and 14 
weeks of gestation, and ending two weeks postpartum. Questionnaires took 
approximately 30 to 40 minutes to complete each time, and the mothers returned the 
questionnaires after the final assessment. Maternal anxiety was measured using the 
Spielberger State and Trait Anxiety Inventory (STAI), commonly used to measure 
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acute situational anxiety (‘state’ anxiety) as well as anxiety as a general, long term 
personality trait (‘trait’ anxiety). Anxiety was assessed using the STAI every two 
weeks, at 14 time points during pregnancy beginning approximately at 12+0 to 13+6 
weeks+days of gestation. The mean scores for first, second and third trimesters, as 
well as the mean score for pregnancy overall, were calculated and used in 
subsequent analyses. Scores for the positive and negative emotion subscales, as well 
as scores for the questions related to curiosity, were also calculated, and the mean 
values for each trimester and over the entirety of pregnancy were used in analyses. 
Maternal personality traits were measured using the NEO Personality Inventory at 
the first assessment, between approximately 12 and 14 weeks of gestation. 
Personality was assessed by 96 questions measuring Neuroticism and Extraversion. 
Each item was measured using a five-point scale, ranging from ‘Strongly disagree’ 
(score 0) to ‘Strongly agree’ (score 4). Anxiety was measured as a subcomponent of 
‘neuroticism’ with 8 questions. 
!
2.1.5.3 Sample Collection 
Placenta samples (n = 67) were collected from healthy singleton term (37 to 42 
weeks of gestation) pregnancies a maximum of 90 minutes after vaginal (n = 48) or 
caesarean delivery (n = 19). Given the heterogeneity of the placenta, 9-site biopsies 
were obtained avoiding areas of obvious infarction or damage. Placenta samples 








2.2.1 General Chemicals 
Unless otherweise stated, all chemicals were purchased from Sigma (see Appendix 
for supplier addresses). 
TaqMan Gene Expression Assays 
AmpliTaq Gold PCR master mix 
Applied Biosystems 
GelRed Nucleic Acid Gel Stain Biotium, Inc 
Liquid DAB+ Chromogen System Dako 
Cortisol Radioimmunoassay, 96 tests 
CBG Radioimmunoassay, 96 tests 
DIASource 
1 kB DNA ladder 
NuPage LDS Sample Buffer 
NuPage Transfer Buffer 
NuPage MES SDS Running Buffer 
NuPage Sample reducing agent 
NuPage 4-12% Bis-Tris Gels 
Oligo Primers 
Invitrogen 
Streptavidin Sepharose Beads GE Healthcare 
IRDye goat anti-rabbit 800CW IgG Li-Cor Biosciences 
SeaKem LE Agarose 
PBS 
Lonza 




Taq DNA Polymerase 
1kB DNA ladder 
Reverse Transcriptase 
Promega 
RNeasy Mini Kit 
RNase-free DNase set 
PyroMark Q24 Reagents kit 
PyroMark Wash Buffer 
Epitect Bisulfite Kit 
Qiagen 
LightCycler 480 Probes Master 
Universal Probe Library Probes 
Roche Applied Science 
 
  





Agilent 2100 Bioanalyser Agilent Technologies 
Graduated microtubes 2.0ml  Anachem Ltd 
Power Pack 200 agarose gel system Bio-Rad 
BioMat Class II microbiological Safety cabinet Contained Air Solutions 
Eppendorf 5415 R centrifuge 
Eppendorf 5810 R centrifuge 
Eppendorf 
GS-1 Thermal Cycler G-Storm 
XCell SureLock Mini-Cell Electrophoresis 
System Nitrocellulose Membrane Filter Paper 
Sandwich pore size 0.45 um 
Invitrogen 
Wetzlar 1512 rocking microtome  
 
Leitz 
Odyssey Infrared Imager LI-COR Biosciences 
Milli-Q integral water purification system Millipore 
OPTImax tunable microplate reader Molecular Devices 
Nanodrop ND-1000 Nanodrop Technologies 
0.5ml, 1.5ml tubes Sarstedt 
Surgical Instruments Sigma Aldrich 
0.2 ml strip-tubes with lids StarLab 
Disposable Scalpels Swann-Morton 
Shandon Sequenza racks 
MB35 Premier microtome blades 
Microscopic slides 
Cover Glass Round 22x22mm Thickness no.1 
Sterlilin Petri dishes 
Thermo-Scientific 
UviPro system UviTec 
Zeiss Axioscop Microscope Zeiss 
 
  





Agilent 2100 Bioanalyser 2100 Expert Software (Agilent Technologies) 
LightCycler 480 LightCycler 480 release 1.5 O SP3 (Roche) 
Nano-Drop ND-1000 
spectrometer 
ND-1000 v3.3 (Nanodrop Technologies) 
Odyssey Infrared Imager Odyssey v3.0 (LI-COR Biosciences) 
Statistical analysis Minitab 16 (Minitab) 
GraphPad Prism 5 (GraphPad) 
SPSS (IBM) 
PyroMark Q24 Q-CpG (Biotage/Qiagen) 
Zeiss Axioscop Microscope 
 
KSM 300 3.0 (Zeiss) 
 
 
2.2.4 Solutions and Buffers 
All solutions were prepared with Milli-Q water unless stated otherwise.  
Acid alcohol: 1% v/v hydrochloric acid (37% HCl) in 74OP  
Blocking buffer (western blot): 5% w/v Blotting-grade non-fat dry milk in TBST  
Citrate buffer (10X, immunohistochemistry): 0.1M citric acid, pH 6 
DEPC-water: 1 drop of diethylpyrocarbonate (DEPC) per 100ml, leave for 1-24h, 
autoclave  
DNA ladder: 25% v/v 1kb DNA ladder (Promega), 25% v/v TE buffer, 50% v/v 
Orange G loading dye  
DNA/RNA loading buffer: 0.3% w/v Orange G, 40% v/v glycerol 
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Lysis buffer (SDS-PAGE): 25 mM HEPES, 68.5 mM NaCl, 0.5 mM MgCl2, 0.5 
mM CaCl2, 5 mM NaF, 1 mM EDTA, 5 mM sodium pyrophosphate, 1% NP-40, 
10% glycerol, 1X PIC  
Phosphate buffered saline (PBS): 1 PBS tablet per 200 ml  
PIC (Protease Inhibitor Cocktail, 25X): Tablet of complete protease inhibitor 
cocktail dissolved in 2ml  
Running buffer (SDS-PAGE): 1X NuPAGE MES SDS running buffer 
(Invitrogen), 0.05% v/v NuPAGE® Antioxidant  
Scott’s tap water: 24 mM sodium bicarbonate, 166 mM magnesium sulphate in tap 
water  
TBE (10x): 0.9M Tris, 0.9M boric acid, 12.5 mM EDTA  
TBS (10X): 0.2M Tris, 1.37M NaCl; pH 7.6  
TBST: 0.1% v/v Tween-20 in 1xTBS  
TE: 10 mM Tris pH 8.0, 1 mM EDTA  
Transfer buffer (western blot): 1X NuPAGE Transfer buffer, 20% v/v methanol, 
0.1% NuPAGE Antioxidant  
Tris-Phosphate buffer: 0.1M Tris, 32 mM phosphoric acid; pH 7.8 
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2.3 Laboratory Materials and Methods 
2.3.1 Quantitative Real Time PCR 
The mRNA transcript abundance of specific genes of interest was quantified using 
qPCR. This involves the extraction of RNA from tissues, followed by reverse 
transcription to generate complimentary DNA (cDNA). The cDNA undergoes qPCR 
using specific primers (generally intron-spanning) and Taq DNA polymerase in 
order to amplify specific genes of interest. Quantification is achieved through the use 
of fluorescent probes. These probes incorporate a fluorescent reporter and a 
quencher. The close proximity between the two prevents detection of the reporter’s 
fluorescence. As polymerisation of the cDNA takes place, the 5’ to 3’ exonuclease 
activity of Taq polymerase leads to the degradation of the probe, separating the 
reporter and the quencher. The separation of the reporter from the quencher results in 
an increase in fluorescence. By measuring the rate of change in fluorescence, the 
abundance of mRNA transcript can be determined. The mRNA transcript 
concentrations of genes of interest are assessed relative to the mRNA levels of 
reference, or control, genes, in order to control for reverse transcription efficiency. 
 
2.3.1.1 RNA Extraction From Placenta and Liver 
RNA extraction was performed using RNeasy mini kits from Qiagen, West Sussex, 
UK. 
Approximately 30mg of tissue was excised from each sample on dry ice, and placed 
in a flat-bottomed 2ml microtube with 600µl of buffer RLT with 10µl/ml of b-
mercaptoethanol, as described in the Qiagen RNeasy Mini Kit Handbook Animal 
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Tissues protocol. All samples were homogenised until no visible particles of tissue 
remained in the lysate. Samples were then stored on dry ice prior to RNA extraction.  
Lysates were centrifuged for 3 minutes at 13,000rpm, and the supernatant transferred 
to a 2ml microtube, and the remainder (including pellets) discarded. 600µl of 70% 
ethanol was added to the homogenate and mixed thoroughly with a pipette. Up to 
700µl of this solution was transferred to spin columns placed in 2ml collection tubes. 
The columns were centrifuged for 15 seconds at 10,000rpm. Flow-through was 
discarded. For samples with total volumes exceeding 700µl, the remainder (up to 
700µl each time) was transferred to the spin columns and centrifuged for 15 seconds 
at 10,000rpm, and the flow-through was discarded. 
350µl of Buffer RW1 was added to each spin column, and spin columns were then 
centrifuged for 15 seconds at 10,000rpm. Flow-through was discarded. 80µl of 
DNase I solution (Qiagen) was added to each sample, and left to incubate for 15 
minutes at room temperature. After incubation, 350µl of Buffer RW1 was added to 
each sample, and samples were centrifuged for 15 seconds at 10,000rpm. Flow- 
through was discarded.  
500µl of Buffer RPE (Qiagen) was added to each column, and columns were 
centrifuged for 15 seconds at 10,000rpm. Flow-through was discarded. A further 
500µl of Buffer RPE was added to each column, and columns were centrifuged for 2 
minutes at 10,000rpm. Flow-through was discarded. Each spin column was placed 
into a fresh 2ml collection tube, and centrifuged for 1 minute at 10,000rpm. 
Spin columns were then placed in fresh 1.5ml microtubes. 35µl of RNase-free water 
was added to each column for elution of total RNA. Columns were centrifuged for 1 
minute at 10,000rpm. The flow-through was then re-added to the spin columns, and 
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columns were once again centrifuged for 1 minute at 10,000rpm. Purified samples 
were stored at -80°C.  
 
 
2.3.1.2 RNA Quantification 
The RNA concentration and purity of all samples was assessed using a Nanodrop 
ND-1000 spectrophotometer (Thermo Fisher Scientific, UK). The ND-1000 software 
calculated RNA concentrations in ng/µl using the Beer-Lambert law. 2µl of RNA 
was quantified by ultraviolet absorbance at wavelengths of 260nm, and purity was 
assessed by comparison to absorbance at 230nm (260/230 ratio) for contaminants 
such as salts, and 280nm (260/280 ratio) for contaminants including protein. 
Samples that were measured to have ratios between 1.8 and 2.1 were considered 
suitable for use.  
 
2.3.1.3 RNA Quality Assessment 
The integrity of RNA was confirmed by separating ribosomal RNA (rRNA) using 
electrophoresis in a 1% agarose/0.5xTBE (45mM Tris-borate, 1mM EDTA) gel with 
0.1µl/ml Gel Red (Biotium, Hayward, CA, USA) at ~90V for 30 to 50 minutes. To 
prepare the gels, agarose was melted in TBE buffer using a microwave oven, and 
GelRed nucleic acid dye was added to the molten agarose (at 0.0005% 
concentration). Once cooled, the mix was poured into a tray. Samples were mixed 
with Orange G loading dye in a 1:5 ratio and loaded onto the gel together with a 
DNA ladder.  
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Gels were visualised under UV light (λ=260nm), and RNA integrity was determined 
by the presence of two clear bands corresponding to 28S and 18S RNA with no 
smearing. Smeared samples without clear bands were regarded as degraded RNA. 
 
 
2.3.1.4 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA was reverse transcribed using the Access RT-PCR system (Promega, 
Southampton, UK). 
The measured concentration of total RNA in each sample was used to calculate the 
volume of nuclease free water needed to dilute the RNA concentration to 25ng/µl in 
a total volume of 12.7µl. The total RNA concentration of samples was then 
confirmed using a Nanodrop ND-1000 spectrophotometer as previously described, 
leaving a volume of 10.7µl.  
Diluted samples were then incubated at 70°C for 10 minutes in a PCR machine 
(GS1, G-Storm, Somerset, UK). Reagents were added to each sample as follows:  
 
4µl of MgCl2 (5mM) 
 2µl of 10x AMV RT Buffer  
2µl of 1mM dNTP mixture 
0.5µl of Recombinant RNasin Ribonuclease Inhibitor (1u/µl) 
0.6µl of Avian Myeloblastosis Virus (AMV) RT polymerase enzyme (15u/µg)  
0.2µl of oligo dT mix 
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Two negative controls, one with no RNA and a second with no AMV-RT enzyme, 
were used to ensure that reagents were not contaminated and contained no DNA.  
Samples were incubated at room temperature for 10 minutes for annealing and 
extension, then incubated at 42°C for 15 minutes, then at 95°C for 5 minutes. 
Samples were then stored at -20°C. 
 
2.3.1.5 Real Time Quantitative PCR  
The abundance of cDNA was quantified using a LightCycler 480 machine (Roche 
Applied Science, Burgess Hill, UK). 
2.3.1.5.1 Assay design and Evaluation  
Assays were designed using the Universal Probe Library system (UPL; Roche). This 
system utilises a fluorophore, fluorescein amidite (FAM), to enable quantification of 
PCR product. Oligonucleotide primers for UPL assays were ordered from Invitrogen 
(Invitrogen Ltd, Paisley, UK). UPL assays were designed using the UPL Assay 
Design Centre (Roche) to include intron-spanning boundaries where possible. Where 
no suitable UPL assay was available, a commercially designed assay was used, 
TaqMan Gene Expression Assays purchased from Applied Biosystems (ABI), CA, 
USA). For a list of primers and probes used, see Tables 2-1 and 2-2. !
2.3.1.5.2 Real Time PCR Preparation 
Equal volumes of each sample were pooled together to make a ‘stock’ solution, 
which was serially diluted from 1:4 to 1:2048. These serial dilutions were used as a 
standard curve against which the relative cDNA concentrations of samples could be 
calculated. Primer/probe sequences were validated against the standard curve on 384 
well plates using the Roche Lightcycler 480 system (Roche).  
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Samples (diluted in nuclease-free water to 1:20), standards and controls (diluted as 
per samples) were added, 2µl, to a 384 well plate in triplicate. To this 8µl of master 
mix was added. 
Master mix constitution varied between UPL and ABI assays. For UPL assays, 5µl 
of Lightcycler 480 Master Mix, 2.86µl of PCR-grade water, 0.02µl of 100µM 
forward primer, 0.02µl of 100µM reverse primer, and 0.1µl of probe was added per 
well. For ABI assays, 5µl of Lightcycler 480 Master Mix, 2.5µl of sterile water and 
0.5µl of ABI primer-probe mix was added to each well.  
Plates were sealed, and centrifuged at 1500rpm for 2 minutes to ensure samples and 
mastermix were at the bottom of the wells. Reaction conditions for real-time PCR 
included a pre-incubation step of 5 minutes at 95°C. Samples then underwent 50 
PCR cycles consisting of: denaturation at 95°C (10 sec), annealing at 60°C (30 sec), 
elongation at 72°C (30 sec).  This was followed by a cooling step (30s at 40°C). 
The LC480 software (Roche) measured fluorescence during PCR and plotted 
amplification curves (fluorescence against PCR cycle number). The crossing point 
(Cp) was calculated as the maximum point of the second derivative of the 
amplification curve.  
A standard curve of Cp versus log ‘concentration’ (i.e. serial dilution) was generated 
by the LC480 software. Curves were considered acceptable if reaction efficiency fell 
between 1.8 and 2.1. Mean mRNA ‘concentration’ from triplicates was interpolated 
from this graph for unknown samples using their Cp. The abundance of mRNA 
transcript for each sample was expressed relative to the abundance of a control gene. 
Control genes were selected for each tissue used by identifying genes for which 
abundance did not appear to be affected by maternal phenotype (i.e. BMI). 
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Table 2-1. List of Applied Biosystems TaqMan gene Expression Assays used for qPCR. 
 
Gene Forward Primer Reverse Primer Probe 
PPARγ gacaggaaagacaacagacaaatc ggggtgatgtgtttgaacttg 7 
CDKN1C aaccgctgggattacgact caggcgctgatctcttgc 18 
Leptin ttgtcaccaggatcaatgaca gtccaaaccggtgactttct 25 
GILZ ccgttaagctggacaacagtg atggcctgttcgatcttgtt 36 
LPL  aaactggtgggacaggatgt ccaaggctgtatcccaagag 25 
IGF2R agcagcaggaagataccacaa cacctccaaaatatatcaaggtga 58 
DLK1 gacggggagctctgtgatag gggcacaggagcattcata 68 
IL-6 caggagcccagctatgaact gaaggcagcaggcaacac 45 
GLUT 3 gggtgtggttaatactatcttcactg tcatatgcagagtccttcttcct 31 
H19 ttacttcctccacggagtcg ttgagctgggtagcaccatt 46 
11BHSD1 caatggaagcattgttgtcg ggcagcaaccattggataag 71 
IRS1 tgcatcttcgctccttcc atcctccgagagccaagtct 70 
IL-1β  tacctgtcctgcgtgttgaa tctttgggtaatttttgggatct 78 
MR tgggaattctgacttacttaacca aatacaaaaagctgatgcagacc 58 
Table 2-2. List of UPL designed assays for qPCR. 
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2.3.2 DNA Methylation Analysis 
2.3.2.1 Principle 
DNA methylation status of the genes IGF2, H19, GR and 11βHSD2 was analysed by 
pyrosequencing. Pyrosequencing involves the sequencing of DNA using a 
‘sequencing by synthesis’ principle. A single-stranded DNA sequence of interest is 
sequenced by enzymatic synthesis of a complementary strand one base pair at a time. 
Solutions of specific dNTPs are sequentially added and removed from the reaction. 
Pyrosequencing relies upon the detection of pyrophosphate released after nucleotide 
incorporation by DNA polymerase, producing light that can be detected by a camera 
(see Figure 2-1). 
Treatment of genomic DNA with bisulfite converts cytosine residues to uracil. 
However, 5-methylcytosine, or methylated cytosine (5mC), residues are not affected 
by this process (see Figure 2-2). Bisulfite treatment thus induces specific and 
predictable changes in the DNA sequence in a manner that is dependent upon the 
methylation status of individual cytosine residues. Individual sites of interest (e.g. 
promoter regions) can then be amplified using PCR, whilst retaining the distinction 
between methylated and unmethylated sites. During PCR, uracil residues (i.e. 
unmethylated cytosines in the original sequence) are converted to thymine. 
Bisulfite treated DNA is hybridised to a sequencing primer (and a biotinylated 
primer), and incubated with DNA polymerase, ATP sulfurylase, luciferase, apyrase, 
adenosine 5’ phosphosulfate (APS) and luciferin. One of four dNTPs (dTTP, dGTP, 
dCTP or dATPαS) is added. If DNA polymerase is able to incorporate the dNTP 
(i.e. it is correct and complementary to the original sequence), pyrophosphate (PPi) 
is released. PPi is converted by ATP sulfurylase to ATP in the presence of APS. The 
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ATP generated is used in the luciferase-mediated conversion of luciferin to 
oxyluciferin, producing light proportional to the amount of ATP present. The light 
produced is detected by a camera and quantified and analysed by a software 
program. Unincorporated nucleotides are degraded by the enzyme apyrase, allowing 
the reaction to restart with another nucleotide. 
As bisulfite treatment of DNA selectively modifies unmethylated cytosines to 
thymine while not affecting methylated cytosines, methylation state of the original 
DNA can be determined by comparing the original sequence and the bisulfite-treated 
sequence. Pyrosequencing allows the ratio of C to T at specific sites to be 
determined quantitatively. 
 
2.3.2.2 DNA Extraction 
DNA extraction was carried out using a phenol-chloroform extraction method. This 
method relies on phase separation by centrifugation of a phenol-chloroform mixture 
and an aqueous sample to isolate nucleic acids and protein. Nucleic acids partition 
into the aqueous phase, and can be precipitated using ethanol. 
Approximately 30mg of tissue was incubated overnight at 55°C with 600µl of tail 
buffer (1% SDS, 0.1M NaCl, 0.1M EDTA, 0.05M Tris) and 35µl of proteinase K 
(10mg/ml, Qiagen). Once tissue was fully lysed, 20µl of 20µg/ml DNase-free RNase 
A was added to each sample, and incubated for 2 hours at 37°C. After incubation, 
37.5µl of 2M β-mercaptoethanol (Sigma Aldrich) and 600µl of phenol was added to 
each sample. Samples were rotated on a spinner for 15 minutes before centrifuging 
at 16000g for 2 minutes. The organic lower phase was discarded, while the aqueous 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  
84 
supernatant and interphase layers were then transferred to a fresh tube. To this, 
300µl of phenol and 300µl of chloroform were added. Samples were then rotated 
again on a spinner for 5 minutes, and centrifuged at 16000g for 2 minutes. The 
supernatant layer was then transferred to a fresh tube. DNA concentration and 
integrity were assessed by Nanodrop and agarose gel electrophoresis, as described in 
section 2.3.1.3.  
  





Figure 2-1. Principle of pyrosequncing.  
 
Figure 2-2. Bisulfite-dependent conversion of cytosine to uracil. 
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2.3.2.3 Bisulfite Treatment 
Bisulfite treatment was carried out using the Epitect Bisulfite Kit (Qiagen). Using 
nuclease-free water, 1µg DNA was made up to 20µl in a 200µl PCR tube. To this, 
85µl of bisulfite mix and 35µl of DNA Protect Buffer were added. Bisulfite DNA 
conversion was performed on the mixture using a thermal cycler (G-Storm, UK). 
The thermal cycler conditions were as follows: 
Step Time Temperature 
Denaturation 5 min 95°C 
Incubation 25 min 60°C 
Denaturation 5 min 95°C 
Incubation 85 min 60°C 
Denaturation 5 min 95°C 
Incubation 175 min 60°C 
Hold Indefinite 20°C 
 
Once the bisulfite conversion was complete, the PCR tubes were centrifuged briefly 
and transferred to clean 1.5ml microcentrifuge tubes. To each sample, 560µl of 
Buffer BL containing 10µg/ml of carrier RNA, was added and tubes were briefly 
centrifuged. The mixture was then transferred to a fresh Epitect spin column. 
Epitect spin columns were centrifuged at 14,000 rpm for 1 minute. The flow-through 
was discarded, and 500µl of Buffer BW was added to each. Tubes were then 
centrifuged at 14,000 rpm for 1 minute. Flow-through was discarded, and 500µl of 
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Buffer BD was added to each spin column and incubated at room temperature for 15 
minutes. 
After incubation, spin columns were centrifuged at 14,000 rpm for 1 minute. Flow-
through was discarded and 500µl of Buffer BW was added to each spin column. 
Spin columns were centrifuged at 14,000 rpm, flow-through was discarded and a 
further 500µl of Buffer BW was added to each spin column. Spin columns were 
centrifuged at 14,000 rpm for 1 minute and flow-through was discarded. Spin 
columns were placed into new 2ml collection tubes and centrifuged at 14,000 rpm 
for 1 minute to remove any residual liquid. Spin columns were then placed, with 
open lids, into clean 1.5ml microcentrifuge tubes and incubated for 5 minutes at 
56°C for 5 minutes in a heating block. Spin columns were then placed into clean 
1.5ml microcentrifuge tubes, and 20µl of Buffer EB was dispensed onto the centre of 
each spin column membrane. The purified DNA was eluted by centrifugation for 1 
minute at 12,000 rpm. Purified DNA was stored at -20°C. 
 
2.3.2.4 PCR 
Pyrosequencing primers were designed for exon 1C of GR and for the promoter region of 
11βHSD2 by Amanda Drake using the PyroMark Assay Design 2.0 software (Qiagen). 
Published assays were used for pyrosequencing of DMRs known to control expression of IGF2 
(DMR0, DMR2 and H19 imprinting control region) (Dupont et al. 2004; Murrell et al. 2008). 
IGF2 DMR2 methylation was analysed using two previously published assays, DMR2.1 and 
DMR2.2, covering separate regions within the DMR. Primers for GR and 11βHSD2 were 
designed using the PyroMark Assay Design 2.0 software (Qiagen) Primer sequences and PCR 
conditions are listed in  
Table 2-3. All primers were purchased from Eurogentec (Southampton, UK). 
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2.3.2.5 Agarose Gel Electrophoresis 
PCR products were electrophoresed on a 1.5% agarose/0.5xTBE gel at 90V for 30 
minutes to assess the success of PCR. Agarose was melted in the buffer using a 
microwave oven, and GelRed nucleic acid dye was added to the molten agarose (at 
0.0005% concentration). Once cooled, the mix was poured into a tray. Samples were 
mixed with Orange G loading dye in a 1:5 ratio and loaded onto the gel together with 
a DNA ladder. Gels were visualised under UV light (λ=260nm) using a 
transilluminator. The strength of each visualised band was noted, and PCR was 




Figure 2-3. Example of bisulfite converted PCR product run out on a 1% agarose/0.5xTBE gel 
at 110V for 45 minutes, showing acceptable and unacceptable DNA and a 1Kb ladder. 
 
  




Pyrosequencing was carried out using a Pyromark Q24 instrument. Appropriate volumes of 
enzyme mix (DNA polymerase, ATP sulfurylase, luciferase and apyrase), substrate mix 
(adenosine 5’ phosphosulfate and luceferin) and dNTPs (dATPαS, dCTP, dTTP and dGTP) 
were added to the Pyromark Q24 instrument as indicated by the Pyro Q-CpG assay design 
software. To a 24-well plate, 10µl of PCR product was added, along with 2µl of streptavidin-
coated sepharose beads (GE Healthcare Life Sciences, UK), designed to bind to biotinylated 
compounds, and 40µl of Binding Buffer. The volume was made up to 80µl using 28µl of Milli-Q 
(18.2 MΩ⋅cm) purified water. Plates were sealed using strip caps and agitated constantly for 5 
to 10 minutes at 14000rpm. A second shallow-welled 24-well plate was prepared by adding 
0.3µM sequencing primer in 25µl of annealing buffer (see  
Table 2-3). Samples, bound to the sepharose beads, were then captured using a 
Pyromark suction device and flushed with 70% ethanol for 5 seconds, denaturation 
solution for 5 seconds and washing buffer for 10 seconds whilst under suction. The 
beads were then released into the sequencing primer plate by removing suction. This 
plate was then incubated at 80°C for 2 minutes to facilitate annealing of the 
sequencing primer to samples while the suction device was flushed with Milli-Q 
purified water. Plates were then processed using the Pyromark Q24 instrument and 
analysed using Pyro Q-CpG software. 
Schematic diagrams of the methylated regions for analysis are shown in Figure 2-4. 
  





PCR Primers and hybridization 
temperature Sequencing primer 
Produc
t size 
GR (exon 1C) Forward TTTTTTTTATTTATAGAATT 235 
 GGGGGAGAGTTTTTATTTAAGAAAGT   
 Reverse (biotinylated)   
 CCCCCCTCCTCCATTTTA   
 51°   
    
11βHSD2 Forward GGGGTAGAGATTTTAAGAA 304 
(-763 to -704) GTTTTGGAAGGAAAGGGAAAGA   
 Reverse (biotinylated)   
 CACATCCCCATACCCTTTACTAAT   
 55°   
    
IGF2, DMR0 Forward AAAAGTTATTGGATATATAGT 205 
 TGAGGATGGGTTTTTGTTTGGTAT   
 Reverse (biotinylated)   
 TCCTCAATCCACCCAAAAATAATAT   
 50°   
    
IGF2, DMR2,  Forward GTTTGGTTTTTTTGAA 195 
product 1 GGGTTTTGGGTGGGTAGAGT   
(DMR2.1) Reverse (biotinylated)   
 CCAAAACAACTTCCCCAAAT   
 60°   
    
IGF2, DMR2,  Forward GATTTTTATYGGAAGTA 255 
product 2 GGGAAAGGGGTTTAGGATTTTTAT   
(DMR2.2) Reverse (biotinylated)   
 ATAATTTACTCCCCCTTCAACCTC   
 60°   
    
H19 Forward GTAGGTTTATATATTATAG 220 
 TGGGTATTTTTGGAGGTTTTTTT   
 Reverse (biotinylated)   
 TCCCATAAATATCCTATTCCCAAA   
 57°   
 
Table 2-3. Primer sequences and hybridization temperatures for pyrosequencing assays. 
  







Figure 2-4. Schematic diagaram of the areas assessed for methylation at exon 1C of the GR 
promoter (a), across the 11βHSD2 promoter (b), and across DMR0 and DMR2 of the IGF2 gene 
(c) Exons are shown in lower-case letters; the area assayed is shown as underlined, with specific 
CpGs of interest highlighted in bold lettering. Figure adapted from Drake et al. 2012. 
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2.3.3 Protein Analysis 
2.3.3.1 Protein Extraction 
Total protein was extracted from frozen tissue. Placental tissues were homogenized 
in lysis buffer and incubated for 1 hour at 4°C with rotation before centrifugation at 
10,000g for 5 minutes at 4°C. The supernatant was transferred to a fresh tube and 
stored at -20°C. 
 
2.3.3.2 Protein Quantification 
Total protein concentration was measured using colorimetric assay. Sample 
concentrations were determined using a standard curve derived from a series of 
bovine serum albumin (BSA, Bio-Rad Laboratories, Hertfordshire, UK) dilutions 
ranging from 0 to 1.4mg/ml. 5µl of samples or standards were added to individual 
wells in a 96-well plate, followed by 25µl of Bio-Rad reagent A and 200µl of 
reagent B. The 96-well plate was then incubated for 15 minutes and absorbance at 
750nm at room temperature was recorded using a plate reader (OPTImax tunable 
microplate reader, Molecular Devices, PA, USA). 
 
2.3.3.3 SDS-Page 
Protein samples (30µg) were made up to 14µl with water, 5µl of NuPAGE LDS 
sample buffer and 2µl of sample reducing agent. Samples were incubated at 70°C for 
10 minutes to denature the protein. A Bis-Tris Novex 4-12% pre-cast gel 
(Invitrogen, Paisley, UK) was locked to the buffer core in a vertical XCell SureLock 
electrophoresis tank. The inner chamber was filled with 1x running buffer, and 
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samples were loaded with 5µl of Full-Range Rainbow marker (GE Healthcare Life 
Sciences, Buckinghamshire, UK). The outer chamber was filled with buffer while 
0.5ml of NuPAGE antioxidant was added to the inner chamber. Samples were 
electrophoresed at 200V for 50 to 60 minutes.  
 
2.3.3.4 Western Blotting 
Following electrophoresis, the gel was transferred to a transfer sandwich (comprising 
sponge, paper, gel, membrane, paper, sponge). Sponges were pre-soaked in 4°C 
transfer buffer for 1 hour. The sandwich cassette was placed in the tank, and the 
chambers were filled with transfer buffer. Proteins were transferred at 30V on ice for 
80 minutes. Following transfer, the membranes were placed into blocking buffer and 
incubated with agitation for 1 hour at room temperature. The blocking buffer was 
removed, and the membrane was incubated with primary antibody at 4°C overnight 
at a concentration of 1:2,000 for rabbit anti-11βHSD2 antibody and 1:10,000 for 
rabbit anti-α-tubulin antibody.  The membrane was then washed 3 times, 10 minutes 
each time, in TBST buffer at room temperature with agitation. The membrane was 
then incubated for 1 hour at room temperature with secondary antibodies (kindly 
provided by Kerry McInnes) diluted 1:10,000 in blocking solution. The membrane 
was then rinsed with TBST for ten minutes 3 times. Finally, the membrane was 
scanned using a Licor Odyssey infrared scanner (Licor Biotechnology Ltd, 
Cambridge, UK), and protein bands were quantified suing the Odyssey V3 software 
package. 
 





Representative samples of first trimester, second trimester and term trophoblast 
tissue (3 samples for each time point) were collected in 10% neutral buffered 
formalin (NBF) and stored for 24 hours at room temperature. Samples were then 
dehydrated in an ethanol gradient: 70% ethanol, 95% ethanol and absolute ethanol, 
and soaked in xylene. Samples were then embedded in paraffin wax and blocked. 
Paraffin blocks were cut using a microtome into 5µm slices, and slices were 
mounted onto microscope slides.  
Slides and samples were dewaxed in xylene for five minutes, twice, then rehydrated 
through an ethanol gradient, with 20 seconds in absolute ethanol (twice), 20 seconds 
in 95% ethanol, and 20 seconds in 70% ethanol. Slides were then washed in several 
changes of tap water. Slides were then washed in deionised water for approximately 
30 seconds. 
For antigen retrieval, slides were pressure-cooked, from cold, for 5 minutes at 
pressure in 2 litres of 10 mM TRIS, 1 mM EDTA and 0.05% Tween-20 (pH 9.0). 
Slides were once again washed in distilled water for approximately 30 seconds. 
Slides were then blocked for 30 minutes in 1% Hydrogen Peroxide in TBST (pH 7.5 
20 mM Tris; 150 MM NaCl; + 0.5% Tween20) and washed in several changes of tap 
water. Slides were then washed in TBST for 5 minutes.  Slides were transferred to a 
Sequenza Immunostaining Center apparatus (Thermo Scientific, Waltham, MA, 
USA) and incubated for 15 minutes in a staining buffer of TBST + 5% donkey horse 
serum. Primary antibodies were diluted to 1:10000 in staining buffer, and slides were 
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incubated for 2hrs at room temperature with either rabbit anti-11βHSD2 serum 
(1:10000) for samples, or control rabbit serum (1:10000) for negative controls. 
Slides were then washed in TBST. Slides were then blocked for 5 minutes with 2.5% 
blocking (normal horse) serum (Vector Laboratories, CA, USA). Slides were 
incubated with secondary antibody for 30 minutes (one drop of ImmmPress anti-
rabbit horseradish peroxidase). Slides were washed twice in TBST, and flow-through 
was decanted from the Immunostaining apparatus. Slides were stained with DAB 
(3,3-diaminobenzidine) for 5 minutes, and then washed in TBST 20 and transferred 
to distilled water. Slides were then counterstained with haemotoxylin for 30 seconds. 
Excess haemotoxylin was washed off in tap water and soaked in Scott’s Tap Water 
for 10 seconds. Slides were washed in tap water and examined for excessive 
haemotoxylin staining, with acid alcohol used to reduce any heavy haemotoxylin 
staining. Slides were dehydrated in an increasing ethanol gradient, with 20 seconds 
in 70% ethanol, 20 seconds in 95% ethanol, and two incubations of 20 seconds each 
in absolute ethanol. Slides were then incubated in xylene for 10 minutes, and 
coverslips were mounted with pertex. 
 
2.3.5 Radioimmunoassays 
Radioimmunoassay involves the use of radioactive antigens mixed with a known 
amount of antibody for the antigen. A sample of serum, containing an unknown 
concentration of the same antigen, is added. Radiolabelled and unlabelled antigens 
are thus able to compete for antibody binding sites. A higher concentration of 
unlabelled antigen will reduce the ratio of antibody-bound radiolabelled antigen to 
free radiolabelled antigen. Bound and unbound antigens are then separated, generally 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  
96 
through washing, and the radioactivity of the bound antigens is measured using a 
gamma counter. The separation of bound and unbound antigen may be aided by 
covalent bonding of the antibody to another substance, such as the inner surface of a 
polypropylene tube. A binding curve, generated by the use of known standards, can 
then be used to derive the concentration of antigen in the sample serum. 
 
2.3.5.1 Radioimmunoassay for Cortisol 
To measure serum cortisol levels, ImmuChem Cortisol 125I kits were used (ICN 
Biomedicals, CA, USA). Kits were equilibrated to room temperature prior to 
assaying samples. Samples were defrosted, and 25µl of sample was added in 
duplicate to rabbit anti-cortisol coated tubes. Standards (at concentrations 0, 1, 3, 10, 
30 and 100 µg/dL) were also added to tubes in duplicate. 1ml of I125 labelled cortisol 
was then added to each tube and the tubes were gently vortexed prior to incubation at 
37˚C for 45 minutes. After incubation, all fluid was aspirated. Tubes were then 
washed with 1ml of 0.05% Tween-20 and re-aspirated. The tubes were then left to 
air-dry, inverted on paper towels. Levels of I125 labelled cortisol were then measured 
using a gamma counter calibrated for I125.  
To calculate cortisol levels, the average gamma counts for duplicate tubes were 
divided by the averaged counts of the zero standard, and then multiplied by 100. 
This value (the percentage bound to unbound, or %B/B0) was then plotted against 
the concentration for the cortisol standards (1 to 100 µg/dL) to plot the standard 
curve (see Figure 2-5). Sample concentrations were then calculated by interpolation 
from the standard curve graph.   




                            Unlabelled cortisol (nmole/L) 
Figure 2-5. Example cortisol radioimmunoassay standard curve. The proportion of bound 
radiolabelled cortisol (B/B0, y-axis) decreases as it is displaced by increasing concentrations of 
unlabelled cortisol (x-axis). The cortisol concentration of samples was determined from their 
B/B0 by interpolation from the curve. 
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2.3.5.2 Radioimmunoassay for CBG 
DIAsource CBG-RIA-CT kits (DIAsource, Belgium) were used to measure serum 
CBG. A fixed quantity of 125Iodine labelled CBG competes with sample CBG for a 
known quantity of anti-CBG antibody. These antibodies then bind to goat anti-
mouse antibodies bound to the walls of polystyrene tubes, allowing for 
immobilization and measurement of CBG. 
Serum samples were diluted 25 times in dilution buffer, and 100µl of the diluted 
sample was added in duplicate to tubes coated with goat anti-mouse antibody 
(including two ‘normal’ or total count tubes) Two zero controls (containing 
phosphate buffer but no CBG), and duplicate standards (containing 0.44µg/ml, 
0.81µg/ml, 1.50µg/ml, 2.20µg/ml, 4.00µg/ml, and 8.00µg/ml of CBG in phosphate 
buffer) were also prepared. 100µl of I125 labeled CBG was added to each tube 
(including total count tubes and standards). Finally, 100µl of CBG antiserum was 
added to each tube (excluding the total count tubes). 
Tubes were then incubated for two hours at room temperature with shaking at 
400rpm. The contents of each tube (excluding total counts) were then aspirated. 
Tubes were then washed with 2 ml of working wash solution (tris-HCl), and left to 
stand for two minutes before aspirating the last drops of liquid. 
Levels of I125 labelled CBG were then measured using a gamma counter calibrated 
for I125 for 60 seconds. The mean of the duplicate tubes were calculated and 
concentrations were determined by extrapolation using a standard curve of 
Bound/Unbound values against CBG concentration for each standard. 
 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  
99 
2.3.5.3 Coolen’s Equation for Calculating Free Cortisol 
In order to estimate the levels of free (i.e. unbound) cortisol from total cortisol 
concentration and CBG concentration, Coolen’s equation was used. 
In human serum, cortisol is bound to CBG. A less significant quantity of cortisol is 
bound more weakly to albumin. Coolen’s equation can be used to calculate the levels 
of unbound cortisol not bound to either CBG or albumin (i.e. cortisol which is 
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U represents the unbound cortisol (in µM), C the molar concentration of total 
cortisol (in µM), N the proportion of albumin-bound cortisol, and K the affinity of 
CBG for cortisol at 37˚C. If a value for K is assumed to be 3 x 10-7 M-1 and a value 
of N to be 1.74 (as precise albumin levels were unavailable), the following equation 
can be used: 
 
 
where Z = 0.0167 + 0.182 (T-C) µM. 
 
2.3.6 CRH 
Levels of CRH were measured in serum (collected in tubes coated in lithium 
heparin) by radioimmunoassay as described in Smith et al 1993, and were performed 
by Maria Bowman and Roger Smith at the University of Newcastle, Australia (Smith 
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2.4 Statistical Analysis 
Normal distribution of data was assessed visually using histograms. Data that were 
not normally distributed were normalised using natural log transformation. 
Correlations of normally distributed variables were analysed using Pearson 
correlation. Adjustments for confounding factors (e.g. maternal age, smoking status, 
parity, DEPCAT category, and length of gestation) were performed using multiple 
linear regression. Statistical analyses are described in further detail in experimental 
chapters. 
All data are presented as mean (± s.e.m), and p values of less than 0.05 were 
considered significant. The Bonferroni correction was used to determine values for 
alpha where multiple testing was carried out. 
Analysis was performed using Minitab (Minitab Inc, PA, USA), SPSS (IBM, NY, 
USA) and Statistica (StatSoft Inc, OK, USA). Graphs were prepared using GraphPad 
Prism (GraphPad Software Inc, CA, USA). 




Chapter 3:  
The Maternal HPA Axis in Obese 
Pregnancy and Associations with 
Gestational Weight Gain, Birth 
Weight and Gestation at Delivery 




As previously discussed (see Introduction section 1.3.4), the regulation of the HPA 
axis undergoes dramatic changes during pregnancy, with circulating levels of 
cortisol rising to around three-fold non-pregnant levels by the third trimester 
(Okamoto et al. 1989; Jung et al. 2011). These changes contribute to the changes in 
maternal, fetal, and placental physiology that occur during pregnancy, including fat 
deposition, tissue maturation, and mobilization of fuel to the fetus for growth 
(Murphy et al. 2006). High circulating levels of maternal cortisol have also been 
implicated in ‘programming’ of low birth weight (Goedhart et al. 2010; Reynolds 
2013).  Likewise, the placenta secretes large quantities of CRH into the maternal 
circulation during the second and third trimesters (McLean and Smith 1999). CRH 
concentrations may be important in regulating the timing of delivery, with high 
levels of the hormone at 31 weeks associating with subsequent preterm birth 
(Sandman et al. 2006).  
 
The prevalence of obesity among pregnant women is rising (see Introduction section 
1.6) and is associated with macrosomia and longer gestation (Denison et al. 2008). 
No studies have examined whether changes in the maternal HPA axis in obese 
pregnancy are associated with these adverse pregnancy outcomes.  Indeed, whether 
the HPA axis undergoes the normal physiological changes during pregnancy in 
women who are obese has not been studied.  In the non-pregnant state, obesity is 
associated with increased hepatic/urinary clearance of circulating glucocorticoids 
(Pasquali et al. 1993; Rask et al. 2001; Praveen et al. 2011). Some data suggest that 
plasma cortisol is lower in uncomplicated obesity, however the effects of obesity on 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  
104 
plasma cortisol levels during pregnancy have not been extensively studied (Praveen 
et al. 2011). During pregnancy, the activity of the placental enzyme 11βHSD2 will 
also impact on cortisol levels and it is not known if this differs in women who are 
obese. The aim of this study was to characterize the hormones of the HPA axis in a 
group of very severely obese women and lean controls participating in a longitudinal 
study of obese pregnancy and to test associations with pregnancy outcomes.  
 
3.1.1 Hypotheses 
It was hypothesized that: 
a) maternal obesity would be associated with lower maternal cortisol, CRH and 
CBG levels during pregnancy. 
b) Lower cortisol levels in obese women would be associated with lower 
gestational weight gain 
c) lower maternal cortisol and CRH levels in obese women would be associated 
with higher offspring birth weight and longer gestation, respectively. 
 
3.1.2 Aims 
1.To compare circulating levels of cortisol, CBG and CRH measured at three time 
points in pregnancy and at 3 months post-partum in very severely obese and lean 
pregnant women.  
2. To test the relationship between maternal cortisol and CRH levels and gestational 
weight gain as well as birth outcomes including birth weight and gestation at 
delivery. 




3.2.1 Study Design  
This was a case-control study comparing lean and very severely obese pregnant 
women who had been recruited among participants of a larger prospective cohort 
study. 
 
3.2.2 Subject Recruitment 
Participants for this study were recruited as part of a longitudinal study of obesity in 
pregnancy between April 2008 and September 2012 as described in methods section 
2.1.1.1. Briefly, lean (BMI between 20 and 25 kg/m2) and obese (BMI > 30 kg/m2) 
pregnant women were recruited from the Tommy’s Antenatal Metabolic Clinic in 
Edinburgh. All study participants attended the research clinic at three time points 
during pregnancy: 16 weeks gestation (‘visit 1’), 28 weeks gestation (‘visit 2’), and 
36 weeks gestation (‘visit 3’); fasting morning blood samples were taken at these 
visits to be used for the measurement of cortisol, CBG, and CRH; height and weight 
were also measured by medical staff in order to calculate gestational weight gain and 
BMI. Study participants were also invited to attend a fourth visit 3 months 
postnatally. At Visit 1, women were also asked to collect three saliva samples into 
Sarstedt salivette tubes: one sample was collected at bedtime, a second at waking, 
and a third 30 minutes after waking. Gestational weight gain was calculated as the 
difference in weight between visit 3 and visit 1. Birthweight, gender and gestation at 
delivery and mode of delivery were recorded after delivery. Women who attended 
for blood sampling for any of the three visits during pregnancy were included in the 
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study, while women with gestational diabetes (n=37) and pre-eclampsia (n=17) were 
excluded. Pre-term births (delivery <37 weeks gestation, n=17) were also excluded, 
except when analyzing associations between cortisol and length of gestation. 
 
3.2.3 Laboratory methods 
ImmuChem Cortisol 125I kits (ICN Biomedicals, CA, USA) were used to measure 
serum cortisol concentrations in all samples as described in section 2.3.5.1. Briefly, 
samples were added to rabbit anti-cortisol coated tubes, to which I125 labelled cortisol 
was added. Tubes were incubated at 37°C for 45 minutes, at which point fluids were 
aspirated and tubes were washed to remove unbound cortisol. Bound cortisol was 
measured using a gamma counter calibrated for I125. Similarly, CBG and CRH were 
measured by radioimmunoassay in samples collected from a subset of women for 
whom samples were available at all 3 prenatal visits (as described in methods 
sections 2.3.5.2 and 2.3.6). Free cortisol was calculated in the samples for which 
both cortisol and CBG measurements were available using Coolen’s equation, as 
described in methods section 2.3.5.3.  
 
3.2.4 Statistics 
Normal distribution of data was assessed visually using histograms. Data that were 
not normally distributed (total serum cortisol concentrations, serum CBG 
concentration, calculated free cortisol concentration) were normalised using natural 
log transformation. Comparisons of variables between obese and lean groups were 
tested using independent t-tests. Differences in the pattern of cortisol levels during 
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pregnancy were tested using repeated measures analysis of variance (ANOVA) for 
subjects that had serial cortisol measurements. Correlations between HPA axis 
variables and birth weight and gestational weight gain were tested using Pearson 
correlation. Multiple regression was used to adjust for confounding factors (neonate 
gender, length of gestation, maternal smoking status, parity and ethnicity). All data 
are presented as mean (±s.e.m), and p values of less than 0.05 were considered 
statistically significant. Analysis was performed using Minitab (Minitab Inc, PA, 
USA) and Statistica (StatSoft Inc, OK, USA) software packages. Graphs were 
prepared using GraphPad Prism (GraphPad Software Inc, CA, USA). 
Statistical power calculations were performed to determine the sample size required 
for these analyses. For correlation analyses where alpha = 0.05 and statistical power 
= 0.8, a sample size of 70 was determined to be necessary to detect a correlation of r 
= 0.3, while a sample size of 30 was calculated to be necessary to detect a correlation 
of r = 0.4, and a sample size of 23 was calculated for detection of a correlation r = 
0.5. For multiple regression analyses using 6 predictors (e.g. correcting for neonate 
gender, gestational age, maternal smoking status, parity, and ethnicity) with an alpha 
of 0.05, a sample size of 38 was calculated as being necessary to detect an r2 ≥ 0.3. 
For group analyses, a sample size of 60 was determined to be necessary to detect a 
difference of 20% between groups with a power of 0.8, while a sample size of 238 
was determined to be necessary to detect a difference of 10% between groups. 
 





Table 3-1 shows the characteristics of the 173 obese and 107 lean pregnant 
women. Obese women were younger than lean, had greater social deprivation as 
measured by DEPCAT score and were of significantly higher parity.  
 
3.3.2 Total Serum Cortisol Profiles Differ Between Lean 
and Obese Pregnant Women 
Total serum cortisol concentrations increased throughout pregnancy in both 
obese (p<0.001) and lean women (p<0.0001, see Figure 3-1). Cortisol levels 
were significantly lower in obese than lean at each time-point during pregnancy 
but did not-differ post-partum.  
To explore the pattern of cortisol measurements during pregnancy, only 
participants who had provided samples for all three antenatal time points were 
considered (see Figure 3-2). Using repeated measures ANOVA, while both 
groups were found to rise significantly throughout gestation (p<0.001), the 
pattern of rise did not differ between the two groups. As in the complete group, 
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3.3.3 Salivary diurnal patterns 
Diurnal pattern of cortisol secretion was maintained in both obese and lean 
women with significantly lower levels at bed-time compared to waking and 
30mins post waking. Salivary cortisol concentrations did not differ significantly 
between lean and obese women at any time point (see Figure 3-3). 
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Table 3-1. Demographic data for lean and obese pregnant women. Data are mean (s.e.m), or *N(%). 
Socioeconomic status was measured using deprivation category (DEPCAT) scores based on postcode 
(McLoone 2004). DEPCAT information was unavailable for 1 lean woman and 3 obese women. 
Ethnicity information was unavailable for 13 lean women and 15 obese women. ‘Smokers’ are defined 
as those who considered themselves as current smokers. Parity data was unavailable for 5 lean women 
and 10 obese women. Caesarean Section delivery included elective and emergency caesarean sections. 
 Lean (n=107) Obese (n=173) P-value 
Maternal Characteristics 
BMI (kg/m2) 22.76 (0.16) 44.04 (0.34) <0.0001 
Age (years) 33.30 (0.42) 30.80 (0.39) <0.0001 
Gestational Weight 
Gain (GWG)(16 
weeks to 36 weeks, 
kg) 
10.01 (0.36) 5.96 (0.43) <0.0001 
GWG (16 weeks to 28 
weeks, kg) 
6.46 (0.24) 2.99 (0.29) <0.0001 
GWG (28 weeks to 36 
weeks, kg) 
3.52 (0.23) 2.78 (0.44) 0.09 
Multiparous* 62 (61%) 89 (55%) <0.01 
Nulliparous* 40 (39%) 74 (45%) 








29 (28%) 126 (74%) <0.0001 
White British* 91 (96%) 152 (97%) 0.73 
Other Ethnicity* 3 (4%) 6 (3%) 
Offspring Characteristics (n=280)   
Gestation (days) 283.3 (0.78) 282.10 (0.66) 0.445 
Birth weight (g) 3581 (48.19) 3638 (42.75) 0.276 
Caesarean Section 
Delivery* 
15 (16%) 63 (43%) <0.0005 
Males * 49 (46%) 79 (45%) 0.92 
Females * 58 (54%) 95 (55%) 0.92 




Figure 3-1 Total serum cortisol concentrations measured at three time points during 
pregnancy (16 weeks, 28 weeks and 36 weeks) and 3 months postnatally in lean (n=107) and 
obese (n=173) women (mean ±s.e.m; * difference in cortisol concentration between lean and 
obese p<0.05, *=p<0.01, ***=p<0.005). 
 
Figure 3-2. Total serum cortisol concentrations measured at three time points during 
pregnancy (16 weeks, 28 weeks and 36 weeks) in lean (n=48) and obese (n=62) women; only 
pregnant women who had cortisol measurements at all three time points are shown (mean 
±s.e.m, * difference between cortisol concentration between lean and obese *=p<0.05, 
**=p<0.01).  






















































Figure 3-3. Diurnal profile of salivary cortisol in a subset of lean (n=17) and obese (n=7) 
pregnant women at visit 1 (mean ±s.e.m). Values did not differ between lean and obese at 
bedtime (p=0.43), waking (p=0.35) or 30 minutes post waking (p=0.29). 
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3.3.4 Serum CBG Is Lower in Obese Women than Lean 
Serum CBG was measured in patients with viable cortisol measurements from all 
3 prenatal research visits. At visit 1, serum CBG concentrations did not differ 
between obese and lean. CBG concentrations then increased throughout 
pregnancy in both lean (p<0.0001) and obese women (p<0.05, see Figure 3-4). 
CBG concentrations at both visit 2 and visit 3 were lower in obese compared to 
lean (both p<0.005) and thus the rise in CBG between visits 1 and 3 was 
significantly lower in obese women compared to lean (p<0.05, see Figure 3-5). 
In lean women, serum CBG positively correlated with total serum cortisol at 
visits 1 (p<0.05) and 3 (p<0.0001), but not at visit 2 (see Figure 3-6). The 
association between CBG and total cortisol at visit 1 was no longer significant 
when adjusting for maternal age, parity, ethnicity, social class and smoking 
status (b=0.31, adjusted p=0.3), but remained significant at visit 3 (b=0.62, 
adjusted p<0.005). In obese women, no correlations were seen between CBG and 
cortisol at any time point; other than a trend at visit 2 in adjusted analyses 
(b=0.21, adjusted p=0.051). 
 
3.3.5 Calculated Free Cortisol Differed Only at 36 Weeks 
When unbound, or free, cortisol was calculated using Coolen’s equation, 
calculated free cortisol concentrations did not differ between lean and obese 
women at visits 1 and 2 (p=0.857 and p=0.322 respectively, see Figure 3-7).  At 
visit 3, obese women were observed to have significantly higher calculated free 
cortisol concentration than lean women (t-test, p<0.05).




Figure 3-4. Total serum CBG concentrations measured at three time points during 
pregnancy (16 weeks, 28 weeks and 36 weeks) in lean (n=39) and obese (n=26) women; only 
pregnant women who had cortisol measurements at all three time points are included in 
this analysis (mean ±s.e.m; ** difference in CBG concentration between lean and obese 
p<0.01). 
 
Figure 3-5. Change in CBG concentration (µM) between visits 1 (16 weeks) and visit 3 (36 
weeks) in 26 lean and 15 obese women (data are mean ±s.e.m; *difference in change in CBG 
between lean and obese p<0.05). 



























Figure 3-6. Correlations between serum cortisol and serum CBG in lean women at visit 1 
(A), visit 2 (B), visit 3 (C), and in obese women at visit 1 (D), visit 2 (E), and visit 3 (F). 
 














































































































































Figure 3-7. Calculated free cortisol concentrations in blood measured at three time points 
during pregnancy (16 weeks, 28 weeks and 36 weeks) in lean (n=37) and obese (n=26) 
women as calculated using the Coolens equation; only pregnant women who had cortisol 
measurements at all three time points are included in this analysis (mean ±s.e.m; * 
difference between calculated free cortisol p<0.05). 
  




























Maternal CRH concentrations rose in both lean and obese women throughout 
pregnancy, with the greatest rise occurring between visits 2 and 3 (see Figure 3-
8). While there was no difference in CRH levels between lean and obese women 
at visit 1, by visit 2 obese women had significantly lower CRH measurements 
compared to lean women (p<0.05). Similarly, at visit 3, CRH concentrations in 
obese women tended to be lower than in lean women (p=0.06).  
As CRH is thought to be involved in regulating the timing of parturition, and 
levels of CRH rise near parturition, CRH levels were also compared for those 
women who delivered by spontaneous vaginal delivery (SVD) only. When 
women delivering by SVD only were considered, obese women were found to 
have a significantly lower CRH concentration compared to lean at visit 2 
(p<0.01) and visit 3 (p<0.05). 
 
3.3.7 Gestational Weight Gain 
Table 3-1 and Figure 3-9 show that total gestational weight gain between visits 1 
and 3 was greater in lean than obese (p<0.0001). Lean women gained 
significantly more weight in the period between visits 1 and 2 than in the period 
between visits 2 and 3 (p<0.0001, see Figure 3-9) whereas obese women gained 
similar amounts of weight between visits 1 and 2 compared with 2 and 3 
(p=0.303).  
 




Figure 3-8. Total serum CRH concentrations measured at three time points during 
pregnancy (16 weeks, 28 weeks and 36 weeks) in lean (n=20) and obese (n=20) women 
(mean ±s.e.m; * difference in CRH concentration between lean and obese p<0.05). 
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3.3.8 Gestational Weight Gain and Birth Weight 
Increased gestational weight gain between 16 and 36 weeks correlated with 
increased birth weight in lean women (r=0.26, p<0.01, see Figure 3-10A). The 
association was stronger after adjustment for neonate gender and length of gestation 
(r = 0.31, adjusted p<0.005), and further strengthened after additional adjustment for 
maternal smoking status, parity and ethnicity (r = 0.41, adjusted p<0.005).  
In obese women there was no association between birth weight and gestational 
weight gain (16 to 36 weeks) in unadjusted (r=0.09 p=0.199, see Figure 3-10B) or 
adjusted analyses (p=0.162 adjusted for neonate gender and length of gestation; 
p=0.380 including maternal smoking status, parity and ethnicity in the model). 
 
3.3.9 Associations Between Maternal Cortisol Concentrations 
and Gestational Weight Gain 
Higher maternal serum cortisol concentrations at visit 1 were associated with lower 
gestational weight gain between 16 and 36 weeks in both lean and obese women 
(lean  
r=-0.18, unadjusted p=0.08, adjusted p<0.05 after adjustment for maternal age, 
maternal weight at visit 1, parity, smoking status, social class and ethnicity; obese 
r=-0.16, p<0.05; adjusted p<0.05). No other significant associations were observed 
between total cortisol concentrations and gestational weight gain measurements in 
lean women or obese women. Calculated free cortisol did not correlate with 
gestational weight gain at any time point in either lean or obese women. 
  





Figure 3-9. Gestational weight gain throughout pregnancy. Weight gain was greater in lean 
women compared to obese women between visits 1 and 2 and between visits 1 and 3 (*** 
difference in weight gain between lean and obese p<0.0001, data are mean±s.e.m).  


























Figure 3-10. Gestational weight gain plotted against birth weight for 107 lean (A) and 173 obese 
(B) women, adjusted p with neonate gender, length of gestation, maternal smoking status, 
parity and ethnicity included. 
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3.3.10 Birth weight and Total Maternal Cortisol 
Birth weight did not differ between lean and obese women in unadjusted 
analyses (p=0.276, see Figure 3-11) or after adjustment for gestation at delivery 
and newborn gender (adjusted p=0.18).  
No correlations were found between birth weight and any cortisol measurement 
in obese (see Figure 3-12) or lean women (see Figure 3-13) in univariate 
analyses or after adjustment for gestation at delivery, gender, maternal smoking 
status, parity, ethnicity and social class. 
3.3.11 Birth Weight and Calculated Free Maternal 
Cortisol 
In lean women there was a positive correlation between birth weight and 
calculated free cortisol at visit 1 (r=0.35, p=0.05, see Figure 3-14). When length 
of gestation and neonate gender were adjusted for, the association was weakened 
(b=116, adjusted p=0.08), and was no longer significant when length of 
gestation, neonate gender, maternal social status (as measured by DEPCAT), 
smoking status, parity and ethnicity were adjusted for (b=122, adjusted p=0.112). 
No other correlations were observed between birth weight and calculated 
unbound cortisol in lean women. 
In obese women, lower birth weight was associated with higher calculated free 
cortisol at visit 1 (r=-0.46, p=0.05, see Figure 3-15). This finding was 
strengthened after adjustment for neonate gender and length of gestation (b=-
171, adjusted p<0.05). Furthermore the association remained significant after 
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further adjustment for maternal social status (as measured by DEPCAT), 
smoking status, parity and ethnicity (b=-267, adjusted p<0.05). No other 
correlations were observed between birth weight and calculated unbound cortisol 
at any time point. 
Figure 3-11. Birth weight in grams for lean (n=94) and obese (n=159) groups (p=0.276;, 
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!
 Figure 3-12. Birth weight and concentration of total blood cortisol measured at visit 1 (A), 
visit 2 (B) and visit 3 (C) in 173 obese women. 
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Figure 3-13. Birth weight and concentration of total blood cortisol measured at visit 1 (A), 
visit 2 (B) and visit 3 (C) in 107 lean women.
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Figure 3-14. Birth weight and concentration of calculated free cortisol measured at visit 1 
(A), visit 2 (B) and visit 3 (C) in serum samples from 37 lean women. 
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Figure 3-15. Birth weight and natural logged concentration of calculated free cortisol 
measured at visit 1 (A), visit 2 (B) and visit 3 (C) in serum samples from 26 obese women. 
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3.3.12 Cortisol and Timing of Gestation 
Total cortisol concentration measured at visit 2 was found to correlate with 
length of gestation in lean women in unadjusted analysis (r=0.22, p<0.05; 
adjusted p=0.26), however there were no other associations between length of 
gestation and total cortisol at any time point in either lean (visit 1: r=0.15, 
p=0.14, adjusted p=0.22; visit 3: r=0.003, p=0.98, adjusted p=0.19) or obese 
women (visit 1: r=-0.03, p=0.72, adjusted p=0.29; visit 2: r=-0.06, p=0.50, 
adjusted p=0.54; visit 3: r=0.05, p=0.67, adjusted p=0.16) in unadjusted analysis 
or when mode of delivery was adjusted for.  Furthermore, when only those 
women who gave birth by SVD were analysed, no associations were observed. 
 
Similarly, no associations were found between length of gestation and free 
cortisol at any time point in either lean (visit 1: r=0.16, p=0.42; visit 2: r=0.23, 
p=0.31; visit 3: r=-0.15, p=0.51) or obese women (visit 1: r=0.28, p=0.25; visit 2: 
r=0.23, p=0.42; visit 3: r=0.07, p=0.77) in unadjusted analysis or when mode of 
delivery was adjusted for.  Furthermore, when only those women who gave birth 
by spontaneous vaginal delivery were analysed, no associations were observed. 
 
3.3.13 CRH and Timing of Gestation 
CRH concentration measured at visit 2 was found to correlate with length of 
gestation in obese women in unadjusted analysis, but not when adjustments were 
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made for mode of delivery, maternal age, smoking status, DEPCAT category and 
parity  
(r=-0.48, p<0.05, adjusted p=0.22). No associations were found between length 
of gestation and CRH at any other time point in either lean (n=19, visit 1: r=-
0.37, p=0.12, adjusted p=0.35; visit 2: r=-0.27, p=0.99, adjusted p=0.99); visit 3: 
r=-0.07, p=0.75, adjusted p=0.48) or obese women (n=20, visit 1: r=0.25, 
p=0.29, adjusted p=0.39; visit 3: r=-0.26, p=0.28, adjusted p=0.57) in unadjusted 
analysis or when adjustments were made.   
When only women who gave birth by SVD are included, significant correlations 
between length of gestation and CRH concentration at visit 2 (r=-0.73, p<0.05, 
adjusted p<0.05) and visit 3 (r=-0.73, p<0.05, adjusted p<0.05), but not visit 1  
(r=-0.57, p=0.07, adjusted p=0.09) are observed in obese women in unadjusted 
analysis and when adjusting for maternal age, smoking status, parity and 
DEPCAT category. No associations are observed in lean women who gave birth 
by SVD at visit 1 (r=0.04, p=0.91, adjusted p=0.13), visit 2 (r=0.42, =0.18, 
adjusted p=0.09) or visit 3 (r=0.34, p=0.28, adjusted p=0.35). 
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3.4 Discussion 
An adverse fetal intra-uterine environment has been associated with increased 
risks of metabolic and cardiovascular disorders later in life (Barker et al. 1993a; 
Godfrey et al. 1994; Barker 1995; Godfrey and Barker 2000). In animal models 
exposure to excess glucocorticoids during pregnancy has been associated with 
reduced birth weight, and affects development and maturation of organs (Seckl 
2004) and thus glucocorticoid overexposure is one of the key mechanisms 
proposed to underlie fetal programming.  Here, we demonstrated for the first 
time that total cortisol levels in very severely obese women were lower 
throughout pregnancy than with a normal weight control group. Furthermore, 
levels of CBG were also lower. Reflecting the lower total cortisol and CBG 
levels, free cortisol levels were found to be similar between lean and obese 
women until near term. CRH levels were also found to be lower among obese 
women and predicted length of gestation.  
 
3.4.1 Cortisol Levels are Lower in Obese Women 
Throughout Pregnancy 
Total serum cortisol measurements were found to be lower in obese women 
compared to lean women throughout pregnancy, while postnatal serum 
measurements were similar between the two groups. This suggests a difference 
in overall maternal HPA-axis response to pregnancy during pregnancy according 
to maternal BMI. The lower cortisol levels were observed from the first 
measurement in the early second trimester, but the pattern of change (rise) of 
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cortisol throughout pregnancy did not differ between lean and obese women as 
pregnancy progressed. This suggests that there is a change in HPA-axis activity 
in early pregnancy in obese women, leading to the lower observed total cortisol 
measurements. It is possible that the observed difference in total cortisol levels 
may reflect increased urinary clearance of circulating glucocorticoids in obese 
women compared to lean, a phenotype observed in non-pregnant obese 
individuals (Andrew et al. 1998). However total urinary glucocorticoid 
metabolites did not differ between lean and obese (n=4 per group) (R.Reynolds 
personal communication). It is also possible that differences in the activity of the 
placental glucocorticoid-inactivating enzyme 11βHSD2 may contribute to 
differences in maternal cortisol levels; this will be further explored in Chapter 4. 
Diurnal production of cortisol (as measured by saliva sampling) was maintained 
in both lean and obese in the first half of pregnancy.  Due to the small sample 
size no differences in cortisol measurements between lean and obese were 
observed, despite the lower plasma levels in obese.   A larger sample size is 
required.  
 
3.4.2 CBG Is Lower In Obese Women 
In humans, 90 to 95% of circulating cortisol in the blood is bound to the specific 
steroid transport protein CBG. The concentrations and binding activity of this 
protein is thought to regulate the bioavailability of the steroid to target cells, with 
bound cortisol being considered essentially ‘biologically inactive’ (Fernandez-
Real et al. 1999). However, recent evidence suggests that CBG may in fact be 
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directly involved in signal transduction and bioavailability of glucocorticoids 
(Petersen et al. 2006). In this study, CBG was lower in obese women compared 
to lean, with a significant lower rise throughout pregnancy. The lack of rise in 
CBG may help explain the lower cortisol concentrations observed in obese 
women throughout pregnancy. Furthermore, CBG concentration was found to 
positively correlate with total cortisol concentration in both early and late 
pregnancy in lean women, but not in obese, again suggesting that obese women 
may lack a CBG-dependent rise in plasma cortisol concentrations. The reasons 
for the lack of rise in CBG in obese women are unknown, but may reflect 
differences in estrogen levels in obese pregnant women (which is currently 
undergoing investigation in this cohort), alterations in liver function of obese 
women (Torpy and Ho 2007), insulin levels or inflammatory mediators  
(Fernandez-Real et al. 1999). No association was found between insulin levels 
and serum CBG production (data not shown). 
 
3.4.3 CRH is Lower in Obese Women and Predicts Length 
of Gestation 
Placental CRH is an important regulator of HPA axis activity during pregnancy, 
and plasma concentrations of CRH increase throughout pregnancy to a 
concentration of 1 to 10nmol/L at term (Shibasaki et al. 1982; McLean et al. 
1995). CRH increased from visit 2 onwards in both groups, reflecting increasing 
placental production of the hormone from the second trimester. Obese women 
had a lower level of CRH compared to lean during the second half of pregnancy. 
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As CRH is a key promoter of cortisol production, this finding may explain the 
observed reduction in circulating cortisol, suggesting an overall suppression of 
HPA-axis activity in obese pregnancy. This may have the ultimate effect of 
reducing fetal exposure to maternal glucocorticoids, although further work on 
placental transit and fetal tissue effects is required. CRH concentration was 
found to negatively correlate with length of gestation in obese women who gave 
birth by SVD, reinforcing the hypothesis that this hormone is involved in the 
timing of parturition (McLean et al. 1995). This finding suggests that in obese 
women, increased HPA axis activation may predict length of pregnancy, 
presumably through the maturational effects of glucocortoicoids. Intriguingly, 
this association was not observed in lean women. This may reflect a higher 
sensitivity to the hormone in obese women in response to lower circulating 
levels. However, free cortisol levels are similar in obese and lean women, 
suggesting that sensitivity may in fact be unaffected by weight status. 
The lower levels of CRH observed in obese pregnancy may explain in part the 
lower levels of cortisol and CBG also observed. This in turn may lead to a lower 
production of CBG by the maternal liver to compensate for the lower levels of 
circulating glucocorticoids. This may imply that the changes in CBG are 
primarily directed at regulating maternal glucocorticoid exposure in response to 
lower CRH production; i.e. to ensure sufficient levels of cortisol are present for 
normal physiological function (e.g. gluconeogenesis and immune functions) 
despite reduced production. The regulation of cortisol in pregnancy is 
complicated by the need for balance between regulating fetal exposure and the 
normal physiological role of cortisol in the mother.  
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3.4.4 Free Cortisol Concentrations Are Higher in Obese 
Women by Term 
While total cortisol provides a useful measure of glucocorticoid production, it is 
thought that measurements of free (or unbound) cortisol are more biologically 
significant, reflecting the levels of glucocorticoid that are biologically active and 
available (Arafah 2006). In order to calculate free cortisol values, Coolen’s 
equation was used. This equation uses constant values for variables such as the 
binding affinity of CBG and the albumin content of blood (Coolens et al. 1987). 
The equation has been validated in patients with sepsis and healthy controls (Ho 
et al. 2006; Dorin et al. 2009) but not in pregnancy where CBG binding affinity 
may be altered (Ho et al. 2007). 
Nevertheless the values of calculated free cortisol were found to be very similar 
between lean and obese women between visits 1 and 2, but obese women were 
found to have significantly higher calculated values near term (at visit 3) 
indicating a higher fetal exposure to bioavailable (as opposed to total) cortisol 
(Vogeser et al. 1999; le Roux et al. 2003). Thus the increase in free cortisol at 
the end of pregnancy in obese women may induce late pregnancy specific 
effects, in particular affecting the timing of organ maturation, potentially leading 
to programming effects. In accord with this, in obese the higher free cortisol 
levels at visit 1 were associated with lower birth weight. Importantly, recent 
work has suggested that CBG may act as a transporter or carrier of 
glucocorticoids, with direct involvement in signal transduction in target tissues, 
with CBG thought to be a necessary component of glucocorticoid signaling 
(Henley and Lightman 2011). If this is the case in humans, the lower levels of 
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CBG seen in obese pregnancy, and by association the higher free cortisol levels, 
may not be indicative of higher bioavailability of cortisol to target tissues. 
Regardless, lower levels of total maternal cortisol may have detrimental effects 
on the fetus and pregnancy outcome. Post-traumatic stress disorder has been 
associated with hypocortisolism (Rohleder et al. 2004), and psychological 
trauma among pregnant women associated with the World Trade Center attacks 
in 2001 has been linked to lower maternal salivary morning cortisol levels 
postnatally, longer gestation and reduced infant head circumference at birth 
(Engel et al. 2005; Brand et al. 2006). However, hypocortisolism has not been 
found in all studies of post-traumatic stress disorder, and in fact cortisol levels 
may be normal, or higher or lower than normal (Young et al., 2004; Young and 
Breslau, 2004a; Young and Breslau, 2004b; Fink 2011). Nevertheless, Addison’s 
disease (a condition characterized by reduced production of glucocorticoids) 
during pregnancy, whether diagnosed or undiagnosed, increases the risk of both 
cesarean delivery and preterm delivery (Bjornsdottir et al. 2010). The underlying 
mechanisms are unknown, but in the case of Addison’s disease have been 
suggested to be related to reduced fetal adrenal production of DHEAS, an 
important precursor for placental production of estradiol. The lower estradiol 
production that results may therefore lead to a rise in the estradiol/estriol ratio, 
giving rise to an increased risk of preterm birth (Bjornsdottir et al. 2010). 
Therefore, the lower cortisol production may be a marker rather than a direct 
cause of poor pregnancy outcome in hypocortisolaemic women. Cortisol is also 
crucial for proper fetal development, with roles in the maturation and function of 
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a number of fetal organs, including the liver, lungs and fetal adrenals (Smith et 
al. 1974; Avery 1975; Liggins 1994). 
 
3.4.5 Maternal Weight and GWG 
Obese women were found to gain less weight than lean women throughout 
pregnancy (between 16 and 36 weeks), and in particular obese women gained 
less weight than lean women in the period between visits 1 and 2. Mean 
gestational weight gain was at the lower end of the Institute of Medicine 
guidelines for both lean and obese women (defined as approximately 11 to 16 kg 
for women with a normal BMI and at least 5kg for obese women) (Rasmussen 
and Yaktine 2009). Gestational weight gain between visits 1 and 3 was found to 
correlate positively with birth weight in lean women. This may reflect the 
increased weight of the fetal-placental unit contributing to the mother’s weight, 
or alternatively may suggest that women with higher nutritional intake were 
better able to support increased fetal growth. Gestational weight gain was not 
found to correlate with birth weight in obese women however, suggesting that 
other factors, such as compromised placental function (e.g. nutrient transport), 
may be more important in obese women. Higher maternal serum cortisol 
concentrations in early pregnancy were associated with lower gestational weight 
gain between 16 and 36 weeks in both lean and obese women. This is in 
agreement with the findings of animal studies that have suggested 
glucocorticoids can suppress appetite and inhibit food intake, and highlights a 
possible link between maternal diet and HPA axis activity (Liu et al. 2011). 
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While gestational weight gain may be useful as a surrogate of fetal growth, 
future studies may benefit from a more direct measure such as ultrasound in 
order to more effectively track fetal growth. 
 
3.4.6 Conclusions 
In this study of very severely obese women, total cortisol levels were lower 
throughout pregnancy than in lean women. A lower concentration of total 
cortisol in obese women may indicate a substantial reduction in the level of 
glucocorticoids that the developing fetus is exposed to during pregnancy, 
potentially protecting the baby from detrimental programming effects. If lower 
cortisol measurements are common amongst the wider obese pregnant 
population, this finding may partly explain the increased prevalence of higher 
birth weights and macrosomia amongst obese pregnant women (Ehrenberg et al. 
2004).  
The placenta acts as a barrier to glucocorticoids, but is also intimately involved 
in both the maternal HPA-axis and regulating fetal growth. The effects of 
maternal obesity on this organ, particularly on the barrier enzyme 11βHSD2, 
shall be explored in the next chapter. 
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Chapter 4:  
Placental Gene Expression 
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4.1 Introduction 
In Chapter 3, it was shown that maternal obesity was associated with lower 
levels of total circulating cortisol throughout pregnancy. Glucocorticoids are 
powerful regulators of fetal growth and development, and the lower levels of 
cortisol that the fetus of an obese woman is exposed to may partly explain the 
macrosomia associated with maternal obesity. 
In order to protect the fetus from the potentially harmful effects of circulating 
glucocorticoids, the placenta expresses a ‘barrier enzyme’, 11βHSD2, which 
inactivates cortisol by converting it to the biologically inert cortisone (Brown et 
al. 1993). Deficiencies of this enzyme have been associated with decreased birth 
weight and poor placental development. Maternal malnutrition in rodents has 
been shown to reduce transcript levels of 11βHSD2, suggesting a link between 
maternal diet and the efficacy of the placental glucocorticoid barrier (Lesage et 
al. 2001b). Furthermore, low placental 11βHSD2 has been observed in low birth 
weight babies (Stewart et al. 1995). 
The growth and development of the placenta itself is also an important variable 
when considering birth outcomes. A larger placenta is likely to be more efficient 
than a smaller placenta, due to an increased surface area contacting the maternal 
bloodstream over which nutrient exchange can occur. Placental growth and 
development is dependent on a number of key regulatory genes, including the 
growth factor IGF2 and the nuclear receptor GR. A number of other genes, 
including inflammatory regulators and targets of GR are also important in 
placental function and potential programming effects on the fetus. These genes, 
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which include GILZ, PPARγ, IL6 and IL1β, have been shown to regulate several 
important mechanisms, including steroidogenesis, inflammation, placental 
invasion and growth (Jauniaux et al. 1996; Roth et al. 1996; Roberts et al. 2003; 
Makris et al. 2006; Zhao et al. 2006; Matsuda et al. 2013). The genes IGF2R and 
H19, which are thought to antagonistically interact with the growth factor IGF2 
are also important modulators of fetal and placental growth, and are thought to 
be particularly important in growth restriction through the phenomenon of 
imprinting, whereby allele-specific expression of certain genes, and their 
interactions with one another, tightly regulate both fetal and placental growth, 
with potentially significant impacts on birth weight as a result (Perkins et al. 
2012; St-Pierre et al. 2012; Turan et al. 2012). 
In order to investigate the effects of maternal obesity on placental gene and 
protein levels and localisation, samples were taken from three time points in 
pregnancy: first trimester, second trimester and at term. Furthermore, fetal liver 
tissues were also sampled during the second trimester in order to determine the 
potential effects of maternal obesity in the fetal compartment. 
 
4.1.1 Hypothesis 
It was hypothesized that maternal obesity would be associated with increased 
placental mRNA transcript levels of the glucocorticoid barrier enzyme 
11βHSD2, as well as other key genes involved in nutrient transport, placental 
growth and development, resulting in lower fetal exposure to maternal cortisol 
but higher exposure to nutrients for growth. 
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4.1.2 Aims 
1. To investigate protein localization and abundance of the glucocorticoid barrier 
enzyme 11βHSD2 in placental trophoblast tissue obtained from the first trimester 
and second trimester of pregnancy, and at term. 
 
2. To identify suitable control ‘housekeeping’ genes for use in real time PCR 
analysis for first trimester, second trimester and term tissues. 
 
3. To investigate the effects of maternal obesity on placental mRNA transcript 
levels of key genes, including 11βHSD2, GR and IGF2, and other genes involved 
in growth and development of the placenta in the first trimester and second 
trimester of pregnancy, as well as at term. 
 
4. To investigate the effects of maternal obesity on fetal liver mRNA transcript 
levels of key genes, including the glucocorticoid barrier enzyme 11βHSD2, the 








First and second trimester tissue was collected from women at time of 
termination of pregnancy and term placental tissue was collected at elective 
caesarean section as described in methods section 2.1. For first trimester and 
second trimester studies, where samples were limited in number, placental 
biopsies were collected from women with a range of BMIs, including lean, 
normal, overweight, and obese women. For the term placental gene expression 
arm of the study, placental biopsies were collected from lean women (BMI < 25 
kg/m2) and obese women (BMI > 30 kg/m2) at delivery; the lean and obese 




A single NBF-stored sample selected at random from placental samples from 
each gestation was used for imaging 11βHSD2 protein using 
immunohistochemistry techniques as described in Section 2.3.4.1. 
 
4.2.3 RNA Extraction  
Tissues stored in RNALater were used for RNA purification and extraction as 
described in Section 2.3.1.1. 
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4.2.4 Reverse Transcription and Real Time PCR 
RNA successfully extracted from tissues was converted to cDNA using Roche 
Reverse Transcription kits as described in Section 2.3.1.4. cDNA was used to 
perform qPCR in order to estimate mRNA transcript levels of key target genes as 
described in detail in Section 2.3.1.5. 
4.2.5 Statistical Analyses 
mRNA transcript data was normalised to the control genes PPIA for first 
trimester samples, YHWAZ for term samples, and the mean of TBP and β-ACTIN 
for second trimester samples. Normal distribution of data was assessed visually 
using histograms, and statistically using the D'Agostino & Pearson omnibus 
normality test. mRNA transcript data were not normally distributed and were 
normalised using natural log transformation. Correlations between mRNA 
transcript levels and maternal BMI in first and second trimester tissues were 
analysed using Pearson correlation. Adjustments for confounding factors were 
performed using multiple linear regression. Differences between mRNA 
transcript levels between obese and lean groups at term were compared using 
independent t-tests.  
All data are presented as mean (±s.e.m), and p values of less than 0.05 were 
considered significant. 
Power calculations were performed to determine the sample sizes for analyses at 
each time point during pregnancy. Statistical power calculations are necessary to 
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determine the sample size necessary to limit the probability of commiting a type 
II error (i.e. incorrecty rejection of the null hypothesis) 
For correlation analyses (i.e. first trimester and second trimester gene 
expression), a minimum sample size of 29 biopsies was determined necessary to 
detect a correlation r ≥ 0.4 with an alpha of 0.05 and a statistical power of 0.8. 
For grouped analyses (i.e. term placental tissue), a minimum sample size of 56 
was determined necessary to detect a 20% difference in gene expression between 
groups, based on an alpha of 0.05, and a statistical power of 0.8.  
Analysis was performed using Minitab (Minitab Inc, PA, USA) and Statistica 
(StatSoft Inc, OK, USA). Graphs were prepared using GraphPad Prism 
(GraphPad Software Inc, CA, USA). 




4.3.1.1 11βHSD2 Protein Positive and Negative Controls 
Mouse ectopic trophoblast tissue was used as a positive control for the 11βHSD2 
immunohistochemistry antibody, as shown in Figure 4-1. This antibody has been 
validated in both human and mouse tissues; murine ectopic tissue has also been 
validated and used as a positive control in prior work by Jeremy Brown 
(unpublished data). 
Figure 4-2 shows nuclear counterstaining without use of the 11βHSD2 antibody 
in the same tissue as a negative control. 
 
4.3.1.2 11βHSD2 Protein in First Trimester Placental Tissue 
Figure 4-3 shows a representative slide showing the distribution of 11βHSD2 
protein in first trimester tissue at low and high magnifications. In first trimester 
trophoblast tissue, 11βHSD2 protein appears to be limited to the 
syncytiotrophoblast, or the outermost layer of the placental villi, with an apparent 
absence of any protein in the inner cytotrophoblast tissue (see Figure 4-3B). 
11βHSD2 protein is present throughout the syncytiotrophoblast, forming a 
complete barrier around the entirety of the placental villi. At this stage of 
pregnancy, the syncytiotrophoblast appears as a thick layer surrounding the 
entire villus. Furthermore, the villi appear relatively undifferentiated, with a low 
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surface area to volume ratio, typical of early placental development (see Figure 
4-3A). 
 
4.3.1.3 11βHSD2 Protein in Second Trimester Placental Tissue 
In second trimester tissue, 11βHSD2 protein is again limited to the 
syncytiotrophoblast as seen in first trimester tissue, and again appears to be 
expressed throughout most of the syncytium surrounding the placental villi (see 
Figure 4-4).  It should be noted that there appears to be greater differentiation of 
the villi when compared to first trimester tissues (see Figure 4-4A) and the area 
in which 11βHSD2 is expressed, and by extension, the syncytiotrophoblast 
appear reduced, with a much thinner layer of tissue stained when compared to 
first trimester samples (see Figure 4-4E).  
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Figure 4-4. A-D: Immunohistochemistry staining (positive control) for 11βHSD2 protein 
with nuclear counterstaining (blue) in ectopic trophoblast tissue, A: 50x magnification, B: 
100x magnification, C: 250x magnification, D: 400x magnification of trophoblast villi. 
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Figure 4-2. A-D: Immunohistochemistry staining (negative control) for 11βHSD2 protein 
with nuclear counterstaining (blue) in ectopic trophoblast tissue, A: 50x magnification, B: 
100x magnification, C & D: 400x magnification of trophoblast villi. 
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Figure 4-3. A-D: Immunohistochemistry staining for 11βHSD2 protein (brown) with 
nuclear counterstaining (blue) in first trimester placental trophoblast biopsy tissue, A: 50x 
magnification, B: 100x magnification, C & D: 400x magnification of placental villi. 
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Figure 4-4. A-E: Immunohistochemistry staining for 11βHSD2 protein (brown) with 
nuclear counterstaining (blue) in second trimester placental trophoblast biopsy tissue, A & 
B: 50x magnification, C & D: 100x magnification, E: 400x magnification of placental villi. 
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4.3.2 11βHSD2 Protein in Term Placental Tissue 
Term tissues show 11βHSD2 protein that is localized to the syncytiotrophoblast 
as seen in first and second trimester tissues (see Figure 4-5). The protein appears 
to be expressed throughout the entirety of the syncytium layer, forming a 
complete and continuous layer around even the smallest villi (see Figure 4-5B). 
The villi appear more numerous and more highly branched than at previous time 
points during pregnancy,. There also appears to be greater vascularisation of the 
cytotrophoblast, with a number of blood vessels apparent. Finally, the syncytium 
appears as a very thin monolayer, with characteristic nuclear bulging (see Figure 
4-5D). 
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Figure 4-5. A-E: Imunohistochemistry 
staining for 11βHSD2 protein (brown) 
with nuclear counterstaining (blue) in 
term trophoblast tissue, A: 50x 
magnification, B & C: 100x 
magnification, D & E: 400x 
magnification of placental villi. 
 
C 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
 153 
4.3.3 11βHSD2 Protein Levels 
Figure 4-6 shows western blot results for 11βHSD2 protein in placental tissues 
from a representative sample of first trimester and term samples. Samples A to D 
are derived from four term placentas, while samples E to H are derived from four 
first trimester samples. Table 4-1 shows semi-quantitative protein concentrations 
for the samples relative to α-tubulin protein. Protein levels of 11βHSD2 were 
significantly higher in first trimester samples compared to term samples 
(p<0.005). 
  




        α-tubulin 
        11βHSD2 
 
             A       B     C       D      E        F       G       H  
Figure 4-6. Western blot for 11βHSD2 and α-tubulin protein in term (A-D) and first 



























Table 4-1. Quantification of western blot results for 11 β HSD2 protein in term (A-D) and 
first trimester (E-H) placental samples. 
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4.3.4  mRNA Transcript Levels  
4.3.4.1 First Trimester Placenta Tissue Control Genes 
A number of genes were tested for suitability as a control gene for real time PCR 
in a small sample of first trimester trophoblast tissue (see Figure 4-7). PPIA 
transcript was detected in all samples, and was found to have the lowest 
correlation with BMI (r=0.007, p=0.96) and thus was selected as a control gene 
for use in real time PCR. 
4.3.4.2 Second Trimester Placenta and Liver Tissue control Genes 
TBP, β-ACTIN, SDHA, GAPDH and B2M were investigated as potential control 
genes in small samples of second trimester liver and placenta tissue.  
In the placenta (Figure 4-8), TBP was found to have the lowest correlation with 
BMI, and thus was selected as a control gene for use in real time PCR. In the 
liver (Figure 4-9), a mean value of the genes TBP and β-ACTIN was found to 
have the lowest correlation with BMI, and was therefore used as a control gene 
in real time PCR. 
4.3.4.3 Term Placenta Tissue Control Genes 
Seven control genes, identified as possible candidates through a literature review 
(Meller et al. 2005; Murthi et al. 2008; Cleal et al. 2009), were measured in a 
small sample of term placental tissue from lean and obese women (see Figure 4-
10). Of the genes investigated, YWHAZ was found to have the smallest difference 
in transcript concentration between the lean and obese groups and thus was 
selected as a control gene for use in real time PCR. 




Figure 4-7. Control gene candidates for first trimester placenta samples.!However, YWHAZ 
mRNA transcripts were only detected in 26 of the 32 samples and TBP transcripts were 
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Figure 4-9. Control gene candidates for second trimester liver tissue. 
!
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Figure 4-10. Control gene candidates for term placenta samples. 
!
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4.3.5 Placental mRNA Transcript Levels During the First 
Trimester 
4.3.5.1  Demographics 
Of the 53 first trimester placental tissue samples, RNA of suitable quality for 
real-time PCR could not be extracted from 21 samples. Table 4-2 shows the 
characteristics of the 32 women from whom suitable RNA was obtained, 
including 15 lean women, 5 overweight women, and 12 obese women. BMI did 





BMI (kg/m2) 26.80 (1.27) 
 
Age (years) 24.75 (1.25) 
 
Gestation (days) 66.12 (1.83) 
 
Smokers* 23 (72%) 
 
Nulliparous* 19 (59%) 
 
Multiparous* 13 (41%) 
 
Table 4-2. Demographic data for first trimester tissue samples (n=32) Data are mean (sem) 
or *N (%) 
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4.3.5.2 mRNA Transcript Levels in First Trimester Placental Tissue 
There were significant positive correlations between maternal BMI and mRNA 
transcript levels of 11βHSD2 (r=0.44, p<0.01 see Figure 4-11A), GR (r=0.47, 
p<0.05, see Figure 4-11B) but not IGF2 (r=0.05, p=0.78, see Figure 4-11C) in 
trophoblast tissue obtained from terminations of pregnancy conducted during the 
first trimester. After adjustment for maternal age, parity, smoking status and 
gestational age, the association between 11βHSD2 transcript levels and BMI 
remained significant (b=+0.133, adjusted p<0.01,), while the association was 
weakened for GR and BMI (b=+0.052, adjusted p=0.06,). 
 
No significant correlations were observed between maternal BMI and the relative 
placental mRNA transcript levels of a number of other key genes, including 
IGF2R, H19 and the GR target genes PPARγ and GILZ (see Figures 4-12 and 4-
13). No significant correlations were observed between mRNA transcript levels 
and length of gestation or maternal age. 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
 162 
  
Figure 4-11. mRNA transcript levels of 11βHSD2 (A), GR (B) and IGF2 (C) (all relative to 
PPIA) in first trimester trophoblast tissue plotted against maternal BMI (kg/m2).  The 
retrospective statistical power of the analysis for 11βHSD2 was 0.8 and for GR was 0.81. 
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r=0.38, p<0.05, adjusted p=0.06
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Figure 4-12. mRNA transcript levels of genes in first trimester trophoblast tissue. No 
significant correlations were observed between maternal obesity and mRNA transcript 
levels for any of the genes investigated. LEPTIN mRNA transcript was only detected in 11 
samples and GILZ transcripts were only detected in 20 samples. 
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Figure 4-13. mRNA transcript levels of genes in first trimester trophoblast tissue. No 
significant correlations were observed between maternal obesity and mRNA transcript 
levels for any of the genes investigated. LPL transcripts were detected in 17 samples, IGF2R 
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4.3.6 mRNA Transcript Levels During the Second 
Trimester 
4.3.6.1 Demographics  
Tissue samples were collected from a total of 30 pregnancies. Of these, placental 
tissue samples were collected from 18 pregnancies, while liver tissue samples 
were collected from 26 pregnancies. BMI data was not available for three women 
from whom placentas were collected, and seven women from whom fetal liver 
was collected, and as a result data from these individuals could not be used, 
leaving a final total of 15 placenta samples and 19 liver samples (see Table 4-3). 
   
 
Placenta (n=15) Liver (n=19) 
 
BMI (kg/m2) 22.95 (1.6) 24.67 (1.0) 
 
Age (years)  27.35 (0.65) 27.74 (0.88)  
 
Gestation 
(days) 116.3 (3.12) 115.5 (3.19) 
 
Females * 3 (20%) 3 (15%) 
 
Males *  12 (80%)  16 (85%) 
 
Table 4-3. Demographic data for second trimester tissue samples. All continuous data are 
mean (±s.e.m), categorical data (*) are n (%). 
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4.3.6.2 Placental mRNA Transcript Levels During the Second 
Trimester 
In this small sample size (n=15) IL-1β mRNA transcript levels positively 
correlated with maternal BMI (see Figure 4-15), and a similar trend was 
observed with IGF2 (see Figure 4-14). There were no other significant 
correlations between relative mRNA transcript levels and maternal BMI for any 
of the genes studied in second trimester placental tissue. A number of samples 
(n=5) failed to amplify for 11βHSD2, resulting in a reduced group of 10 samples. 
mRNA transcript of the genes LEPTIN was not detected in four samples, 
resulting in a reduced sample size of 11, while mRNA transcript of IL-1β was not 
detected in one sample. 
 
4.3.6.3 Fetal Liver mRNA Transcript Levels during the Second 
Trimester 
No significant correlations were observed between maternal BMI and mRNA 
transcript levels of any of the genes studied in second trimester fetal liver tissue 
(see Figure 4-16 and Figure 4-17). 11βHSD2 mRNA transcript was not detected 
in 10 samples, leaving a reduced sample size of 9 for this gene. While previous 
studies have demonstrated expression of 11βHSD2 in ovine liver, little work has 
been carried out on the fetal hepatic expression of this gene in humans (Langlois 
et al. 1995). 
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Figure 4-14. mRNA transcript levels of key genes relative to TBP in second trimester 
placental tissue.
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Figure 4-15. mRNA transcript levels (relative to TBP) in second trimester placental tissue. 
No significant correlations were found between relative mRNA transcript levels and 
maternal BMI. Statistical power was calculated as 0.8 for IL-1B. !
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Figure 4-16. mRNA transcript levels of key genes (relative to B-ACTIN and TBP) in second 
trimester fetal liver tissue.
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Figure 4-17. mRNA transcript levels (relative to B-ACTIN and TBP) in second trimester 
fetal liver tissue.  
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4.3.7 mRNA transcript levels at term 
4.3.7.1 Demographics 
Table 4-4 shows the characteristics of 60 women from whom term placental 
tissue was collected, according to BMI. Of the twenty-eight obese women, 
twenty had children with birth weights between 2500 grams and 4000 grams 
(‘appropriate for gestational age’ [AGA]), while eight delivered children with 
birth weights greater than or equal to 4000 grams (‘large for gestational age’ 
[LGA]). All infants born to lean women were AGA. AGA and LGA descriptions 
are calculated based on the gestational age. 
Lean and obese women did not differ significantly in terms of birth weight or 
gestation, however the mean age of the lean group was higher than that of the 
obese group (p<0.05). Subsequent analysis showed that mean birth weights did 
not differ between the lean and obese AGA groups (p=0.34), but did differ 
significantly between lean and obese LGA (p<0.0001), and between obese AGA 
and obese LGA (p<0.0001).  
Mean length of gestation did not differ between lean and obese AGA groups 
(p=0.61), between lean and obese LGA groups (p=0.44) or between obese AGA 
and obese LGA groups (p=0.26). 
Mean maternal age did not differ significantly between lean and obese AGA 
groups (p=0.16), or between obese AGA and obese LGA groups (p=0.47). Obese 
LGA tended to be younger than lean (p=0.058). Parity did not differ between 
obese AGA and obese LGA groups (p=0.415). However, parity was significantly 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
 172 
higher in the obese AGA compared to lean (p<0.00001), and significantly higher 
in obese LGA compared to lean (p<0.05). 
Significantly more obese women were of lower socioeconomic status than lean 
women (p<0.0005). No differences in socioeconomic status were observed 
between lean women and obese women with AGA babies (p=0.33), lean women 
and obese women with LGA babies (p=0.19) or obese women with AGA babies 
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4.3.7.2 mRNA Transcript Levels in Term Placental Tissue 
There were no significant correlations between maternal age, parity, length of 
gestation, neonate birth weight or gender and mRNA transcript levels of any of the 
genes studied. 
 
No differences in placental 11βHSD2 or GR transcript levels were observed between 
lean and obese women when no consideration was given to offspring birth weight in 
unadjusted analyses, or after adjustment for maternal age, smoking status, length of 
gestation and neonate gender (11βHSD2 unadjusted p=0.96, adjusted b=+0.62, 
p=0.1; GR unadjusted p=0.56, adjusted b=-0.58, p=0.22). Placental IGF2 expression 
was significantly lower in obese pregnancy compared to lean (see Figure 4-18) and 
this finding remained significant in regression analyses (unadjusted p<0.05,  
b=-1.11,adjusted p<0.05). 
 
However, when the obese group was divided according to offspring birth weight, 
significant differences in mRNA transcript levels of these three key genes was 
revealed. Levels of mRNA transcript of 11βHSD2 differed significantly between 
placentas from lean, obese AGA, and obese LGA pregnancies (one-way ANOVA, F 
= 1.473, p < 0.005); mRNA transcript levels were significantly higher in placentas of 
obese women with LGA babies compared to obese women with AGA babies 
(p<0.05, adjusted p<0.05, see Figure 4-19A). mRNA transcript levels of GR also 
differed significantly between placentas from lean, obese AGA, and obese LGA 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  175 
pregnancies (one-way ANOVA, F = 2.119, p < 0.001); mRNA transcript levels were 
significantly lower in placentas of obese women with LGA babies compared to obese 
women with AGA babies (p<0.05, adjusted p=0.11, see Figure 4-19B), and tended to 
be lower in obese women with LGA babies compared to lean women (p=0.059). 
Further, mRNA transcript levels of IGF2 also differed significantly between 
placentas from lean, obese AGA, and obese LGA pregnancies (one-way ANOVA, F 
= 1.004, p < 0.01); mRNA transcript levels were significantly lower in obese women 
with LGA babies compared to lean women (p<0.01, adjusted p<0.05, see Figure 4-
19C).  
No significant differences in mRNA transcript levels were observed between 
placental tissues from lean and obese pregnancies for a number of other genes 
studied, including 11βHSD1, IGF2R and H19 (see Figure 4-20). Furthermore, when 
the obese group was divided into those with AGA and LGA babies, no difference 




Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  176 
 
Figure 4-18. mRNA transcript levels of 11βHSD2, GR and IGF2 (relative to YWHAZ) in term 
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Figure 4-19. A: mRNA 
transcript levels of 11βHSD2 
(relative to YWHAZ) in term 
placental tissue for lean (BMI 
of <25 kg/m2, n=30), obese with 
appropriate for gestational age 
offspring (maternal BMI >30 
kg/m2, birth weight <4000g, 
n=20, Obese AGA) and obese 
with large for gestational age 
offspring (maternal BMI 
>30kg/m2, birth weight >4000g, 
n=8, Obese LGA).  B: mRNA 
transcript levels of GR (relative 
to YWHAZ) in term placental 
tissue for lean, obese with 
appropriate for gestational age 
offspring and obese with large 
for gestational age offspring.  
C: mRNA transcript levels of 
IGF2 (relative to YWHAZ) in 
term placental tissue for lean, 
obese with appropriate for 
gestational age offspring and 
obese with large for gestational 
age offspring.  Data are mean 
(±sem).


































































Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  178 
 
Figure 4-20. mRNA transcript levels of genes in term placental tissue. No significant differences 
were observed between lean and obese placental transcript levels for any of the genes 
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4.4 Discussion 
In this chapter, immunohistochemistry techniques and western blotting were used to 
analyse the abundance and localization of the placental enzyme 11βHSD2. 
Additionally, mRNA transcript levels of a number of key genes, including 11βHSD2, 
were analysed in human placental tissues obtained from each trimester of pregnancy 
in both lean and obese women. Finally, mRNA transcript levels of a number of genes 
in the fetal liver as a representative fetal glucocorticoid sensitive target tissue were 
also measured during the second trimester of pregnancy. The size of the study was 
smaller than initially planned due in part to the difficulty in extracting RNA of 
suitable integrity and in sufficient quantities from the target tissue, despite attempts 
to minimise the time between tissue collection and mRNA extraction. A number of 
samples were found to be unsuitable and thus could not be used. 
Using immunohistochemistry it was demonstrated that 11βHSD2 protein is present 
in first trimester, second trimester and term placental tissues, implying continuous 
presence throughout pregnancy. Furthermore, the protein appears to be localized 
exclusively to the syncytiotrophoblast, the epithelial lining of the placental villi. This 
pattern of localisation likely contributes to the formation of a complete and 
continuous barrier against glucocorticoid transmission between the maternal blood 
stream and fetal tissues at the point of most intimate contact between the two. This 
finding reinforces previous literature demonstrating that the placental glucocorticoid 
barrier (as assessed by mRNA levels of 11βHSD2) is present throughout the entirety 
of the syncytiotrophoblast for the duration of pregnancy (McTernan et al. 2001) and 
confirms that levels of this protein in human pregnancy differ markedly from the 
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patterns observed in rodents, where levels are initially high, but subsequently drop 
mid-gestation (Waddell et al. 1998; Thompson et al. 2002).  Surprisingly, protein 
levels of 11βHSD2 were found to be higher during the first trimester when compared 
to term, a finding that contradicts previous studies showing that mRNA transcript 
levels of 11βHSD2 increase dramatically throughout human pregnancy (McTernan et 
al. 2001). This suggests that post-transcriptional regulation of the enzyme may be 
occurring, explaining the disparity between gene expression and protein levels. 
However, the sample size in this part of the current study was small, and further 
study of post-translational regulation of 11βHSD2 may be an important area of future 
research. 
 
Excess exposure to glucocorticoids during pregnancy has been associated with 
reduced fetal growth and lower birth weight, which is in turn associated with 
increased risk of hypertension, type 2 diabetes and cardiovascular disease later in life 
(Barker et al. 1993a; Moore et al. 1996; Rich-Edwards et al. 1997). The placental 
enzyme 11βHSD2 has been hypothesised to protect the developing fetus from the 
increasing levels of glucocorticoids in maternal blood by converting active cortisol to 
inactive cortisone, although the barrier is thought to be incomplete (Brown et al. 
1993; Benediktsson et al. 1997). The levels of the enzyme are thought to be an 
important determinant of its effectiveness in forming a coherent barrier to maternal 
cortisol and dysfunction of the enzyme has been hypothesised to allow more active 
glucocorticoids to cross the placenta into the fetal bloodstream, leading to 
organisational effects on the developing fetus, including neurological and growth 
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effects (Edwards et al. 1993; Welberg et al. 2000). In support of this, 11βHSD2 
activity has been shown to correlate with birth weight in human pregnancy (Stewart 
et al. 1995; Murphy et al. 2002b). The enzymatic activity of 11βHSD2 was not 
measured in this study, and therefore it is difficult to draw strong conclusions 
regarding the effects of maternal weight status on 11βHSD2 activity in this cohort. 
The determination of useful control (or housekeeping) genes was important to 
consider before performing real time PCR in placental tissue. While a handful of 
studies have investigated candidate control genes for placental mRNA transcript 
levels, the results have often been contradictory, reflecting the diverse nature of the 
sources of tissues used (Meller et al. 2005; Murthi et al. 2008; Cleal et al. 2009). No 
studies have been published investigating suitable control genes in an obese 
pregnancy paradigm, and therefore it was important to establish a suitable candidate.  
Candidates were initially chosen from a small pool of genes described previously in 
the literature and the most suitable candidate chosen did differ according to gestation 
studied.  
In the first trimester, increased placental mRNA transcript levels of 11βHSD2 in 
association with obesity may protect the fetus from excess glucocorticoid exposure 
and may also contribute ultimately to the higher birth weights observed in obese 
pregnancy. As described in chapter 3, obese pregnant women have lower circulating 
levels of glucocorticoids compared to lean women. Lower circulating levels of 
cortisol coupled with increased levels of placental 11βHSD2 mRNA transcript may 
lead to a reduced fetal exposure to maternal glucocorticoids and therefore higher 
birth weight, possibly due to delayed organ maturation. Furthermore, increased 
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placental mRNA transcript levels of GR in early obese pregnancy may lead to an 
increase in growth of the placenta, potentially leading to higher birth weight. 
Increased transcript levels of GR may also confer immunosuppressive and anti-
inflammatory effects, potentially allowing for more effective invasion and growth of 
the placenta in early pregnancy. These changes in mRNA transcript levels may allow 
the placenta to maximise its growth in response to increased maternal nutrients early 
in pregnancy, at a time when placental growth is at a peak. This may in turn allow for 
a more efficient delivery of nutrients to the fetus throughout pregnancy, particularly 
during the second and third trimesters, when fetal growth is maximal.  This arm of 
the study was somewhat limited by the relatively small sample size used. While 
preliminary power calculations suggested that the intended sample population was 
sufficiently powered, difficulties in obtaining viable mRNA samples from placental 
biopsies reduced the number of samples available for analysis. Furthermore, assays 
for some genes did not produce sufficient signal strength for all samples, again 
significantly limiting the sample size for some analyses. These limitations are likely 
to have impacted the power of the study. Nevertheless, it is possible that this work 
will be an important basis for future experiments involving a larger population of 
patients from whom first trimester placental tissue biopsies can be obtained.  
As low birth weight has previously been linked to reduced placental 11βHSD2 levels, 
it was hypothesised that maternal obesity would be associated with increased 
placental 11βHSD2 near term, leading to a higher birth weight through an increased 
placental barrier to maternal glucocorticoids. While no significant differences in 
placental gene transcript levels were observed between lean and obese pregnancies, 
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when individuals were separated into groups by birth weight, levels of 11βHSD2 
mRNA transcript were significantly higher in obese women who gave birth to LGA 
babies when compared to those who gave birth to AGA babies. Thus, higher levels 
of 11βHSD2 in the placentas of some obese pregnant women may protect the 
developing fetus more effectively, allowing greater levels of growth in utero and thus 
a higher birth weight. This may reflect an adaptation to excess nutrients, delaying 
maturation in order to maximise growth in a nutritionally rich environment. 
Additionally, no difference in mRNA transcript levels of GR at term was observed 
between lean pregnancies and obese pregnancies with appropriate for gestational age 
offspring. However, when the obese group were divided by offspring birth weight 
placental GR mRNA transcript levels were lower in obese women with LGA babies 
compared to obese women with AGA babies. As glucocorticoids, acting via GR, are 
fundamental regulators of decidualisation, implantation, placental development and 
angiogenesis, this may reflect a difference in placental growth and function between 
obese women with AGA and LGA pregnancies (Korgun et al. 2012). However, it is 
important to note that GR target genes such as GILZ did not appear to be affected by 
maternal BMI, suggesting that the biological significance of the altered gene 
expression of GR may be questionable. It will be important to examine the effects of 
maternal obesity on other GR target genes. 
IGF2 transcript levels were lower in obese pregnancy compared to lean and were 
lowest in the in obese women with LGA babies. This apparent incongruity, that the 
expression of this growth-promoting gene is lower in pregnancies resulting in larger 
offspring, is not easy to explain. However, it is possible that this pattern represents 
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placental-specific down-regulation of this gene and that expression in the fetus 
remains unchanged at a time when placental growth is less important.  
The planned sample population for the term arm of this study was adequately 
powered based on initial power calculations. However, difficulties encountered in 
obtaining mRNA of suitable quality from placental samples led to a reduction in the 
sample size. This may have limited the power of the study. Nevertheless, the final 
sample size was calculatd to be sufficiently powered, although will be important for 
future studies to utilise larger populations in order to validate the preliminary 
findings presented herein.  
The results of this study suggest that the changes in placental mRNA transcript levels 
of these three key genes (11βHSD2, GR and IGF2) may be, at least, useful markers 
of underlying processes or even contributory factors in the determination of offspring 
birth weight and pregnancy outcome in obese pregnancy. Unanswered questions 
remain to be explored as to whether the two birth weight groups differ in terms of 
vulnerability to later life disease, and whether low birth weight in obese pregnancy is 
more indicative (and predictive) of future pathology than high birth weight. It seems 
possible that, as a state of nutrient excess, one may expect obese pregnancy to result 
in higher birth weight as the fetus maximises growth in response to the increased 
availability of nutrients. Alternatively, higher birth weight may represent an aberrant 
outcome of obese pregnancy, an inappropriate overgrowth response to excess 
nutrients. Whatever the case may be, alterations to the mRNA transcript levels of the 
genes 11βHSD2, GR and IGF2 represent a potential mechanism by which changes in 
fetal-placental growth, and therefore birth weight, may be mediated. 
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The results of a small-scale exploratory study suggested that no effect of obesity was 
observed on either placental or fetal liver mRNA transcript levels during the second 
trimester of pregnancy, with the exception of placental mRNA levels of the pro-
inflammatory cytokine gene IL-1β. The positive association between IL-1β and BMI 
may indicate increased levels of placental invasion in obese individuals, as placental 
IL-1β production has been shown to correlate with invasive potential in 
cytotrophoblast cells (Librach et al. 1994). Alternatively, the increased levels of IL-
1β may reflect a pro-inflammatory environment in obese pregnancy, as IL-1β is 
primarily produced by infiltrating inflammatory cells (Ikoma et al. 2003). Increasing 
concentrations of IL-1β have been associated with the onset of labour, suggesting a 
role in the timing of parturition (Romero et al. 1989). While the lack of observed 
effects may indicate changing vulnerability to maternal obesity during the course of 
pregnancy, indicating a protective response to the maternal environment at a time 
when growth and organ development are occurring and are potentially most 
vulnerable to excess nutrients, it may also be the result of the relatively small number 
of samples obtained at this time point. Second trimester tissues are difficult to obtain, 
and thus numbers were limited for this study. This analysis was likely insufficiently 
powered to adequately determine whether obesity significantly affects, and 
potentially increased the risk of a type II error. As a pilot study, however, this 
analysis may serve as a useful basis for future work utilizing larger sample sizes in 
order to draw firmer biological conclusions.  
Furthermore, the use of liver tissue, rather than other fetal tissues (e.g. brain) may be 
an important limitation, as the liver may not be susceptible to such insults at this time 
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point during human pregnancy. Finally, mRNA transcript level is not necessarily 
directly reflective of protein levels and post-translational regulation may affect the 
level of active protein, independently of mRNA transcription.  
A summary of the BMI-associated changes in mRNA transcript levels of key genes 
at each time point during pregnancy is presented in table 4-5. 
Alterations in mRNA transcript levels of 11βHSD2 in obese pregnancy, particularly 
the increased mRNA transcript levels observed in early gestation, may help explain 
the reduced levels of total circulating cortisol in obese pregnant women observed in 
Chapter 3. While urinary clearance of cortisol is elevated in non-pregnant obesity, it 
is possible that placental clearance of cortisol through inactivation by the barrier 
enzyme 11βHSD2 may contribute to changes observed in the blood measure of HPA 
axis activity in obese pregnant women. Testing such a relationship experimentally 
may be difficult, however, particularly in a clinical setting. It may be possible to 
perform animal experiments in which 11βHSD2 is knocked out in a tissue specific 
manner in the placenta, allowing for the investigator to track changes in maternal 
glucocorticoids throughout pregnancy in the absence of placental 11βHSD2; 
likewise, it may also be possible to perform experiments wherein placental 11βHSD2 
is overexpressed.  
The results of this study suggest that maternal obesity may be associated with 
changes in the placental expression of key genes. The mechanisms that are thought to 
influence gene expression are complex. The effects of obesity on one such 
mechanism, DNA methylation, will be explored in the next chapter. 
Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
  187 
 
 








11βHSD2 Increased with 
increased BMI 
No difference No difference Increased in obese 
LGA pregnancy 
relative to obese 
AGA 
GR Increased with 
increased BMI 
No difference No difference Decreased in obese 
LGA pregnancy 
relative to obese 
AGA 
IGF2 No difference Trend for 
increase with 
increasing BMI 
(p = 0.057) 
No difference Decreased in obese 
pregnancy relative to 
lean pregnancy; 
decreased in obese 
LGA pregnancy 
relative to obese 
AGA 
Table 4-5. Summary of BMI-associated changes in mRNA transcript levels of 
key genes at three time points during pregnancy. 
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Chapter 5:  
Methylation 
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5.1 Introduction 
The mechanisms by which adverse early-life conditions affect the fetus remain 
unclear. There is a growing body of evidence to suggest that epigenetic processes, 
the modification of DNA and histones without alterations to the nucleotide sequence, 
may be an important mechanism underlying fetal and early life programming 
(Waterland and Jirtle 2004; Mathers and McKay 2009) (see Introduction section 1.9). 
In chapter 4 the roles of a number of key placental genes were explored in an obese 
pregnancy paradigm, including GR and 11βHSD2, key genes involved in the 
regulation of fetal glucocorticoid exposure. These genes have been suggested to be 
regulated by epigenetic modifications, specifically DNA methylation, and their 
methylation status has been associated with programming effects (Heijmans et al. 
2008; Oberlander et al. 2008; Wright et al. 2008). Human and animal studies have 
suggested that the prenatal environment, particularly maternal stress, can alter 
methylation of the GR promoter (Mueller and Bale 2008; Oberlander et al. 2008; 
Turner et al. 2008; Turner et al. 2010; Cao-Lei et al. 2011). Animal work has 
suggested that IUGR is associated with increased methylation of 11βHSD2 in the 
kidney, and methylation of the genes 11βHSD2 and GR in blood is positively 
associated with increased adiposity and blood pressure later in life in human 
offspring exposed to an unbalanced maternal diet prenatally (Baserga et al. 2010) 
(Drake et al. 2012). Maternal depression is associated with increased methylation of 
GR in neonatal cord blood (Oberlander et al. 2008). 
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Imprinted genes, including the IGF2-H19 locus, have been suggested to act as 
nutrient sensors, optimising fetal nutrient supply via modulation of their epigenetic 
changes, ultimately leading to changes to the placental phenotype; alterations in the 
methylation state of such genes may have consequences for placental and fetal 
growth, reflecting the potent level of influence that these genes exert over 
development (Fowden et al. 2011). Accordingly, methylation of IGF2 in placental 
samples is associated with changes in birth weight in humans, and altered 
methylation of this gene has been shown to be altered in individuals exposed to 
famine prenatally (Heijmans et al. 2008; St-Pierre et al. 2012).  
The placenta is crucial to the maintenance of pregnancy and the development of the 
offspring. Thus, changes in epigenetic profiles within the placenta may contribute 
directly to programming effects through alterations in the transcriptional activity of 
genes involved in nutrient supply to the fetus, as well as placental function and 
growth. By studying the methylation status of genes such as 11βHSD2 and GR in the 
placenta, one may potentially gain an insight into the mechanisms underlying the 
differences in gene expression observed in obese and lean pregnancy. By studying 
the changes in DNA methylation at the imprinted growth factor IGF2 and its 
neighbour H19, insight may be gained into mechanisms that finely regulate placental 
growth and development. Furthermore, as the placenta is of partly fetal origin, such 
study may potentially provide clues as to the effects of maternal obesity on 
methylation in other fetal tissues.  
An increasing number of animal studies (and a smaller number of clinical studies) 
have explored the role of altered DNA methylation in obese pregnancy (Gemma et 
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al. 2009; Milagro et al. 2009; Plagemann et al. 2009; Vucetic et al. 2010), although 
no studies have examined the effects of maternal obesity on the methylation status of 
IGF2, GR or 11βHSD2 in human pregnancy. In this chapter, DNA methylation of 
these genes was studied in both first trimester and term placental tissues in samples 
collected from obese and lean women. 
 
5.1.1 Hypothesis 
It was hypothesized that changes described in Chapter 4 in the mRNA transcript 
levels of the genes 11βHSD2, GR and IGF2 associated with maternal obesity in first 
trimester and term placental tissues would be associated with alterations in DNA 
methylation status in regions of these genes involved in transcriptional regulation. 
 
5.1.2 Aims 
This pilot study aimed to investigate whether maternal obesity is associated with 
changes in the DNA methylation of key genes in placentas collected in the first 
trimester of pregnancy, as well as at term, and whether DNA methylation of these 
genes correlates with mRNA levels. 
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5.2 Methods 
5.2.1 Tissues 
First trimester tissue was collected from 22 women at time of termination of 
pregnancy and term placental tissue was collected at elective caesarean section from 
55 women as described in methods section 2.1.2. The samples were from the same 
women as the samples used for gene expression in chapter 3. 
 
5.2.2 DNA Extraction 
DNA purification was performed using a phenol/chloroform extraction method as 
described in Section 2.3.2.2. DNA quantity and integrity were measured using a 
Nanodrop spectrophotometer (Thermo Scientific, DE, USA) and by running on 
TBE/agarose gels. 
 
5.2.3 Bisulfite Treatment 
DNA extracted from placental samples was bisulfite treated using Epitect Bisulfite 
Kits (Qiagen, Hilden, Germany). 
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5.2.4 PCR 
PCR for IGF2 (DMR0 and DMR2), GR and 11βHSD2 was performed on bisulfite-
treated DNA as described in methods section 2.3.2.4. DMR 2 of IGF2 was assayed 
using two previously published assays covering separate regions of the DMR, these 
assays will be referred to as DMR2.1 and DMR2.2. 
 
5.2.5 Pyrosequencing 
Methylation of DNA was measured by pyrosequencing as described in methods 
section 2.3.2.6. 
 
5.2.6 Statistical Analysis 
Normal distribution of methylation data was assessed visually using histograms, and 
statistically using the D'Agostino & Pearson omnibus normality test. Correlations 
between methylation levels and maternal BMI in first trimester tissues were analysed 
using Pearson correlation. Adjustments for confounding factors (including maternal 
age, BMI, smoking status, parity and gestational age) were performed using multiple 
linear regression. Differences between methylation levels between obese AGA, 
obese LGA and lean groups at term were compared using independent t-tests.  
All data are presented as mean (±s.e.m), and p values of less than 0.05 were 
considered significant. For a statistical power of 0.8 and an alpha of 0.05, a sample 
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size of 23 biopsies was determined to be necessary for correlation analyses (r ≥ 0.4), 
while a sample size of 12 was determined to be necessary to detect a 5% difference 
(sigma 6%) between groups for grouped analyses. 
Analysis was performed using Minitab (Minitab Inc, PA, USA) and Statistica 
(StatSoft Inc, OK, USA). Graphs were prepared using GraphPad Prism (GraphPad 
Software Inc, CA, USA). 
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5.3 Results 
5.3.1 First Trimester Placenta 
5.3.1.1 Demographics 
Table 5-1 shows the characteristics of the 22 women from whom first trimester 
placental tissue samples were collected. The characteristics of this subset of women 
involved did not differ significantly from the larger cohort (see chapter 4). 
 Mean (sem) or N (%) 
BMI (kg/m2) 28.05 (1.59) 
Age (years) 24.25 (1.43) 
Gestation 
(days) 69.24 (1.90) 
Smokers* 9 (41%) 
Nulliparous* 11 (50%) 
Multiparous* 11 (50%) 
Table 5-1. Characteristics of first trimester study participants. Data are mean (s.e.m) or *N(%). 
 
5.3.1.2 Methylation 
IGF2 DMR0 had a mean methylation of 51.34%, DMR2 had a mean methylation of 
44.93%, H19 had a mean methylation of 45.50%, while the mean methylation of 
11βHSD2 promoter region was 9.79%, and GR promoter 1C had a mean methylation 
of 2.67%.  
No associations were observed between maternal BMI and methylation of any of the 
regions studied in either unadjusted analysis or when adjusting for maternal age, 
parity, smoking and gestational age (see Figure 5-1).  
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A positive trend was observed between methylation of DMR 0 and transcript 
abundance of IGF2 in unadjusted analysis and a negative trend between methylation 
of DMR 2.1 and transcript abundance of IGF2, the latter association was significant 
when adjusted for maternal age, BMI, smoking status, parity and gestational age (see 
Figure 5-2). No other associations were observed between methylation and transcript 
concentration for any of the genes studied in either unadjusted or adjusted analysis. 
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Figure 5-1. Methylation of differentially methylated regions of IGF2, H19 ICR, 11βHSD2 
promoter region and GR exon 1C in trophoblast samples collected during the first trimester. 
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Figure 5-2. Associations between methylation and transcript abundance of IGF2, 11βHSD2 and 
GR in first trimester placenta. 
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5.3.2 Term Placenta 
5.3.2.1 Demographics 
Table 5-2 shows the characteristics of 55 women from whom term placental tissue 
was collected, according to BMI. Of the twenty-four obese women, sixteen had 
children with birth weights under 4000 grams (‘appropriate for gestational age’ 
[AGA]), while eight delivered children with birth weights greater than or equal to 
4000 grams (‘large for gestational age’ [LGA]). All infants born to lean women were 
AGA. A greater proportion of obese women were of lower socioeconomic class (and 
fewer were of higher socioeconomic class) when compared to the lean group, and the 
obese group also had a higher proportion of male offspring compared to the lean. The 
subset of women involved in this study were similar to the larger cohort in terms of 
BMI, age, smoking status, birth weight, gestation and sex of baby. However, the 
proportion of women who were multiparous and who had lower socioeconomic 
status was lower when compared to the larger cohort (both p<0.05). 
Obese women with LGA babies were significantly more likely to be multiparous 
(p<0.05) and less likely to be smokers (p<0.05) compared to obese women with 
AGA babies. No other differences were observed between the characteristics of 
obese women with LGA babies and those with AGA babies. 
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5.3.2.2 Methylation 
Mean methylation of each region was similar to levels observed in first trimester 
tissue. No differences in methylation were observed between lean and obese women 
for any of the regions studied (see Figure 5-3). 
When the obese group was subdivided into women with AGA babies and women 
with LGA babies, region 1C of GR was found to have significantly lower 
methylation in obese women with LGA babies compared to lean women (see Figure 
5-4). No other differences in methylation were observed. 
No associations were observed between methylation and transcript concentrations at 
term in either unadjusted analysis or when adjusting for maternal age, parity, BMI 
and length of gestation (see Figure 5-5). 
Methylation of GR was found to negatively associate with birth weight at term in 
unadjusted analysis (p<0.05), but not after adjustment for maternal BMI, parity, 
neonate gender and gestational age (see Figure 5-6). No other associations with birth 
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Figure 5-3. Methylation of differentially methylated regions of IGF2, H19 ICR, 11βHSD2 
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Figure 5-4. Methylation of differentially methylated regions of IGF2, H19 ICR, 11βHSD2 
promoter region and GR exon 1C in placenta samples collected from lean women, obese women 
with AGA babies and obese women with LGA babies at term. 
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Figure 5-5. Associations between methylation and transcript concentration of IGF2, 11βHSD2 
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Figure 5-6. Associations between birth weight and placental methylation of differentially 
methylated regions of IGF2, H19 ICR, 11βHSD2 promoter region and GR exon 1C collected 
from lean and obese women at term. 
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5.4 Discussion 
A growing body of evidence is emerging to suggest that epigenetic mechanisms are 
an important contributor to the phenomenon of fetal programming of adult disease, 
with a number of animal studies in particular demonstrating an association between 
maternal nutrition and alterations in DNA methylation of a number of genes involved 
in growth and metabolism, including IGF2 and PPARγC1A (Waterland and Jirtle 
2004; Gemma et al. 2009; Mathers and McKay 2009; Vucetic et al. 2010). To date 
however, the effects of maternal obesity on gene methylation have not been 
extensively studied. This is due in part to the tissue specific nature of DNA 
methylation patterns. While ethical and practical considerations often necessitate the 
use of peripheral tissues (e.g. umbilical cord blood) for epigenetic studies in humans, 
the data derived from these studies may not necessarily reflect DNA methylation 
patterns in tissues more directly involved in the disease process. In spite of this, a 
number of studies have suggested a role for epigenetic mechanisms, in particular 
methylation, in fetal programming (Oberlander et al. 2008; Devlin et al. 2010; Turan 
et al. 2012). The use of peripheral tissues, along with the development of 
increasingly robust methods of assaying DNA methylation, has allowed for an 
increasing number of clinical epigenetic studies to be undertaken. 
In chapter 4, the expression of two genes involved in the regulation of glucocorticoid 
effects, GR and 11βHSD2, were found to be altered in obese pregnancy compared to 
lean controls in both first trimester and term placental samples. Regulation of 
11βHSD2 transcriptional activity has been suggested to be an important factor in 
pregnancy outcome, influencing variables such as birth weight; furthermore, 
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methylation of the gene is thought to be important, as increased methylation of the 
11βHSD2 promoter is associated with lower transcription, and increased methylation 
of this gene in the placenta has also been shown to associate with lower birth weight 
(Alikhani-Koopaei et al. 2004; Marsit et al. 2012).   
A handful of studies have suggested that methylation of the GR promoter is affected 
by maternal stress in the early-life environment (Mueller and Bale 2008; Oberlander 
et al. 2008; Turner et al. 2008; Turner et al. 2010; Cao-Lei et al. 2011; Hompes et al. 
2013). There is also evidence of a role for GR methylation in predicting pregnancy 
outcome, as increased methylation of the GR promoter in the placenta has been 
linked to higher birth weight (Filiberto et al. 2011). Furthermore, a study by Drake et 
al found that methylation of the genes 11βHSD2 and GR positively associated with 
increased adiposity and blood pressure later in life (Drake et al. 2012).  
In this study, methylation of the GR 1C promoter in term placenta negatively 
correlated with birth weight in unadjusted analysis, and was found to be lower in 
placentas of obese women with LGA pregnancy than lean women at term. This is 
counter to expectations, as mRNA levels of this gene were found to be lower in LGA 
obese pregnancy compared to lean. It is worth noting, however, that the association 
was found to be not significant in multivariate analysis. This may indicate that other 
epigenetic changes, including changes in the methylation of other GR promoters, 
may be more important regulators of transcriptional activity of this gene. Despite the 
link between maternal obesity and later adiposity in offspring, no associations were 
found between maternal BMI and methylation of GR 1C in the first trimester or the 
11βHSD2 promoter region at either time point. Furthermore, no associations were 
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observed between methylation and mRNA transcript levels for GR or 11βHSD2 in 
first trimester and term tissues, indicating that other mechanisms may be regulating 
gene transcription in this population. This calls into question the significance of the 
difference in methylation seen between groups for GR. If levels of methylation do 
not associate with expression, it seems unlikely that changes in the methylation at the 
sites analysed has biological significance.  
When considering the signifiance of differences in methylation, it is worth noting 
that while pyrosequencing is a robust method of measuring levels of methylation, it 
is limited by an inability to distinguish between methylation and 5-
hydroxymethylation (Radford et al. 2012). 5-hydroxymethylation involves the 
substitution of the C5 hydrogen in cytosine with a hydroxymethyl group. While the 
function of this form of methylation is unclear, it is currently thought to act either as 
an intermediate in DNA demethylation pathways, or as a novel form of epigenetic 
regulation (Guo et al. 2011; Bhutani et al. 2011; Kim et al. 2013). If 5-
hydroxymethylation reflects a step in a process of demethylation, it may be inferred 
to function in a manner antagonistic to methylation. Methods such as pyrosequencing 
that do not distinguish between the two forms may therefore be of limited use until 
improvements in detection are made. In order to fully elucidate the influence of 
methylation on gene expression, and by extension, pregnancy outcomes, it will be 
necessary to utilise novel methods that can distinguish between the different forms of 
methylation. Significantly, the inability to differentiate between methylation and 
hydroxymethylation may explain the lack of associations observed between 
methylation and gene expression in this study. 
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This study was also limited by the relatively small number of samples used, as good 
quality DNA proved difficult to extract from both first trimester and term tissues 
despite optimisation. Both phenol/chloroform and column-based methods of DNA 
extraction were attempted, and extractions were attempted a number of times for 
each sample. In addition, a number of samples did not generate sufficient 
fluorescence when assayed to effectively quantify DNA methylation, despite 
repeated attempts. This further decreased the effective sample size, significantly 
limiting the conclusions that can be drawn from this analysis. While the intended 
sample population size was determined to be adequately powered, the difficulties 
encountered with DNA extraction and assay efficiency may have detrimentally 
affected the statistical power of the analyses. However, despite the relatively small 
size used in this study when compared with some larger analyses (e.g. Heijmans et 
al. 2008; Filiberto et al. 2011), this work is comparable in size to a number of other 
clinical methylation studies in which significant effects were observed (McMinn et 
al. 2006; Guo et al. 2008; Oberlander et al. 2008; Gemma et al. 2009; Bourque et al. 
2010; Drake et al. 2012; Marsit et al. 2012). 
Additionally, studies involving pyrosequencing are often limited by the relatively 
poor lower limit of detection inherent to the method.  Particularly small changes in 
methylation may fall below the lower limit of detection for pyrosequencing assays, 
generally considered to be approximately 5% (Tsiatis et al. 2010). In this study, the 
relatively low levels of methylation of both GR and 11βHSD2 may have had an 
effect: methylation levels of both GR and the 11βHSD2 promoter were found to be 
low (less than 20%), a finding which is similar to other studies, raising the question 
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of whether small changes in methylation can have significant biological effects 
(Oberlander et al. 2008; Drake et al. 2012). Similarly low levels of methylation have 
been shown to be functionally relevant in another hormone receptor, ER 
(approximately 0.5% change) (Champagne et al. 2006). Even in the case of highly 
methylated genes, such as IGF2, the difference in methylation levels seen between 
groups in this study was rarely greater than 10%. More precise measurements of 
methylation may be possible in the future, as current methods are refined, or new 
techniques are developed. 
Finally, while this study provides some insight into the epigenetic processes at work 
in the placenta, it remains to be seen whether similar patterns are present in fetal 
tissues. It will be important to follow up any findings in the placenta with similar 
studies involving fetal tissues, where possible, in order to confirm whether epigenetic 
changes are similar in the placenta and the fetus. 
In chapter 4, mRNA transcript levels of the gene IGF2 were found to be significantly 
lower in obese LGA placentas than in placentas from lean pregnancy at term; 
however, no differences were observed in methylation of the gene. This agrees with 
the findings of a previous study, where IGF2 methylation was found to have no 
association with prenatal maternal BMI; however methylation of IGF2 was not found 
to be associated with birth weight, a finding which contrasts with previous work and 
may reflect the relatively small size of this study (St-Pierre et al. 2012). Furthermore, 
methylation of IGF2 did not appear to be associated with mRNA transcript levels at 
either time point studied. This suggests that other mechanisms may be regulating the 
activity of this gene in the placenta such as histone modifications. No obesity-related 
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changes were observed in H19 ICR methylation in either first trimester or term 
placental tissues. Furthermore, H19 ICR methylation did not correlate with IGF2 
mRNA levels at either of the time points studied.  
In summary, this study suggests that maternal obesity may not significantly affect 
methylation of the genes GR, 11βHSD2, IGF2, or H19 in placenta despite associating 
with altered transcriptional activity of these genes. Further work is necessary, and 
should focus on the role of other mechanisms regulating gene transcription (such as 
histone modification, microRNAs, and hydroxymethylation) in the regulation of gene 
transcription in the placentas of obese women. If alterations in other epigenetic 
marks are found in peripheral tissues such as the placenta, they may prove to be 
useful biomarkers of programming effects induced by maternal obesity.  
Obesity may be considered a type of physiological stress due to its metabolic, 
inflammatory and HPA axis effects. In the next chapter, the effects of psychological 
stress and mood during pregnancy on placental gene expression in two cohorts, one 
from Edinburgh and another from Finland, will be investigated. 
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Chapter 6:  
Maternal Stress During Pregnancy 
and Placental Gene Regulating 
Fetal Glucocorticoid Exposure 
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6.1 Introduction 
In Chapter 4, it was shown that the physiological stressor of maternal obesity has 
effects on placental mRNA concentration for a number of key genes regulating 
glucocorticoid metabolism. Psychological stress during pregnancy has been 
recognised to have programming effects on the developing offspring, with increased 
risk of anxiety and ADHD postnatally (O'Connor et al. 2003; O’Connor et al. 2005; 
Phillips et al. 2005; O'Donnell et al. 2009; Motlagh et al. 2010). It has been 
suggested that this may be to prepare the unborn child for survival in a hostile 
postnatal environment (Glover 2011). A retrospective study by O’Donnell et al. 
demonstrated that placental mRNA concentration of 11βHSD2 is down-regulated by 
maternal anxiety, as measured by the State/Trait Anxiety Index on the day before 
caesarean section (O’Donnell et al. 2012). The authors suggested that this may 
contribute to increased exposure of the fetus to maternal glucocorticoids.  
 
The aim of the work in this chapter was to investigate the effects of maternal anxiety 
on placental levels of key genes involved in glucocorticoid metabolism in a 
prospective study, in a cohort of pregnant Finnish women in whom maternal stress 
was evaluated throughout pregnancy. We then aimed to evaluate whether the 
findings could be replicated in another cohort using samples collected from the very 
severely obese and lean Scottish women (described in Chapters 2 and 3) in whom 
stress and anxiety had been assessed during pregnancy. 
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6.1.1 Hypothesis 
It was hypothesised that maternal stress/anxiety during pregnancy would be 
associated with altered levels of key genes regulating glucocorticoid metabolism 
including decreased mRNA levels of the gene 11βHSD2 in the placenta at term. 
6.1.2 Aims 
1. To determine the effects of psychological stress on term placental mRNA 
transcript levels of key genes, particularly those involved in regulating 
glucocorticoid transfer to the fetus, in a cohort of pregnant women in whom 
stress and anxiety levels were assessed during each trimester. 
2. To test whether any of the findings observed in aim 1) were replicated in the 
subset of obese and lean women described in Chapter 4 who had also 
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6.2 Methods 
6.2.1 Helsinki Cohort 
6.2.1.1 Subject Recruitment 
Participants for this study were recruited as part of the PREDO-Project (Prediction 
and Prevention of Pre-Eclampsia) between September 2005 and December 2010 in 
Finland, as described in Methods section 2.1.5.1 (Villa et al. 2013). Participants 
attended ultrasound screening between 12 and 14 weeks of gestation in one of ten 
hospital maternity clinics. 
 
6.2.1.2 Assessing Maternal Mood During Pregnancy 
All participants of the PREDO were invited to complete a set of standardized and 
validated questionnaires, aimed at measuring stress, depression, anxiety and anger 
throughout pregnancy at two-week intervals between 12 and 14 weeks of gestation 
and ending two weeks postpartum. Maternal anxiety was measured using the State-
Trait Anxiety Inventory (STAI), while maternal personality traits were measured 
using the NEO Personality Inventory as described in Methods section 2.1.5.2. 
 
6.2.1.3 Tissues 
Placenta samples (n = 67) were collected from healthy singleton term (37 to 42 
weeks of gestation) pregnancies a maximum of 90 minutes (median=45.9, standard 
deviation=21.2 minutes) after vaginal (n=48) or caesarean delivery (n=19). Given the 
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heterogeneity of the placenta, biopsies were obtained avoiding areas of obvious 
infarction or damage. Placenta samples were collected in RNAlater solution and 
stored at -20C. 
 
6.2.2 Edinburgh Cohort 
The Edinburgh arm of the study was a case-control study comparing lean and obese 
pregnant women who had been recruited among participants of a larger prospective 
cohort study, as described in chapter 4. Participants were recruited as part of a 
between April 2008 and September 2012.  
Term placental tissue was collected at elective caesarean section as described in 
methods section 2.1.4. 
 
6.2.2.1 Assessing Maternal Anxiety during Pregnancy 
Participants were asked to complete validated questionnaires to assess mood 
(including stress at home, work, stress over money, stress over life events, 
satisfaction with life and anxiety), Spielberger State and Trait Anxiety Inventory and 
the Hospital Anxiety and Depression Subscale (HADS). Questionnaires were 
completed at ~16 weeks gestation and at ~28 weeks gestation, as described in 
Methods section 2.1.1.2. 
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6.2.3 RNA Extraction  
Tissues stored in RNALater were used for RNA purification and extraction as 
described in Section 2.3.1.1. 
 
6.2.4 Reverse Transcription and Real Time PCR 
RNA successfully extracted from tissues was converted to cDNA using Roche 
Reverse Transcription kits as described in Section 2.3.1. cDNA was used to perform 
real time PCR in order to estimate mRNA levels encoding for the genes GR, 
11βHSD1, 11βHSD2 and MR as described in detail in Section 2.3.1.5 Samples in the 
PREDO cohort were corrected to TBP. 
 
6.2.5 Statistical Analyses 
Normal distribution of data was assessed visually using histograms. mRNA transcript 
data were not normally distributed were normalised using natural log transformation. 
Correlations between mRNA transcript levels and maternal mood assessment scores 
were analysed using Pearson rank correlation. Adjustments for confounding factors 
(in the Edinburgh cohort: maternal age, smoking status, parity, DEPCAT category, 
and length of gestation; in Helsinki cohort: maternal age, smoking status, parity, 
education, mode of delivery, length of gestation, birth weight and time between 
sampling and placental birth) were performed using multiple linear regression. Lean 
and obese women were analysed separately in the Edinburgh cohort. As each of the 
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measures used tested a different psychological component of stress and anxiety, the a 
priori hypothesis was to test each stress and anxiety questionnaire individually. In 
order to control for the effects of multiple testing, the Bonferroni correction was 
carried out for all analyses. The Bonferroni correction can aid in controlling for the 
increased probability of a type I error (i.e. falsely rejecting the null hypothesis) that 
can occur with multiple testing. All data are presented as mean (±s.e.m), and overall 
p values of less than 0.05 were considered significant. 
Statistical power calculations were performed to determine the sample size required 
for these analyses. For correlation analyses where alpha = 0.05 and statistical power 
= 0.8, a sample size of n = 70 was required to detect a correlation of r = 0.3, n = 30 
for a correlation of r = 0.4, and n = 23 for a correlation of r = 0.5. For multiple 
regression analyses using 8 predictors (e.g. correcting for maternal age, parity, 
education, mode of delivery, neonate birthweight, gestational age, and time to 
sampling) with an alpha of 0.05, a sample size of 45 was calculated as being 
necessary to detect an r2 ≥ 0.3. 
Analysis was performed using Minitab (Minitab Inc, PA, USA), SPSS (IBM, NY, 
USA) and Statistica (StatSoft Inc, OK, USA). Graphs were prepared using GraphPad 
Prism (GraphPad Software Inc, CA, USA). 
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6.3 Results 
6.3.1 Helsinki Cohort 
6.3.1.1 Demographics 




Associations between stress evaluation results and placental mRNA transcript levels 
of the gene 11βHSD1 are shown in Table 6-2. The majority of associations were with 
first trimester anxiety measures: 11βHSD1 was found to positively correlate with 
NEO personality inventory scores for neuroticism at 12 weeks. This association 
remained significant after adjustment for maternal age, length of gestation, birth 
weight, smoking status, parity, education and mode of delivery. 11βHSD1 positively 
correlated with Spielberger state anxiety scores in the first trimester of pregnancy in 
adjusted analysis and was found to associate with the score for Spielberger state 
anxiety negative anxiety subscale in first trimester in both univariate and adjusted 
analysis. 11βHSD1 did not associate with Spielberger state anxiety curiosity subscale 
score in either univariate or adjusted analysis. For trait anxiety there were only trends 
for correlations of 11βHSD1 and total trait score in adjusted analysis with a similar 
pattern if only the negative anxiety subscale effects (i.e., high negative affect) were 
considered. After adjusting for the effects of multiple testing, however, only negative 
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anxiety in the first trimester was found to significantly correlate with placental 
11βHSD1 expression.!
While a trend was observed for Spielberger state anxiety (negative anxiety subscale) 
in adjusted analysis during the second trimester, the association was no longer 
present by the third trimester; no associations were observed between 11βHSD1 and 
Spielberger state anxiety score in the second and third trimesters of pregnancy, or the 
mean state anxiety score over pregnancy. 
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Age (years) 31.45 (0.51) 
Parity* 
Nulliparous 29 (43%) 
Multiparous 38 (57%) 
Education* 
Lowest 3 (4%) 
Intermediate 23 (34%) 
Highest (university level) 41 (62%) 
Length of Gestation (days) 280.41 (0.81) 
Birth weight (g) 3440.74 (45.07) 
Birth length (cm) 49.86 (0.22) 
Gender* 
Male 32 (48%) 
Female 35 (52%) 
    
NEO personality 
inventory Anxiety (12 weeks) 12.62 (5.14) 
Spielberger Trait 
Anxiety 
Total (12 weeks) 38.73 (6.65) 
Negative Trait 
Anxiety (12 weeks) 16.92 (3.77) 
Positive Trait Anxiety 
(12 weeks) 28.77 (3.54) 
Spielberger State 
Anxiety 
1st trimester 29.79 (7.76) 
2nd trimester 33.24 (7.79) 
3rd trimester 33.52 (8.21) 




1st trimester 13.54 (3.04) 
2nd trimester 14.48 (3.35) 
3rd trimester 14.43 (3.49) 
Spielberger 
curiosity subscale 
1st trimester 33.75 (5.25) 
2nd trimester 31.23 (5.07) 
3rd trimester 30.90 (5.14) 
 
Table 6-1. Demographic data for Helsinki cohort. All data are mean (±s.e.m), Categorical data 
(*) are expressed as n (%). 
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Predictor variable β P β P 
NEO personality 
inventory Anxiety (12 weeks) 2.84 <0.01 4.18 <0.01 
Spielberger 
Trait Anxiety 
Total (12 weeks) 0.27 0.06 0.31 0.05 
Negative Trait 
Anxiety (12 weeks) 0.24 0.08 0.26 0.09 
Positive Trait 
Anxiety (12 weeks) -0.13 0.38 -0.27 0.11 
Spielberger 
State Anxiety 
1st trimester 0.27 0.057 0.3 <0.05 
2nd trimester 0.05  0.72  0.22  0.16  
3rd trimester -0.03  0.81  0.06  0.69  





1st trimester  0.39 
<0.005
  0.35  <0.05  
2nd trimester  0.15 0.28   0.28 0.054  
3rd trimester  0.05 0.72  0.10 0.48  






1st trimester  -017 0.24  -0.24  0.12  
2nd trimester  0.01 0.93  -0.15 0.33  
3rd trimester  0.09 0.54  -0.02  0.90  
Total 0.02 0.87 -0.11 0.48 
Table 6-2 Associations between 11βHSD1 and stress measures in a cohort of pregnant Finnish 
women by Pearson correlation. Linear regression adjusted for maternal age, smoking status, 
parity, education, mode of delivery, length of gestation, birth weight and time between sampling 
and placental birth. Using Bonferroni correction, p values > 0.003 were considered significant. 
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6.3.1.3 11βHSD2 
No associations were observed between 11βHSD2 mRNA transcript levels and any 
of the stress measures examined at any time point during pregnancy (see Table 6-3). 
 
6.3.1.4 GR 
In adjusted analyses, there was a positive association between GR and total 
Spielberger trait anxiety score at 12 weeks, (see Table 6-4) and a negative 
association with Spielberger trait anxiety score when considering only positively-
worded anxiety items (i.e., low positive affect) at 12 weeks. After adjusting for the 
effects of multiple testing, however, no associations were found to be significant. 
GR did not associate with Spielberger trait anxiety score at 12 weeks when 
considering negative anxiety subscale influences only. Similarly, no associations 
were observed between GR and NEO personality index neuroticism anxiety score at 
12 weeks, in either unadjusted or adjusted analysis. No associations were observed 
between GR and state anxiety in the first trimester.  
There were trends for an association between GR and state anxiety in the second 
trimester although after adjustment the association was no longer significant. Similar 
trends were observed between GR and state anxiety in the third trimester as well as 
between GR and mean state anxiety throughout pregnancy in unadjusted and adjusted 
analysis. GR was not found to associate with either Spielberger State anxiety 
subscale or curiosity subscale scores at any time point in pregnancy. 
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11βHSD2  Unadjusted model Adjusted model 








(12 weeks)  0.11 0.48  0.09  0.61  
Negative Trait 
Anxiety  
(12 weeks)  0.17 0.25   0.16 0.33  
Positive Trait 
Anxiety  
(12 weeks) 0.01  0.92  0.07  0.71  
Spielberger State 
Anxiety 
1st trimester 0.09  0.54  0.06  0.73  
2nd trimester 0.07  0.65  0.08  0.63  
3rd trimester 0.14  0.34  0.09  0.60  




1st trimester  0.08 0.58   0.11 0.46  
2nd trimester 0.11  0.47  0.13 0.44 
3rd trimester  0.11 0.46  0.04  0.82  
Total 0.11 0.47 0.08 0.61 
Spielberger 




1st trimester  -0.08 0.57  -0.01  0.94  
2nd trimester  -0.04 0.79  -0.04 0.81  
3rd trimester  -0.14 0.32  -0.11  0.52  
Total -0.09 0.56 -0.70 0.68 
Table 6-3 Associations between 11βHSD2 and stress measures in a cohort of pregnant Finnish 
women by Pearson correlation. Linear regression adjusted for maternal age, smoking status, 
parity, education, mode of delivery, length of gestation, birth weight and time between sampling 
and placental birth. Using Bonferroni correction, p values > 0.003 were considered significant. 
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GR  Unadjusted model Adjusted model 




Anxiety (12 weeks) 
0.05 0.74 0.13 0.42 
Spielberger 
Trait Anxiety 
Total (12 weeks) 0.22  0.12  0.30  <0.05  
Negative Trait 
Anxiety (12 weeks)  0.15  0.29  0.15  0.32 
Positive Trait 
Anxiety (12 weeks)  -0.27 0.052  -0.37 <0.05  
Spielberger 
State Anxiety 
1st trimester 0.13 0.36 0.096 0.51 
2nd trimester 0.24  0.09  0.23 0.11 
3rd trimester 0.25 0.07 0.27 0.054 





1st trimester  0.09 0.51   0.05 0.74  
2nd trimester  0.17 0.24  0.20 0.15  
3rd trimester  0.19 0.19  0.19  0.16  






1st trimester  -0.14 0.33   -0.12 0.42  
2nd trimester  -0.25 0.07   -0.23 0.13  
3rd trimester  -0.26 0.06  -0.23  0.13  
Total -0.26 0.06 -0.23 0.13 
Table 6-4 Associations between natural logged GR and stress measures in a cohort of pregnant 
Finnish women by Pearson correlation. Linear regression adjusted for maternal age, smoking 
status, parity, education, mode of delivery, length of gestation, birth weight and time between 
sampling and placental birth. Using Bonferroni correction, p values > 0.003 were considered 
significant. 
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6.3.1.5 MR 
No associations were observed between MR and NEO personality inventory anxiety 
score at 12 weeks (see Table 6-5). 
No associations were observed between MR and total Spielberger trait anxiety score 
at 12 weeks, or with either the positive or negative trait anxiety subscales. 
MR positively correlated with Spielberger state anxiety scores in the first trimester, 
and was found to negatively associate with Spielberger state anxiety curiosity 
subscale (i.e., low curiosity) score measured in the first trimester in adjusted analysis. 
MR also positively correlated with Spielberger state anxiety scores in the second 
trimester and was also found to negatively associate with Spielberger state anxiety 
curiosity subscale score in adjusted analysis. MR was found to positively correlate 
with Spielberger State negative anxiety subscale score in adjusted analysis in the 
second trimester. A positive correlation was also observed between MR and 
Spielberger state anxiety scores measured in the third trimester, as well as with the 
mean anxiety score for the entirety of pregnancy. MR was also found to negatively 
associate with Spielberger state anxiety curiosity subscale score in adjusted analysis 
in the third trimester. MR was found to correlate positively with mean Spielberger 
state negative anxiety and negatively with mean Spielberger state curiosity subscale 
scores measured over the entirety of pregnancy. 
After adjusting for the effects of multiple testing, GR expression was found to 
negatively associate with scores for state anxiety curiosity in the second trimester 
only; other observed associations found to be weakened.  
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MR  Unadjusted model Adjusted model 
Predictor variable β P β P 
NEO personality 
inventory Anxiety (12 weeks) -0.004 0.97 0.07 0.69 
Spielberger 
Trait Anxiety 
Total (12 weeks) 0.19 0.20 0.33 0.09 
Negative Trait 
Anxiety (12 weeks)  0.11 0.46   0.22 0.21  
Positive Trait 
Anxiety (12 weeks) -0.22 0.14 -0.323 0.085 
Spielberger 
State Anxiety 
1st trimester 0.22 0.13 0.3 0.054 
2nd trimester 0.27 0.058 0.46 <0.01 
3rd trimester 0.22 0.13 0.36 <0.05 





1st trimester  0.07 0.51   0.13 0.41  
2nd trimester  0.22 0.13   0.35 <0.05  
3rd trimester  0.20 0.17  0.29  0.07  




score refers to 
high anxiety) 
1st trimester -0.27  0.06   -037 <0.05  
2nd trimester  -0.28 0.05  -0.47  <0.005  
3rd trimester  -0.21 0.15  -0.38  <0.05  
Total -0.26 0.07 -0.45 <0.01 
Table 6-5 Associations between natural logged MR and stress measures in a cohort of pregnant 
Finnish women by Pearson correlation. Linear regression adjusted for maternal age, smoking 
status, parity, education, mode of delivery, length of gestation, birth weight and time between 
sampling and placental birth. Using Bonferroni correction, p values > 0.003 were considered 
significant. 
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6.3.2 Edinburgh Obesity in Pregnancy Study 
6.3.2.1 Demographics 
The demographics of a subset of participants in a longitudinal study of the effects of 
obesity during pregnancy who self-reported their stress throughout gestation and for 
whom term placental samples were available are reported in Table 6-6. Obese 
women had higher reported stress at home at visit 2, stress over money at visit 2, 
state anxiety at visits 1 and 2, and lower satisfaction with life at visit 2. Obese 
women were also more likely to be of a lower socioeconomic status compared to 
lean women. Baseline characteristics of subjects who completed stress questionnaires 
did not differ from the rest of the cohort (data not shown).!
 
6.3.2.2 11βHSD1 
In lean women, 11βHSD1 correlated with a number of measures of anxiety at visit 1, 
including Spielberger state and trait anxiety, with trends for associations with anxiety 
measured at the same time point (see Table 6-7). However, only financial stress in 
the second trimester was found to correlate with placental 11βHSD1 expression after 
correcting for the effects of multiple testing. Additionally, many of these associations 
were weakened when adjusting for confounding factors. At visit 2, 11βHSD1 
correlated with money-related stress in both univariate and adjusted analysis. In 
univariate analysis, placental 11βHSD1 was also found to positively correlate with 
measures of anxiety measured at visit 2, while there was a negative trend with 
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satisfaction with life, although the association was not significant in multivariate 
analysis.  
In obese women, 11βHSD1 was found to correlate with the participants’ reported 
satisfaction with life and there was a trend with Spielberger state anxiety at visit 2 in 
univariate analysis, but neither association was significant with adjustment. No other 
associations were observed. 
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BMI 23.08 (0.33) 41.57 (0.95) <0.0001 
Age (years) 33.88 (0.75) 31.87 (1.06) 0.12 
Birthweight (g) 3490 (69.47) 3635 (94.4) 0.21 







Nulliparous 13 (33%) 10 (28%) 0.52 
Multiparous 17 (44%) 21 (59%) 0.14 
Depcat category* 
0 17 (44%) 8 (23%) <0.05 
1 12 (31%) 21 (59%) <0.05 
Smokers* 9 (23%) 5 (14%) 0.14 
Non-smokers* 21 (53%) 23 (64%) 0.31 
Ethnicity* 
White 16 (41%) 25 (70%) <0.01 
Non-white 1 (3%) 1 (3%) 1.00 
Stress measures:     
 
Stress at work 
Visit 1  1.33 (0.14)  1.43 (0.19) 0.83 
Visit 2 1.53 (0.27) 1.58 (0.26) 0.89 
Stress at home 
Visit 1 0.94 (0.17) 1.0 (0.19) 0.81 
Visit 2 0.67 (0.16) 1.21 (0.15) <0.05 
Stress over money 
Visit 1 0.31 (0.12) 0.73 (0.18) 0.56 
Visit 2 0.40 (0.13) 0.79 (0.14) <0.05 
Stress events 
Visit 1 0.56 (0.20) 0.67 (0.41) 0.62 
Visit 2 
0.067 
(0.067) 0.68 (0.20) <0.01 
Satisfaction with 
life 
Visit 1 27.75 (1.37) 26.13 (1.10) 0.26 
Visit 2 28.27 (1.33) 24.11 (1.47) <0.05 
Anxiety 
Visit 1 5.33 (0.97) 5.87 (1.04) 0.71 
Visit 2 5.60 (1.01) 6.95 (0.95) 0.34 
State Anxiety 
Visit 1 29.19 (2.03) 36.33 (2.92) <0.05 
Visit 2 30.33 (2.44) 38.47 (2.92) <0.05 
Trait Anxiety 
Visit 1 34.06 (2.84) 34.53 (2.80) 0.89 
Visit 2 34.20 (3.11) 40.42 (3.32) 0.18 
 
Table 6-6. Demographics of lean and obese cohorts. All continuous data are mean (±s.em.). 
Categorical data (*) are expressed as percentages. Socioeconomic status was measured using 
deprivation category (DEPCAT) scores based on postcode, with depcat category 0 indicating 
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6.3.2.3 11βHSD2 
In lean women, no associations were observed between 11βHSD2 mRNA levels and 
maternal pre-pregnancy anxiety (see Table 6-8). 
In obese women, there were trends for 11βHSD2 to be associated with increased 
Spielberger trait anxiety at visit 1 in univariate analysis, with self-reported stress at 
work at visit 2 in both univariate and multivariate analysis and with decreased 
satisfaction with life reported at visit 2 in univariate analysis.  
 
6.3.2.4 GR 
Stress at work at visit 1 was positively associated with expression of GR in adjusted 
analysis. However, this association was not found to be significant after adjustment 
for multiple testing. No other associations were observed between GR transcript 
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6.3.2.5 MR 
In the lean group, increased stress over money at visit 1 was found to associate with 
reduced MR transcript levels (see Table 6-10), although the association was 
weakened with multivariate analysis. No other associations were observed.!
 
In the obese group, increased MR was found to correlate with a number of measures 
of increased maternal stress at visit 1 although neither association was significant 
after adjustments for other factors or after adjustment for the effects of multiple 
testing. At visit 2, measures of maternal stress and anxiety positively associated with 























































































































































































































































een natural logged M
R
 and stress m
easures in a cohort of obese and lean pregnant w
om
en by Pearson correlation. 
L
inear regression adjusted for m
aternal age, sm





 category, and length of gestation. U
sing B
onferroni correction, p 
values > 0.003 w
ere considered significant.




Effects of maternal stress and obesity on human feto-placental glucocorticoid exposure 
   237 
6.4 Discussion 
Maternal stress and anxiety have been associated with an increased risk of adverse 
postnatal outcomes in the child; these include autism, schizophrenia and behavioural 
problems (Van den Bergh and Marcoen 2004; Gutteling et al. 2005; Rodriguez and 
Bohlin 2005a; van den Bergh et al. 2006; Khashan et al. 2008a; Kinney et al. 2008; 
Van den Bergh et al. 2008). Over-exposure of the fetus to excess glucocorticoids 
through alterations in the maternal HPA axis, and particularly the placental barrier 
enzyme 11βHSD2, has been the main focus of research to date into the programming 
effects of maternal stress and anxiety. 
 
6.4.1 11βHSD1 is up-regulated with maternal anxiety 
The results of these analyses suggest that increased levels of mRNA encoding the 
glucocorticoid-activator 11βHSD1 may associate with increased maternal anxiety 
during pregnancy in both cohorts, and also negatively correlated with satisfaction 
with life. However, these associations were limited to specific components of anxiety 
and stress in the first trimester, and were significantly weakened when the potential 
effects of multiple testing were controlled for. It will therefore be important for the 
results of this preliminary analysis to be validated in a larger cohort with a specific 
focus on anxiety in the first trimester. 
NADP-dependent 11βHSD1 is predominantly localised to the maternal compartment 
of the placenta, whereas 11βHSD2 is predominantly localised to the fetal 
compartment (McMullen et al., 2004). 11βHSD1 acts to increase local levels of 
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glucocorticoids, in contrast to 11βHSD2. The increased levels of glucocorticoids on 
the maternal side of the placenta that result are thought to aid in the inhibition of 
inflammatory and immune responses to the fetal allograft and placental invasion 
(McMullen et al., 2004). In both rodents and humans, rising mRNA concentrations 
of 11βHSD1 in the placenta during the last week of pregnancy may augment the 
surge in glucocorticoids at that time (Burton et al. 1996; Murphy and Clifton 2003). 
This is particularly important in rodents where both 11βHSD2 mRNA levels and 
activity drop at the end of pregnancy.  In humans, 11βHSD2 activity drops between 
weeks 38 and 40, producing a synergistic increase in placental cortisol concentration 
(Murphy and Clifton 2003). Thus, increasing 11βHSD1 gene expression may 
represent, in tandem with lowered 11βHSD2 enzyme activity, an important 
mechanism by which fetal and placental exposure to maternal cortisol may be 
regulated, particularly at term. Previous studies have suggested that placental 
11βHSD1 and 11βHSD2 work together to control the concentration of maternal 
glucocorticoids reaching the fetus (Sun et al. 1997). Maternal anxiety may lead to 
programming effects through an up-regulation of 11βHSD1 and an alteration of the 
finely-controlled glucocorticoid concentration at the placenta (Sun et al. 1997).  This 
in turn could potentially lead to increased fetal exposure to maternal glucocorticoids, 
and thus hasten fetal maturation, potentially leading to programming effects. 
These data suggest that the effects of maternal stress on placental 11βHSD1 may be 
less pronounced in obese women than their lean counterparts. This may indicate that 
the placentas of obese women are somewhat protected against the effects of maternal 
stress and anxiety, or that the adverse effects of obesity may override any adverse 
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effects of anxiety. The HPA axis of obese women may be less sensitive to stress as a 
result of attenuation of the normal negative feedback of cortisol on the higher centres 
of the system. In baboons, increased estrogen production has been linked to a 
changed placental preference from cortisone reduction to cortisol oxidation in mid-
gestation (Pepe et al. 1988). It is possible that increased adipose tissue estrogen 
production in obese women decreases the reactivity of 11βHSD1 to other forms of 
regulation. This may explain the ceiling effect seen within this group when compared 
to their lean counterparts. However, placental 11βHSD1 mRNA transcript levels did 
not differ between obese and lean women (as described in chapter 4). 
Furthermore, placental mRNA levels of 11βHSD1 at term appear to be more 
sensitive to stresses in early and mid-pregnancy, with third trimester stressors 
ultimately having little apparent effect on transcript levels in the Helsinki cohort. 
This suggests that the timing of maternal stress and anxiety is critical. The finding 
may also imply that the chronic effects of maternal anxiety are important, and that 
stressors experienced earlier in pregnancy may produce effects on placental gene 
activity that persist until term, even if the stressor is no longer present.  
Due to the large number of tests carried out, and the relatively low number of 
significant associations found, it will be important to validate the findings of this 
study. However, this study may prove a useful starting point for furture 
investigations into the relationship between term placental 11βHSD1 expression and 
anxiety during early pregnancy,  
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6.4.2 11βHSD2 did not respond to maternal anxiety 
11βHSD2, the cortisone-reductive counterpart of 11βHSD1, and the main component 
of the placental barrier to maternal glucocorticoids, was not associated with maternal 
anxiety during pregnancy in either cohort, other than weak trends in the obese 
women. This stands in contrast to the findings of a study by O’Donnell et al, in 
which prenatal maternal anxiety was associated with a down-regulation of placental 
11βHSD2 (O’Donnell et al. 2012). This anxiety-associated down-regulation has been 
suggested to be indicative of increased fetal exposure to maternal cortisol, potentially 
leading to programming effects. 
This discrepancy may be due to the different approach to measuring maternal 
anxiety. In the study by O’Donnell et al, stress questionnaires were administered on 
the day before caesarean section, rather than throughout pregnancy. It seems 
plausible that the anxiety associated with the impending operation and delivery may 
have affected maternal responses in a manner absent from prospective testing. 
Pregnant women in the study by O’Donnell et al generally scored more highly on 
both state and trait anxiety scores (mean state anxiety of 43) when compared to 
participants in this study (mean state anxiety 39 in the obese and mean 30 in the lean) 
or the Helsinki study (mean state anxiety 33). It seems plausible that the impending 
operation may have influenced self-reported anxiety. 
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6.4.3 Glucocorticoid and Mineralocorticoid Receptors 
Placental GR mRNA transcript levels appeared to be positively associated with some 
measures of maternal anxiety, particularly trait anxiety, in the Helsinki cohort only. 
This may indicate effects on placental growth and hormone production in response to 
chronic stress. This stands in apparent contrast to the findings of previous studies, 
which suggest that increased exposure to glucocorticoids results in a decrease in GR 
transcription in human placenta (Johnson et al. 2008b). Up-regulation of placental 
GR may increase placental susceptibility to maternal glucocorticoids. 
MR appeared to be positively associated with a number of measures of maternal 
stress and anxiety, with the strongest associations being observed in obese women. 
11βHSD2, high levels of which are found in the placenta, normally confers 
specificity on MR by conversion of active glucocorticoids to inactive forms, 
allowing the much lower concentrations of aldosterone to bind to the non-specific 
MR (Edwards et al. 1988; Funder et al. 1988). Aldosterone is important for placental 
growth and function, and deficiency of this substance has been linked to pre-
eclampsia; aldosterone concentration has also been positively linked with placental 
size in humans (Brown et al. 1997; Gennari-Moser et al. 2011). The anxiety-induced 
up-regulation of 11βHSD1 may weaken this conferred specificity by increasing the 
concentration of active cortisol in the placenta. Thus, the up-regulation of MR 
transcription may be a compensatory response to the anxiety-induced increase in 
mRNA levels of 11βHSD1; i.e. as baseline activation of MR increases, greater 
number of receptors are required in order to compensate for the altered 
glucocorticoid signal to noise ratio. However, while 11βHSD1 has been shown to be 
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expressed predominantly in the chorion and the intermediate trophoblasts, MR is 
thought to be expressed in the syncytiotrophoblast, cytotrophoblasts, and the villous 
core, suggesting that the proposed interaction may not occur (Hirasawa et al. 2000).  
6.4.4 Limitations 
This study was limited by the use of multiple testing when considering the 
associations between maternal anxiety and placental gene expression. While the 
indices used measure different components of stress and anxiety, it is important to 
acknowledge the potential effects of multiple testing. When performing a large 
number of analyses on a single dataset, the probability of errors of inference (i.e. 
erroneously rejecting the null hypothesis, or a type I error) increases. This is due to 
the fact that when performing a single test at the 5% level (i.e. accepting p values < 
0.05 to be significant), one accepts that there is a 5% chance that an association will 
be seen by chance alone, and the null hypothesis will be incorrectly rejected. When 
performing multiple tests on the same dataset, the number of expected incorrect 
rejections increases. For example, when performing 100 tests, one will expect 5 
incorrect rejections of the null hypothesis to occur. Techniques such as the 
Bonferroni correction can help to minimize this effect by allowing the statistician to 
revise the significance level, or alpha, of the tests performed. Nevertheless, it will be 
important for future investigations concerning anxiety during pregnancy to control 
for the effects of multiple testing. This may be accomplished by focusing on specific 
anxiety criteria, or on a specific timepoint during pregnancy. In the case of 11βHSD1 
for example, it may be illuminating to concentrate on the effects of stress during 
early pregnancy. 
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6.4.5 Conclusions 
Similar findings were observed in both the Helsinki and Edinburgh cohorts. By using 
two cohorts, it was hoped that the effects of multiple statistical testing would be 
mitigated, however when correcting for multiple testing many of the observed 
associations were found to be no longer significant. The observed replication of 
findings lends confidence to the conclusion that 11βHSD1 may play an important 
role in the regulation of placental glucocorticoid metabolism, however it will be 
important to validate these findings in a larger single cohort focusing on anxiety 
during early gestation. Whether changes in 11βHSD1 mRNA transcript levels lead to 
programming effects, presumably via alterations in fetal exposure to maternal 
cortisol, remains unclear. This enzyme, while often overlooked in studies, may prove 
to be an important component of the programming effects of maternal stress. 
Interestingly, the admittedly limited effects of maternal stress and anxiety on 
placental mRNA transcript levels of 11βHSD1 and MR appeared to differ between 
lean and obese women. While placentas from obese women did not appear to have 
significant changes in 11βHSD1 transcription, strong associations were seen between 
maternal stress and MR transcript levels. This may indicate that the placentas of 
obese women are more protected against placental effects of maternal stress, 
specifically minimising the conversion of inactive cortisone to cortisol and through 
the increased availability of MR for activation by aldosterone. However, as MR and 
11βHSD1 do not appear to be co-localised in placental cells, the nature of such an 
interaction, if it occurs at all, remains unclear. 
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Chapter 7:  
Discussion 
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The work in this thesis aimed to test the hypothesis that the programming effects of 
maternal obesity and maternal stress are mediated by altered action of 
glucocorticoids on the developing fetus. This was carried out by examining the 
relationship between maternal obesity and a number of pregnancy parameters, 
including the mother’s HPA axis activity and placental gene expression. 
Obesity is an increasing problem, of global pandemic proportions (WHO 2013). 
Rates of obesity during pregnancy have increased dramatically throughout the world, 
with developed and developing countries alike affected (Prentice et al. 2005; 
Heslehurst et al. 2007a; Heslehurst et al. 2007b; Prentice 2009; Heslehurst et al. 
2010). As maternal obesity increases the risk of childhood and adulthood obesity 
amongst the offspring of obese women, obesity may be to some extent self-
perpetuating and cyclical. 
With the increasing rates of obesity during pregnancy, and the programming effects 
of this state, it is becoming increasingly important to identify the mechanisms 
through which obesity affects pregnancy health, pregnancy outcome, and the long-
term health of the offspring. It will also be important to establish potential 
biomarkers for future disease risk in this rapidly growing section of the population. 
 
7.1 Obesity and the Maternal HPA Axis 
It was shown that maternal obesity has significant effects on the maternal HPA axis. 
As glucocorticoids are involved in fetal-placental growth and maturation, and excess 
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fetal exposure to glucocorticoids has been implicated in a number of programming 
effects, this observation is of great importance.  
Total circulating cortisol levels were found to be significantly lower throughout 
pregnancy in obese women when compared to their lean peers. Similarly, circulating 
levels of CBG and CRH, two important regulators of cortisol activity and production, 
were also found to be lower in obese pregnant women compared to lean counterparts. 
This suggests that maternal HPA axis activity may be reduced in obese pregnancy, 
potentially due to a reduction in cortisol production as a result of lower levels of 
placental CRH. As excess glucocorticoids are associated with reduced birth weight, 
this finding may help to explain the increased incidence of macrosomia amongst the 
offspring of obese women. A logical next step would be to more closely examine the 
effects of maternal obesity on placental CRH production. This may involve 
measurements of CRH gene expression, and investigation of factors influencing both 
expression and post-transcriptional regulation. 
Significantly, CRH levels were found to predict length of gestation in obese 
pregnancy. This finding is in agreement with previous studies, and adds weight to the 
hypothesis that CRH acts as a ‘placental clock’ regulating the timing of parturition 
(Sandman et al. 2006). Obesity-related reductions in CRH may explain the longer 
gestations that are generally observed in obese pregnancy, a phenomenon that may 
also help explain the increased incidence of macrosomia among children of obese 
mothers (Challis et al. 2001; Sandman et al. 2006). 
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7.1.1 Free cortisol 
While total cortisol was found to be lower in obese women compared to lean women 
during pregnancy, calculated levels of free cortisol were found to be higher in obese 
women by term, due largely to correspondingly lower levels of CBG. This may have 
important ramifications when considering the effects of maternal obesity on fetal 
glucocorticoid exposure. However, one must bear in mind that the method of 
calculating free cortisol represents an approximation, and does not necessarily reflect 
the actual circulating levels of unbound cortisol. Therefore, it will be an important 
goal of follow-up studies to confirm these findings through direct measurement of 
free cortisol. 
 
7.1.2 Other Regulators of the HPA Axis 
Future work may be also carried out to investigate the role of AVP as a regulator of 
HPA-axis function during obese pregnancy. As CRH levels increase throughout 
gestation, AVP is thought to increasingly regulate stress response and other HPA 
axis functions (Chowdrey et al. 1995). Furthermore, the roles of estradiol, estriol, 
fetal DHEA, and insulin as regulators of CBG production and activity may also be 
explored in follow-up studies. Measurements of these substances, particularly 
estrogen, were unavailable for the cohort studied, however it will be important for 
future studies to take them into consideration as potential mediators of the effects of 
obesity on the HPA axis during pregnancy, particularly when considering the effects 
of maternal obesity on the levels of free cortisol. 
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While this study attempted to investigate the effects of maternal obesity on diurnal 
rhythms of cortisol production, the small number of samples obtained limited 
interpretation of results. As changes in the diurnal production profile potentially 
influence overall glucocorticoid exposure, repeating this experiment with a larger 
cohort may be greatly beneficial. 
 
Overall, this section of the study highlighted the significant effect of maternal obesity 
on HPA axis activity, as well as the potential importance of HPA axis activity as a 
potential biomarker of maternal obesity-related effects on pregnancy outcome, 
including length of gestation. With further work, a more complete understanding of 
this relationship may be established, including the mechanisms by which maternal 
obesity alters CRH and cortisol production, whether at the placenta or other sites. 
 
7.2 Obesity and the Placenta 
The placenta is intimately involved in the regulation of fetal growth and development 
thanks to its role as a regulator of nutrient transfer, hormone production and its 
function as a glucocorticoid barrier. 
Of the many genes involved in placental function, genes involved in the regulation of 
fetal glucocorticoid exposure, and fetal and placental growth were studied. Of these 
genes, three were found to be affected by maternal obesity. The gene encoding the 
placental glucocorticoid barrier enzyme 11βHSD2 was more highly expressed in 
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obese pregnancy during the first trimester. This suggests that the offspring of obese 
pregnant women may be better protected from circulating maternal glucocorticoids 
compared to the offspring of lean women. Intriguingly, this pattern was also partially 
present at term, with placental 11βHSD2 expression found to be highest in the 
placentas of obese women who gave birth to macrosomic offspring. Given the 
negative relationship between excess glucocorticoid exposure and birth weight 
reported in other studies (Reinisch et al. 1978; French et al. 1999; Bloom et al. 
2001), an increased placental barrier to cortisol may help contribute to increased fetal 
growth. In combination with the observed reduction in total cortisol levels in obese 
pregnancy, it seems possible that the offspring of obese women may be exposed to a 
significantly lower level of maternal glucocorticoids compared to those of lean 
women. 
As with 11βHSD2, GR expression was found to be higher in obese compared to lean 
pregnancy in the first trimester. This is suggestive of increased placental sensitivity 
to glucocorticoids. As glucocorticoids are important regulators of growth and 
development, this finding may predict altered in placental growth and maturation in 
obese pregnancy. Interestingly, both GR and IGF2, an important growth factor, were 
less highly expressed in placentas from macrosomic obese pregnancies, suggesting 
that by late pregnancy placental growth has slowed in these individuals. This may 
represent a shift in balance from placental to fetal growth, again helping to explain 
the observed macrosomia. 
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7.3 Maternal Stress and the Placenta 
Contrary to the findings in maternal obesity, maternal stress and anxiety were found 
to be associated with increased expression of the gene 11βHSD1, a gene encoding an 
enzyme principally involved in reactivation of glucocorticoids. This finding is novel 
and previously unreported, and suggests that in pregnancies complicated by stress 
and anxiety, the fine control by 11βHSD1 and 11βHSD2 over fetal glucocorticoid 
exposure may be disrupted (Sun et al. 1997). Importantly, 11βHSD2 did not appear 
to be affected by maternal stress, a finding that conflicts with previous studies 
(O’Donnell et al. 2012). This conflict may be due to the different nature of the 
stressors involved, and highlights the importance of effective study design, as well as 
the complex relationship between mood and placental gene expression. Taken 
together with the findings for maternal obesity however, it seems clear that the 
placental control over glucocorticoid exposure is particularly sensitive to maternal 
influences. As a result, it may be beneficial to further explore the use of 11βHSD1 
and 11βHSD2 as biomarkers of potential programming effects in a maternal obesity 
or maternal stress context. 
 
7.4 DNA Methylation was not Affected by Maternal 
Obesity 
As the expression of a number of genes was associated with maternal obesity, 
consideration was given to how such changes may be regulated. One mechanism that 
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has come under scrutiny in a number of studies is DNA methylation. This epigenetic 
mark can be analysed relatively quickly and easily through the use of techniques 
such as pyrosequencing. Maternal obesity does not appear to significantly affect 
methylation of any of the genes studied. Other transcription regulating mechanisms 
may be involved, including micro-RNAs and histone modification; these may prove 
useful in future studies. Epigenetic marks are excellent candidates as biomarkers of 
future disease, representing as they do a likely mechanism by which gene expression 
is altered in maternal obesity. While DNA methylation does not appear to be affected 
by maternal overnutrition, other mechanisms may be more sensitive to such 
influences. 
Problems were encountered in this study with DNA extraction from placental tissues, 
leading to a smaller than planned sample size. This represents a potentially 
significant limitation of the study, and further work using a larger cohort would be 
extremely beneficial. 
7.5 Proposed Future Work 
This study was limited in a number of key ways, particularly by sample size, 
particularly for the maternal CRH and placental DNA methylation arms. These 
limitations were due to a number of factors, including costs and difficulties with 
DNA and RNA extraction. Data was also unavailable for some of the variables that 
may have otherwise proven useful to study, including estrogen levels during 
pregnancy. Ideally, the first step in creating follow-up studies would be to repeat the 
key experiments with a larger number of women. 
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The study was also limited by the absence of a long-term follow-up arm. While 
significant insight has been gained into some of the effects of maternal stress and 
obesity on placental and HPA-axis function during gestation, the long-term 
programming effects remain to be fully explored. Ideally, the effects of stress and 
obesity on health at offspring middle-age could be studied, with particular focus on 
risk of obesity, cardiovascular disease, anxiety and metabolic disorders; in doing so, 
the usefulness of potential biomarkers including 11βHSD2 may be validated. 
 
7.6 Conclusions 
Maternal obesity appears to have significant effects on the glucocorticoid milieu 
during pregnancy. Generally, maternal obesity lowers circulating total cortisol and 
CRH levels, as well as being associated with increased expression of the 
glucocorticoid inactivating enzyme 11βHSD2. This suggests an overall reduction of 
fetal glucocorticoid exposure. This may help to explain the increased length of 
gestation and birth weights observed in obese pregnancy, as well as the associated 
increased risk of programming effects such as adiposity and obesity. 
Importantly, this study also highlighted the potential role of the enzyme 11βHSD1 in 
mediating the effects of maternal stress on fetal development. While 11βHSD2 has 
been widely studied, 11βHSD1 has received relatively little focus. The reported 
finding may contribute to further exploration of the role of this enzyme in the fine 
control of fetal-placental glucocorticoid exposure, and its disruption in response to 
maternal stress and anxiety. 
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Appendix I: Suppliers’ Addresses 
Agilent Technologies: 610 Wharfedale Road, Wokingham, RG41 5TP, UK   
Anachem Ltd: 1 & 2 Titan Court, Laporte Way, Luton, LU4 8EF, UK  
Applied Biosystems: 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, 
UK 
Bio-Rad Laboratories: Maxted Road, Hemel Hemstead, HP2 7DX, UK 
Biotage AB: Box 8, SE-751 03 Uppsala, Sweden 
Biotium, Inc: Munro House, Trafalgar Way, Cambridge, CB23 8SQ, UK  
Contained Air Solutions: Unit 4, Greengate, Middleton Junction, Manchester M24 
1RU, UK  
Dako: Cambridge House, St Thomas Place, Ely, Cambridgeshire, CB7 4EX, UK 
DIASource Immunoassays SA: Rue du Bosquet, 2 1348 Louvain-La 
Neuve, Belgium  
Eppendorf: Arlington Business Park, Stevenage, SG1 2FP, UK 
Invitrogen: 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK  
GE Healthcare: Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK 
GraphPad Software, Inc: 2236 Avenida de la Playa, La Jolla, CA 92037, USA 
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G-Storm Ltd: Somerton Biotechnology Centre, Ricksey Lane, Catcombe, Somerton, 
Somerset, TA117JH 
Li-Cor Biosciences: St. John's Innovation Centre, Cowley Road, Cambridge CB4 
0WS, UK  
Lonza: 228 Bath Road, Slogh, Berkshire, SL1 4DX, UK 
Millipore: Croxley Green Business Park, Watford, WD18 8YH, UK  
Minitab Ltd: Brandon Court, Unit E1-E2, Progress Way, Coventry, CV3 2TE, UK 
Nanodrop Technologies: 3411 Silverside Rd, Wilmington, DE 19810, USA  
New England BioLabs: 75/77 Knowl Piece, Wilbury Way, Hitchin, SG4 0TY, UK  
Promega: Southampton Science Park, Southampton, SO16 7NS, UK  
Qiagen: Fleming Way, Crawley, West Sussex, RH10 9NQ, UK  
Roche Applied Science: Charles Avenue, Burgess Hill, RH15 9RY, UK  
Sarstedt: 8 Boston Road, Beaumont, LE4 1AW, UK 
Sigma Aldrich: The Old Brickyard, New Road, Gillingham, Dorset SP8 4XT,  
UK 
Swann Morton: Owlerton Green, Sheffield S6 2BJ, UK 
Thermo Fisher: Blenheim Road, Epsom, Surrey, KT19 9AP, UK 
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UVITec Ltd: Unit 36, St John’s Innovation Centre, Cowley Road, Cambridge C54 
0WS, UK 
Zeiss: 509 Coldhams Lane, Cambridge, CB1 3JS, UK  
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Appendix II: Placental expression of key 
genes using various housekeeping genes 
 
First trimester placental expression of key genes using various housekeeping genes  
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First trimester placenta
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